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ABSTRACT 
The microvascular endothelium serves as the barrier between the blood and perfused 
tissues. Proper function of the endothelium is dependent on the ability of the 
endothelial cells to produce nitric oxide and form tight junctions between themselves. 
Dysfunction occurs when stresses overwhelm the endothelial cell, with oxidative stress 
being a leading cause. Intracellular metabolism of purine nucleosides and nucleobases 
has been implicated in the production of oxidative stress. Nucleosides (e.g. adenosine) 
and nucleobases (e.g. hypoxanthine) are moved across cell membranes by a specialized 
family of proteins called equilibrative nucleoside transporters (ENTs).  
We characterized primary human cardiac microvascular endothelial cells (MVECs) for 
expression, function, and regulation of nucleoside and nucleobase transporters. It was 
discovered that nucleobase transport in these MVECs was mediated by a novel, purine 
selective transporter that was insensitive to inhibitors of ENTs, which we named 
equilibrative nucleobase transporter 1 (ENBT1). ENBT1 and the nucleoside selective 
transporter ENT1 were differentially regulated by a number of intracellular protein 
kinases, vascular endothelial growth factor, and oxidative stress.  
The role of nucleoside and nucleobase transport in the physiology of MVECs was also 
studied, using primary MVECs isolated from wild-type (WT) and ENT1-/- mice. Altered 
gene expression of adenosine metabolizing enzymes and adenosine signaling was 
identified and confirmed at the protein level, however, there was no compensatory 
changes in other nucleoside or nucleobase transporters. Coinciding with the loss of 
iv 
 
adenosine transport capabilities, ENT1-/- mice had elevated adenosine plasma 
concentrations compared to WT and lowered blood pressure. 
Unexpectedly, the ENT1-/- began to develop hind limb paralysis at about 12 months old. 
Post-mortem analysis revealed abnormal mineralization on the spine leading to spinal 
cord compression. MicroCT analysis was used to determine a time course of 
development, with mineralization being apparent as early as 2 months old. The pattern 
of mineralization resembled the human condition known as diffuse idiopathic skeletal 
hyperostosis (DISH). 
Nucleoside and nucleobase transporters are important in the regulation of 
cardiovascular effects of purines, with special consideration to oxidative stress and 
blood pressure. We may have also discovered a novel role for ENT1 in the development 
of DISH. 
 
Keywords: adenosine, hypoxanthine, microvascular endothelium, transporters, 
metabolism, reactive oxygen species, regulation, ischemia-reperfusion injury, 
hypotension, diffuse idiopathic skeletal hyperostosis 
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CHAPTER ONE 
INTRODUCTION 
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The work presented in this thesis was focused on understanding the function, 
regulation, and physiological roles of nucleoside and nucleobase transporters expressed 
in microvascular endothelial cells (MVECs). Following a brief introduction and 
information on the hypotheses addressed in this thesis, research will be presented in 
two main sections. The first section, which includes Chapters Three and Four, discuss 
the expression, function, and regulation of nucleoside and nucleobase transporters in 
primary human MVECs. The second section, which includes Chapters Five and Six, focus 
on mouse models for nucleoside and nucleobase transport and with the aid of a 
nucleoside transporter deficient mouse, it aims to help further the understanding of the 
physiological importance of nucleoside and nucleobase transporters. The thesis will 
conclude with a concise chapter pulling together all the information discussed and 
provide clear concepts that can be derived from the work as a whole. 
1.1 The Endothelium 
The bulk of the research presented in this thesis was conducted with endothelial cells. 
The following section will highlight the importance of this cell type and the unique 
properties of the endothelium as a tissue. The endothelium is the specialized lining of 
both the cardiovascular and lymphatic systems. It is estimated to cover 350 m2 in the 
average person and is the barrier between the blood and tissues (44). The endothelium 
is also an important regulator of vascular tone and other important biological processes 
including angiogenesis (the formation of new blood vessels), fluid and solute transport, 
and inflammation (44). The endothelium can perform these multiple functions because 
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rather than being one single identical sheet, there is a great deal of heterogeneity across 
organs and even within continuous vascular beds(44).  
1.1.1 Classifications of Endothelia 
The simplest distinction of endothelia is based on the size of the vasculature where they 
are found. There are two classifications: macrovasculature and microvasculature. 
Macrovasculature includes any vessel 500 µm or greater in diameter. This includes 
major arteries like the aorta, and major veins, like the superior vena cava. Everything 
else is thus considered microvasculature, the major component of which is the 
capillaries, which have a diameter of 10 µm or less. The microvasculature can also 
include smaller arterioles and venuoles (55).  
The other important classification of endothelia is based on the cellular morphology, 
which also determines permeability. There are three types of morphologies: continuous, 
fenestrated, and discontinuous (44). Continuous endothelium is the least permeable, 
with cells forming tight junctions between themselves. Continuous endothelium exists 
where controlling exchange between the blood and tissue is most important, for 
example at the blood-brain barrier. Fenestrated endothelia have very fine pores 
(fenestrae) less than 100 nm in diameter that are sealed with a semi-permeable 
diaphragm. This design allows for increased permeability of hydrophilic, low-molecular 
weight molecules and water. Fenestrated endothelium is found in locations were 
absorption and secretion are important, for example in the kidney glomerulus or in 
endocrine glands. Finally, discontinuous endothelium is the most permeable, with larger 
fenestrae (up to 1 µm in diameter). However these fenestrae lack the diaphragm seen in 
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fenestrated endothelium, and are also either lacking a basement membrane or the 
basement membrane is also porous. Discontinuous endothelium is commonly found in 
organs like the liver and spleen where they act as less selective filters for 
macromolecules or aid in filtering the blood, respectively (44). 
1.1.2 The Endothelial Cell 
1.1.2.1 Identification and Function 
Endothelial cells, the specialized cell type that makes up the endothelium tissue, can be 
identified by several unique characteristics. These characteristics contribute to the 
normal functioning of the endothelial cell, and therefore the endothelium tissue as a 
whole.  
The endothelial cell is most well known for the expression of endothelial nitric oxide 
synthase (eNOS). eNOS produces nitric oxide (NO) from the amino acid L-arginine, which 
can then alter transcription of genes in the endothelial cell and reduce vascular tone by 
promoting the relaxation of smooth muscle cells through the activation of soluble 
guanylate cyclase.   
An important feature of the endothelial cell is the endothelial glycocalyx, a layer of 
gylcoproteins and proteoglycans about 100 nm thick on the surface of the endothelial 
cell. Of the proteoglycans in the glycocalyx, up to 90% are heparin sulphate 
proteoglycans. These heparin sulphate proteoglycans bind antithrombin III, and this 
combination is what gives the endothelial surface its anti coagulation properties (44). 
The endothelial surface layer also limits mechanical stress both on the circulating red 
blood cells and the endothelial cell itself. The loss of the endothelial surface layer can 
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alter blood clotting, red blood cell life-span, blood flow dynamics through capillaries, 
and mechanical damage to endothelial cells (44). 
Endothelial cells can also be identified by the presence of specific proteins they express. 
These proteins include eNOS, vascular endothelial growth factor receptor 2, von 
Willebrand factor, vascular endothelial cadherin, and E-selectin (28).  
1.1.2.2 Endothelial Dysfunction 
Endothelial dysfunction is a blanket term that covers any change that prevents the 
endothelial cell from functioning normally. However, in practice, endothelial 
dysfunction is most commonly used to describe the decreased ability of the endothelial 
cell to produce NO, leading to increased smooth muscle tone and hypertension. 
Additionally, endothelial dysfunction may refer to a loss of the barrier function, resulting 
in vascular leakage. The inability to prevent coagulation, leading to the formation of 
clots is also a type of endothelial dysfunction. Ultimately, dysfunction may lead to the 
loss of endothelial cells through cellular death.        
Endothelial dysfunction can be caused a number of different factors including 
inflammation (43) and reactive oxygen species (ROS) (59; 63), or conditions that 
promote inflammation or ROS production such as hypertension (9) and diabetes (18).  
 
1.2 Ischemia and Reperfusion 
Ischemia is the lack of blood flow to a tissue. The area affected by ischemia is 
characterized by reduced oxygen concentrations, known as hypoxia, and nutrient 
supply. There is also an accumulation of metabolic products that cannot be removed 
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due to the lack of blood flow. It is important to know that hypoxia can occur without 
ischemia. Reperfusion is the return of oxygenated blood flow to the tissue that was 
previously ischemic.  
1.2.1 Cardiovascular Ischemia 
Ischemia in the cardiovascular system is a life threatening condition. Cardiac ischemia 
can cause a myocardial infarction, or heart attack.  The length and severity of the 
ischemic attack can influence the extent of cardiomyocyte death (30).  
1.2.2 Reperfusion and the Microvasculature 
The return of oxygenated blood flow to an ischemic tissue, especially in the heart, is 
mandatory for survival of the cardiomyocytes. However, reperfusion is the start of a 
second wave of damage, one that affects the microvascular endothelium. Perhaps the 
best evidence that the microvasculature can be damaged as a result of ischemia is the 
‘no-reflow’ phenomenon seen in cardiac angiograms 24 hours after reperfusion. No-
reflow is the lack of the return of blood flow to the microvasculature in a previously 
ischemic area of the heart, usually in correlation to the infarct zone (7; 47). 
1.2.2.1 Reperfusion-Induced Inflammation 
During ischemia the lowered oxygen concentrations lead to the release of P-selectin and 
the activation of the transcription factor NF-κB, which in turn increases the expression 
of adhesion molecules on the endothelial cell surface (7). With reperfusion, the 
returning blood brings white blood cells, including leukocytes. The leukocytes are 
attracted to the adhesion molecules expressed on the endothelial cell and are slowed 
down, a process called leukocyte rolling. Once the leukocytes have slowed enough, they 
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will adhere to the endothelial cell and then migrate through inter-endothelial spaces 
into the surrounding tissue. At this time the leukocytes are activated and release ROS 
damaging the endothelial cells ultimately leading to endothelial dysfunction and the no-
reflow phenomenon (7; 23). 
1.2.2.2. Reperfusion and ROS 
In addition to the ROS produced by recruited leukocytes, intracellular processes 
contribute to the production of ROS and endothelial damage. The return of oxygen 
allows mitochondria and intracellular oxidation proteins to function again. However, 
mitochondrial electron transport processes are uncoupled, leading to more ROS 
production and the opening of the mitochondria permeability transition pore, which 
leads to cellular apoptosis (12). Increased ROS formation through NADPH oxidase and 
xanthine oxidase interfere with the proper functioning of eNOS and directly react with 
NO, effectively reducing NO bioavailability and thus contributing to endothelial 
dysfunction (12; 23; 30).  
1.2.3 Purines and Cardiovascular Ischemia 
As mentioned above, the purine metabolizing enzyme xanthine oxidase, is capable of 
producing ROS during reperfusion. This thesis will focus on the role of purine 
transporters and metabolism in the microvascular endothelium in the context of 
ischemia-reperfusion. The following sections of this chapter will introduce the necessary 
concepts of purines, purine metabolism, and purine transport required to appreciate 
the work presented in subsequent chapters. 
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1.3 Nucleobases, Nucleosides, and Nucleotides 
Nucleobases (also known as nitrogenous bases) are the building blocks of some of the 
most important molecules in life. The bases are classified in two types, purine or 
pyrimidine. Purine bases have a double ring structure compared to the pyrimidine single 
ring structure. In fact, purine bases are pyrimidine rings fused to an imidazole ring. 
Nucleosides are nucleobases bound to a ribose or deoxyribose sugar through an N-
glycosidic bond. Nucleosides, especially the purine adenosine, have important biological 
roles. Nucleosides can also have phosphate groups added to them to become 
nucleotides. Nucleotides are the monomers of DNA and RNA. Nucleotides are also used 
as cellular energy molecules and in intracellular signalling cascades. Figure 1.1 outlines 
the relationship between these molecules. 
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Figure 1.1. Nucleobase, nucleosides, and nucleotides. 
A schematic showing the relationship between nucleobases, nucleosides, and 
nucleotides. Purine and pyrimidine nucleobases are shown in blue on the right hand 
side of the figure. On the bases, R represents the location of where the base is attached 
to the sugar moiety by the glycosidic bond. The yellow sugar in the middle of the figure 
can vary at the 2’ position, where the presence of an OH group defines a ribose, where 
as if there is only an H, the sugar is a deoxyribose, and thus a nucleoside or 
deoxynucleoside respectively. When phosphate groups, shown in red, are bound to a 
nucleoside, a nucleotide is formed. The number of phosphate groups determines the 
type of nucleotide.  
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1.4 Adenosine 
The purine nucleoside adenosine is one of the most important molecules in biology. In 
addition to well known roles as the starting point of the cellular energy molecule 
adenosine triphosphate (ATP), free adenosine can regulate the physiology of a variety of 
different systems including the CNS (sleep, anxiety, addiction), cardiovascular, renal, and 
immune system (4; 11; 27; 56). Adenosine is also important in pathophysiology, acting 
as a protector of cardiac and neuronal tissue during ischemic insult (33; 36; 40; 46). To 
accomplish these feats, adenosine must be present in the extracellular space to interact 
with specific adenosine receptors. 
1.4.1 Adenosine Bioactivity 
Adenosine mediates cellular effects through the family of P1 purinergic G protein 
coupled receptors, more commonly referred to as adenosine receptors.  To date, 4 
adenosine receptor subtypes have been identified and cloned: A1, A2A, A2B, and A3 (20).  
A1 and A3 receptors have been shown to signal through Gi, inhibiting cAMP production 
by adenlyate cyclase, where as the A2 subtypes signal through Gs, stimulating cAMP 
production (20).  
1.4.2 Adenosine in Ischemia-Reperfusion 
During ischemia adenosine is released from cardiomyocytes and local extracellular 
concentrations can rise from nanomolar to micromolar levels (26). Adenosine is formed 
in cardiomyocytes during ischemia from two major sources: breakdown of ATP and s-
adenosylhomocystine catabolism (26; 32). 
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1.4.2.1 Adenosine and Cardioprotection 
The release of adenosine during ischemia is a defensive mechanism to reduce cardiac 
infarct size. 
The A1 receptor subtype has been the most extensively studied and is the key player in 
the ability of adenosine to protect cardiac myocytes from infarction following an 
ischemic insult (10; 40; 66; 69).  In fact, A1 receptor agonism with pharmacological 
ligands can also confer cardioprotection (29; 60; 65).  However, vascular endothelial 
cells, which are also susceptible to damage from ischemia/reperfusion, do not express 
A1 receptors; the A2 subtypes are the predominant receptors (16; 19; 51). 
1.4.2.2 Endothelial Adenosine Metabolism  
While adenosine is initially cardioprotective – reducing infarct size – this excess 
adenosine will eventually accumulate in the microvasculature.  The surrounding cardiac 
microvascular endothelium acts as a ‘sink’ removing approximately 65% of released 
adenosine from the interstitium (8). 
Adenosine is metabolized intracellularly by two distinct pathways: a high affinity 
pathway via adenosine kinase, producing adenosine-5`-monophosphate, and a low 
affinity pathway via adenosine deaminase, producing the nucleoside inosine (32).  
Under normal conditions, adenosine kinase works below its Km value due to low 
intracellular free adenosine concentrations.  However, during ischemia, the excess 
adenosine leads to adenosine kinase saturation and inactivation, thus shifting 
metabolism to adenosine deaminase, increasing intracellular inosine concentrations.  
Inosine is metabolized by purine nucleoside phosphorylase to form the purine 
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nucleobase hypoxanthine. Xanthine oxidase then catalyzes the conversion of 
hypoxanthine to xanthine and xanthine to uric acid (Figure 1.2) (38). These reactions 
result in the production of superoxide anion which is converted to hydrogen peroxide by 
superoxide dismutase.  Hydrogen peroxide can either be detoxified to water and oxygen 
through the enzymes catalase and glutathione peroxidase or can be used to form strong 
oxidizing chemicals such as hypochlorous acid by myeloperoxidase (5).  In addition to 
enzymatic reactions, hydrogen peroxide can spontaneously form hydroxyl radicals in the 
presence of ferrous iron by the Fenton reaction. Hydroxyl radicals are extremely 
reactive and will oxidize almost any cellular target. In endothelial cells, nitric oxide 
produced by endothelial nitric oxide synthase can also react with hydrogen peroxide to 
form the reactive peroxynitrite anion radical. Xanthine oxidase mediated superoxide 
production is thought to contribute to cellular damage upon reperfusion, when the 
return of oxygen allows the enzyme to metabolize the hypoxanthine that accumulated 
during ischemia. In fact ROS generated by xanthine oxidase have been implicated in 
microvascular endothelial dysfunction (5; 48). 
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Figure 1.2. Endothelial purine metabolism during ischemia-reperfusion. 
During cardiac ischemia, adenosine is released from cardiomyocytes and accumulates 
within the surrounding endothelial cells. This schematic highlights the deamination 
pathway of adenosine metabolism that is enhanced when the adenosine kinase enzyme 
becomes saturated. Adenosine is metabolized to inosine by enzyme 1, adenosine 
deaminase. Enzyme 2, purine nucleoside phosphorylase, catalyzes the formation of the 
nucleobase hypoxanthine from inosine. This pathway will not progress until reperfusion 
and the return of oxygen. During reperfusion, enzyme 3, xanthine oxidase, is capable of 
metabolizing hypoxanthine to xanthine, and xanthine to uric acid. Xanthine oxidase 
mediated oxidation of hypoxanthine and xanthine produces ROS, specifically superoxide 
anion, which contributes to endothelial damage and dysfunction. 
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1.5 Nucleoside Transporters 
Regulation of extra- and intracellular nucleoside concentrations is important in 
controlling energy balance as well as cellular signalling in response to physiological 
stimuli. However, nucleosides are hydrophilic and therefore are incapable of crossing 
the plasma membrane. Two families of the solute carrier (SLC) superfamily of 
membrane transporters specialize in the transmembrane flux of nucleosides; the 
concentrative nucleoside transporters (SLC28A) and the equilibrative nucleoside 
transporters (SLC29A). 
1.5.1 Concentrative Nucleoside Transporters 
Concentrative nucleoside transporters (CNTs) are a family of sodium-dependent 
transporters. CNTs move substrates against their concentration gradients into a cell, 
while co-transporting sodium ions. CNTs require energy from ATP to function, however 
the energy is used indirectly as CNTs do not catalyze ATP hydrolysis. Since CNTs require 
sodium as a co-transported ion, they depend on larger extracellular sodium 
concentrations compared to intracellular. This gradient is achieved by the sodium-
potassium ATPase (24). 
 To date, three CNTs have been cloned: CNT1-3. CNT1 transports pyrimidines, CNT2 
purines, and CNT3 is broadly selective (24). CNTs have very specialized expression, with 
CNT1 being localized to the kidney and liver and CNT2 having highest expression in the 
intestine (41). 
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1.5.2 Equilibrative Nucleoside Transporters 
Equilibrative nucleoside transporters (ENTs) are sodium-independent, facilitative 
diffusion transporters. As such, ENTs mediate the transmembrane flux of nucleoside 
down their concentration gradient, either in to or out of the cell. Currently four 
members of the family have been identified and cloned; ENT1-4. All members share a 
common 11 membrane spanning domain topology with an intracellular N-terminus, and 
extracellular C-terminus, a large glycosylated extracellular loop between TMD1 and 
TMD2, and a large intracellular loop between TMD6 and TMD7. The orientation of the 
termini and loops was confirmed by the work of Sundaram and colleagues in 2001 (57). 
(Figure 1.3).  
1.5.2.1 ENT1 
ENT1 is the most widely distributed and most studied of the ENTs. Before the gene was 
cloned, ENT1 was defined pharmacologically as the nucleoside transport system that 
was sensitive to nanomolar concentrations of the nucleoside analogue 
nitrobenzylmercaptopurine riboside (NBMPR). Consequently, this transporter was 
referred to as es, or equilibrative sensitive (1; 68). ENT1 is also inhibited by vasoactive 
drugs dipyridamole, draflazine, and dilazep (62). Inhibition of ENT1 by these drugs 
promotes local increases in adenosine concentrations, leading to enhanced adenosine 
receptor signalling and a vasodilation response (34).  ENT1 is also exploited in 
chemotherapy to mediate the uptake of nucleoside analogue drugs in to tumour cells 
(13; 25; 61), or cells infected with parasites (e.g. malaria) (61; 68) or viruses (e.g. HIV) 
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(21; 35; 45). The level of expression of ENT1 in various cancers has been linked to 
chemotherapy resistance and survival rates (17; 42). 
The human ENT1 transporter was first cloned in 1997 (25), followed by the mouse in 
2000 (31). Interestingly, the mouse ENT1 differed from human in respect to a variety of 
splice variants that produced three different proteins, mENT1a, mENT1b, and 
mENT1∆11(31). The mENT1a and 1b variants differed in the number of protein kinase 
CKII consensus sites, which resulted in a sensitive (1b) or insensitive (1a) transporter to 
the effects of inhibiting CKII with the compound TBB(6). The human ENT1 is more like 
the mENT1b variant (6). The mENT1∆11 variant lacked the last three transmembrane 
domains. Interestingly, the protein was still made and fully functional, but lacked the 
ability to be irreversibly linked to NBMPR via photoaffinity labelling (50).  
1.5.2.2 ENT2 
ENT2 varies from ENT1 in several key ways. First, ENT2 is insensitive to NBMPR, leading 
to the early identifier of ei, equilibrative insensitive. Chimeric proteins of rat ENT1 and 
ENT2 identified transmembrane regions 3-6 as the site of NBMPR sensitivity (58). In  
studies using human transporters, two glycine residues, G154 and G179, in 
transmembrane domains 4 and 5 respectively, were identified as conferring NBMPR 
sensitivity to ENT1 (53; 54). In fact, in ENT2, the residue at position 154 is a serine, 
which may contribute to the lack of NBMPR sensitivity (54). Second, ENT2 is capable of 
transporting nucleobases, in addition to nucleosides. This feature of ENT2 will be 
discussed in Section 1.6.  
17 
 
ENT2 also has a more discrete expression profile compared to ENT1, with the highest 
level of expression in skeletal muscle (41). Other tissues that express ENT2 at notable 
levels are kidney, small intestine, stomach, and pituitary gland (41).  
1.5.2.3 ENT3 
Unlike ENT1 and ENT2, ENT3 is not found on the plasma membrane (68). Instead, ENT3 
is localized to lysosomes due to  a endosomal/lysosomal targeting motif in the N-
terminal of the protein (2). ENT3 is broadly selective for nucleosides and is capable of 
transporting the nucleobase adenine, but not hypoxanthine (2). Additionally, ENT3 
differs from ENT1 and ENT2 by requiring an acidic pH of 5.5 to operate optimally (2).   
1.5.2.4 ENT4 
ENT4 was originally identified as a monoamine transporter in the brain and named 
plasma membrane monoamine transporter (PMAT) (15; 70). Substrates were 
neurotransmitters such as serotonin and dopamine, and the neurotoxin MPP+ (14). 
However, it was subsequently found that ENT4 was expressed in the heart and gained 
the ability to transport adenosine at acidic pH, whereas serotonin transport was 
insensitive to pH (3). To date, no other nucleoside (or nucleobase) substrates of ENT4 
have been identified (68).  
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Figure 1.3. Predicted 2-dimensional structure of ENT proteins. 
The predicted 2-dimenstional structure of ENT proteins with the intracellular N-
terminal, extracellular C-terminal, and 11 transmembrane domains. A large gylcosolated 
extracellular loop can be found between transmembrane domains 1 and 2. Between 
transmembrane domains 6 and 7 there is a large intracellular loop. The circle represents 
the location of the endosomal/lysosomal targeting motif found in ENT3. The solid 
square highlights the regions of transmembrane domains 4 and 5 where G154 and G179 
are found that confer NBMPR sensitivity to ENT1. The dashed line box around 
transmembrane domains 5 and 6 represent the part of ENT2 that is responsible for 
conferring the ability to transport nucleobases. 
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1.6 Nucleobase Transporters 
As with nucleosides, nucleobases are unable to cross the plasma membrane without 
specialized transport proteins to facilitate the process. However, unlike nucleoside 
transport, nucleobase transport in mammalian cells not been highly studied. 
1.6.1 ENT2 
As mentioned in Section 1.3.2.2, the nucleoside transporter ENT2 is also capable of 
transporting nucleobases. Substrates recognized include the purine nucleobase 
hypoxanthine (39; 49), the pyrimidine nucleobase uracil (67), and the chemotherapeutic 
nucleobase analogues 6-mercaptopurine and 6-thioguanine (37). Uptake of nucleobases 
by ENT2 is sodium-independent and can be inhibited by excess nucleobases and 
nucleosides (67). Additionally, the nucleoside transport inhibitors NBMPR and 
dipyridamole prevent hypoxanthine uptake through ENT2 at concentrations of 10 µM 
(49; 67).  
The affinity of ENT2 for nucleobases varies in the literature. Recombinant human ENT2 
and rat ENT2 expressed in Xenopus oocytes have reported Km values for hypoxanthine of 
700 ± 100 µM and 1000 ± 100 µM respectively (67). In primary rat microvascular 
endothelial cells (MVECs), the reported Km value for hypoxanthine was 300 ± 100 µM 
(49).  
In addition to uptake, ENT2 is capable of releasing nucleobases from cells.  In primary 
rat MVECs, hypoxanthine was released from cells with a Km of 189 ± 67 µM, very similar 
to the reported uptake affinity in the same cells (49). The efflux of hypoxanthine was 
inhibited by dipyridamole (49). 
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Using chimeras of rat ENT1 and ENT2 proteins, it was found that ENT1 gained the ability 
to transport hypoxanthine when transmembrane regions 5 and 6 were replaced with 
the corresponding regions from ENT2 (Figure 1.3) (67).  
1.6.2 SLC23a4/Sodium-dependent nucleobase transporter 1 (SNBT1) 
Recently, a novel nucleobase transporter was cloned from rat small intestine (64). This 
transporter belonged to the SLC23 family, the sodium-dependent ascorbic acid 
transporter (SVCT) family, and was predicted to have 12 transmembrane domains. 
Recombinant SNBT1 expressed in HEK293 cells was able to transport guanine, 
hypoxanthine, xanthine, thymine, and uracil. Notably, SNBT1 was unable to transport 
adenine or ascorbic acid. Transport of xanthine and uracil was sodium-dependent and of 
high affinity, with Km values of approximately 80 µM and 20 µM respectively (64). 
Uptake could be inhibited by nucleobase analogues 5-fluorouracil and 6-
mercaptopurine, as well as the ENT inhibitor dipyridamole. Nucleosides had no effect on 
SNBT1-mediated transport of nucleobases, nor did another ENT inhibitor, NBMPR (64). 
A human ortholog was found by in silico analysis; however the human gene for SNBT1 
contained seven exons instead of the twelve exons found in the rat gene. The exons 
missing corresponded to highly conserved, transmembrane domain encoding regions in 
the rat gene (64). Reverse-transcriptase polymerase chain reaction (RT-PCR) was 
performed and it was determined that the human SNBT1 gene is in reality a 
pseudogene, and thus does not produce a functional protein (64). 
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1.6.3  SVCT/Nucleobase-ascorbate Transporter (NAT) 
It seems strange to discuss ascorbic acid transporters in a section on nucleobase 
transporters, as the chemical structure of ascorbic acid resembles a sugar more so than 
a nucleobase (52). Moreover, there is no evidence that SVCTs can transport nucleobases 
at all.  
As mentioned in the previous section, SVCTs belong to the SLC23 family of transport 
proteins. In humans, the SLC23 members are SVCT1 and SVCT2 (52). However, in lower 
organisms like bacteria, fungi, and plants, NATs are common and actually transport 
nucleobases (although they may not necessarily transport ascorbic acid) (22).  The most 
well known transporters, UrpA, UrpC, and UraA are fungal uric acid-xanthine 
transporters found in Aspergillus nidulan, and bacterial uracil transporter of Escherichia 
coli respectively.   
In fungi, NATs are thought to be scavengers of uric acid and xanthine as a source of 
nitrogen. Bacteria, on the other hand, use NATs to scavenge uracil for nucleoside 
synthesis, which can then be used for nucleotide and DNA/RNA production. 
It is not understood how or why the evolutionary progression of NATs in lower 
organisms resulted in the SVCT proteins in humans that are incapable of transporting 
nucleobases.  
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RESEARCH QUESTIONS, GENERAL HYPOTHESES, AND COMMON METHODOLOGIES 
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2.1 Research Questions 
The microvasculature has been an understudied tissue with respect to nucleoside and 
nucleobase transport. Human umbilical vein endothelial cells have been a popular 
model to study nucleoside transport, however these cells are derived from a 
macrovessel. Nucleobase transport in humans is even less studied and those studies 
that have been conducted tend to focus on infection or cancer, as there are a variety of 
nucleobase analogues used as chemotherapeutic agents, including 5-FU, 6-MP, and 6-TG 
(18; 29; 31). 
Thus, to understand nucleoside and nucleobase transport and metabolism in the human 
microvasculature, the most direct approach is to use human primary microvascular 
endothelial cells. What purine transporters are expressed in MVECs? Are MVECs capable 
of transporting nucleobases? These are the kinds of basic questions that were 
addressed early on in this work. 
Once those basic questions are answered, the focus turns to regulation of the 
transporters. ENT1 regulation is an area of extensive research, however the models 
used are generally cancer cells lines, artificial over-expression systems, non-human cell 
lines, and even non-mammalian organisms. While important for general understanding 
of ENT1 regulation, these data may not be readily extrapolated to normal human cells. 
Does ENT1 respond in the same manner to intracellular kinase activity in primary cells as 
compared to cancerous or artificial cell lines? How are nucleobase transporters 
regulated? Additionally, questions regarding how nucleoside and nucleobase 
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transporters are affected by reactive oxygen species and hypoxia/ischemia have not 
been addressed.  
Finally, the role of ENT1 in the regulation of purine homeostasis is still not completely 
understood. By using an ENT1 null animal, questions regarding compensatory 
mechanisms in purine handling can be addressed. As well, given the important 
cardiovascular role of adenosine, questions about the cardiovascular health and 
functionality of animals with comprised adenosine handling can also addressed. 
 
2.2 Hypotheses 
2.2.1 Chapter 3 – Human Primary MVEC Characterization 
As outlined in Chapter 1, movement of nucleosides and nucleobases across the cell 
membrane requires specialized transport proteins. Both ENT1 and ENT2 contribute to 
nucleoside transport, and as in the case with primary rat MVECs from skeletal muscle, 
ENT2 can contribute up to 50 % of nucleoside transport capacity (3). Nucleobases, on 
the other hand appear to be transported only by ENT2 as other known nucleobase 
transporters do not exist in human cells (39; 40). Therefore it is hypothesized that: 
 Uptake of nucleosides, as measured with 2-[3H]chloroadenosine, in human 
MVECs is mediated by ENT1 and ENT2. ENT2 will contribute up to 50 % of total 
uptake capacity. 
 Nucleobase uptake, as measured with [3H]hypoxanthine, is facilitated by ENT2, 
not ENT1 in human MVECs.  
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2.2.2 Chapter 4 – Regulation of purine transporters in human primary MVECs. 
Evidence has been amassed in other cell types that support the regulation of ENT1 
function by a variety of molecular mechanisms, including intracellular kinases PKA (10), 
PKC (9; 21), CKII (4; 35), adenosine A2 receptors(15; 32), and a receptor tyrosine kinase 
(RTK) (37). Transcriptional regulation of ENT1 has also been studied and found to be 
altered by hypoxia inducible factor 1 alpha (1; 13), elevated glucose (33), and nitric 
oxide (16; 17).  ENT1 and ENT2 function has been shown to decrease in response to 
hypoxia in a variety of models (5; 6; 19; 27; 28). However, ENT2 may not be affected by 
elevated glucose (2). Additionally, adenosine uptake has been affected by peroxynitrite 
treatment (36). Therefore it was hypothesized that: 
 Both ENT1 and ENT2 function is regulated by the activation and/or inhibition of 
the intracellular kinases PKA, PKC, or CKII. 
 Nucleoside and nucleobase uptake is diminished after hypoxia, ischemia, or 
oxidative stress. 
 Nucleoside and nucleobase uptake is sensitive to regulation by vascular 
endothelial growth factor (VEGF), a major protein produced during hypoxia that 
acts through a family of RTKs  (41).  
2.2.3 Chapter 5 – MVECs from ENT1-/- Mice 
The ENT1-/- mouse generated by Choi and colleagues (8) has been studied at the level of 
the central nervous system (7; 8; 30; 38), the heart (34), kidney (22), and anti-viral 
pharmacokinetics (14). No studies on the vasculature have been conducted. Given the 
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importance of nucleosides in the vasculature, MVECs were isolated from wild-type and 
ENT1-/- mice and characterized. 
It was hypothesized that:  
 As previously found in rat MVECs, mouse primary MVECs from skeletal muscle 
will express ENT1 and ENT2, with ENT2 accounting for up to 50% of total 
nucleoside uptake capacity. 
 ENT2 expression or other ENT subtypes will be up-regulated in ENT1-/- MVECs to 
compensate for the lack of the primary nucleoside transporter ENT1. 
 Genes related to metabolism, and/or signalling would have altered expression 
levels to compensate for changes in cellular purine metabolite concentrations. 
 Mouse ENT1 and ENT2 would respond in a similar manner to hypoxia, ischemia, 
and oxidative stresses compared to human ENT1 and ENT2. 
2.2.4 Chapter 6 – Additional Phenotypes of ENT1-/- Mice 
The ENT1-/- mouse appeared phenotypically normal, however only ethanol consumption 
and anxiety behaviour was examined (7; 8). No in-depth phenotype profile was 
generated. An independent laboratory generated their own ENT1-/- mouse and found 
altered gene expression with quantitative PCR that was different between tissues (20). 
Adenosine accumulates in extracellular spaces during times of stress, otherwise the 
amount of free adenosine is minimal (11). 
Therefore it was hypothesized that: 
 Circulating adenosine concentrations will be reduced in resting ENT1-/- mice 
relative to wild-type. 
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 Organs will have altered expression of genes related to purine transport and 
metabolism 
 
2.3 Common Methodologies 
Many of the experiments relied on a common set of techniques and methods. In the 
interest of clarity and readability, the basics of those techniques are described here, 
allowing the unique details of each experiment to stand out without being lost in 
repetition. 
2.3.1 Mammalian Cell Culture 
The most common cell type used was primary human cardiac microvascular endothelial 
cells obtained from Lonza (Walkersville, MD). These cells were used between passage 4-
7 and cultured in EGM2-MV medium as supplied by the manufacture. Medium was 
changed 24 hr following seeding and then every 48 hr thereafter. Generally, MVECs 
were passaged at a ratio of 1:7 as determined by cell counting to seed 5,000 cells/cm2 
growth area as instructed by the supplier. 
Additional cell types used when required are described in the appropriate chapter. All 
cultured cells were maintained in a humidified atmosphere of 95% air-5% CO2 at 37°C. 
2.3.1.1 Cell Harvesting 
All [3H]NBMPR binding assays and transport assays were conducted with cell 
suspensions to achieve the short incubation times required for transport kinetic 
analysis. All cell types were harvested in the same manner. Cells were first washed with 
phosphate-buffered saline (PBS: in mM: 137 NaCl, 6.3 Na2HPO4, 2.7 KCl, 1.5 KH2PO4, 0.9 
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CaCl2·2H2O, 0.5 MgCl2·6H2O; pH 7.4) followed by trypsinization with 0.05% trypsin-0.53 
mM EDTA. Trypsinized cells were then diluted 4-fold in 500µg/ml trypsin inhibitor in PBS 
and collected by centrifugation at ~220 x g for 5 minutes. Pellets were washed in the 
desired assay buffer, re-centrifuged, and resuspended in the same buffer for immediate 
use in the assay. 
2.3.2 [3H]NBMPR Binding Assay 
To measure the amount of ENT1 protein present on the cell membrane, radioligand 
binding using [3H]NBMPR was employed. NBMPR is a high affinity, non-transported 
ligand that is selective for ENT1. Assays were conducted in 13x100 mm boroscillicate 
glass tubes in duplicate. A working stock of [3H]NBMPR at a desired concentration 
(usually 1.5 or 5 nM) was made by diluting stock [3H]NBMPR PBS and adjusted to the 
required disintegrations per minute (DPM) as dictated by the specific activity of the 
stock. Volumes of [3H]NBMPR were added to give the desired concentration in a final 
volume of 1 ml. PBS was added to a volume of 925 µl and the reaction was started by 
adding 75 µl of cell suspension. To determine non-specific binding, a set of tubes 
included 10 µM nitrobenzylthioguanine riboside (NBTGR) or dipyridamole. Reactions 
were incubated at room temperature (~22°C) for 45 min to allow equilibrium to be 
achieved. Assays were terminated by filtration using a 24-port Brandell Cell Harvester 
with ice cold 10 mM Tris buffer (pH 7.4) and collected on Whatman A-937 grade filter 
paper strips. Perforated filter paper circles were placed in scintillation vials, mixed with 
5 ml of liquid scintillation cocktail and incubated overnight (≥12 hr) before counting on a 
liquid scintillation analyzer.  
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Data were obtained as DPM and converted to pmol using the equation:  
pmol = DPM/specific activity (DPM/fmol)/1000.  
Specific binding was defined as the difference between total binding (no inhibitor 
present) and non-specific binding (in the presence of 10 µM inhibitor). Equilibrium free 
concentrations of [3H]NBMPR were determined for each condition (total, specific, non-
specific) by subtracting pmol bound from pmol added and dividing by the assay volume 
of 1 ml. Since one molecule of [3H]NBMPR binds to one ENT1 protein (23; 24), specific 
bound pmol [3H]NBMPR were converted to ENT1 per cell using the equation ENT1/cell = 
pmol/cells ml-1 * 6.023x1011 molecules pmol-1. Cell concentrations were obtained using 
a haemocytometer or a Bio-Rad TC-10 automated cell counter. 
2.3.3 Oil-Stop Transport Assay 
To measure accurately the transport kinetics of transporters a reliable, reproducible, 
efficient stopping technique is required. To achieve this, the oil-stop method was 
employed. A schematic overview of the technique is presented in Figure 2.1. 
2.3.3.1 [3H]Substrate Preparation 
In contrast to [3H]NBMPR binding, much higher concentrations of substrate are required 
for transport assays. To reduce the amount of [3H]substrate required, the desired 
concentrations of substrate were established with non-radioactive versions of the 
substrate. These non-radioactive substrate concentrations were then spiked with small 
amounts of radioactive substrate to allow the accumulation of substrate inside the cell 
to be measured by liquid scintillation counting. Standards of the spiked substrate were 
taken to determine the specific activity of each concentration using the equation:  
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specific activity  = dpm/[substrate]*volume of standard 
2.3.3.2 Transport Assay Setup – Nucleoside Substrate 
A mixture of Dow 550 silicone oil was mixed with light mineral oil in a 21:4 v/v ratio. This 
mixture had a specific gravity of 1.04, allowing aqueous solutions to be layered on top of 
the oil. Transport assays were performed in 1.5 ml microcentrifuge tubes, in which 200 
µl of oil was added. On top of the oil cushion, 250µl of 2-[3H]chloroadenosine (prepared 
as described in Section 2.3.3.1) was placed. Tubes were centrifuged briefly to establish a 
clean aqueous-oil interface. Cells were harvested as described in section 2.3.1.1 and 
divided into lots for ‘total’ uptake and ‘non-mediated’ uptake. ‘Non-mediated’ uptake 
cells were pretreated with 10 µM NBMPR and 10 µM dipyridamole for 15 min at room 
temperature, whereas ‘total’ uptake cells were treated with an equal volume of DMSO 
(vehicle control). To initiate uptake, a 250µl aliquot of cell suspension was added to the 
microcentrifuge tube and incubated at room temperature for a desired time point 
(range 3-180 s). 2-Chloroadenosine is an agonist at adenosine receptors and thus there 
is a potential that uptake may be affected by adenosine receptor signaling. Peak cyclic 
AMP production by 2-chloroadenosine varies on cell type and has been reported in the 
range of 30 s to 5 min (12; 25; 26). Since the most common time point used in uptake 
studies was 10 s, contribution of adenosine receptor activation was expected to be 
negligible. Following incubation the tube was centrifuged at ~10,000 x g for 10 s to 
pellet the cells in the oil layer of the tube while the aqueous [3H]substrate remains 
above the oil. This removal of the cells from the substrate stops transport. The aqueous  
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Figure 2.1. Schematic of the Oil-Stop Method. 
A [3H]labelled substrate was layered on top of Dow 550 silicone oil was mixed with light 
mineral oil (21:4 v/v). Cells harvested by trypsinization were resuspended in buffer. An 
aliquot of cells was added to the tube and incubated with the [3H]substrate for the 
desired treatment time. Uptake was terminated by centrifugation at ~10,000 x g for 10 s 
to pellet the cells in the oil layer. The aqueous [3H]substrate was removed and the oil 
layer was washed with ddH2O before removal. The cell pellet was digested overnight in 
1 M sodium hydroxide. The following day, the cell digest was transferred to a liquid 
scintillation vial and mixed with liquid scintillation fluid for determination of [3H] content 
by liquid scintillation counting. 
(Original schematic drawn by Kevin Robillard) 
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[3H]substrate was then removed by aspiration and the top of the oil was washed with 
ddH2O. 
Subsequently, the water and oil were removed by aspiration to expose the cell pellet. 
Cells were digested overnight in 250µl of 1 M NaOH at room temperature. A 220 µl 
aliquot of cell digest was then transferred to a scintillation vial, mixed with 5 ml of liquid 
scintillation cocktail and allowed to sit overnight before counting on a liquid scintillation 
analyzer. 
2.3.3.3 Transport Assay Setup – Nucleobase Substrate 
The set up for nucleobase transport was essentially the same as nucleoside uptake 
except for one key difference. Most experiments were performed with a competing, 
non-radioactive nucleobase for the non-mediated condition. Since this competitor could 
also be transported and metabolized by cells, pre-incubation with the cells was not a 
possibility. Therefore, a high concentration of the competing nucleobase had to be 
included with the [3H]substrate in the microcentrifuge tube. The most common inhibitor 
was adenine, where 25 µl of 20 mM adenine was added to uptake tubes for non-
mediated uptake; total uptake tubes received 25 µl of buffer. To maintain the a final 
volume of 500 µl in the uptake tube after the addition of cells, only 225 µl of cell 
suspension was added to the uptake tubes to initiate uptake. From the addition of cells 
on, nucleobase transport assays were treated identically to the nucleoside uptake tubes, 
with the exception of longer incubation times to account for slower transport rates.  
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2.3.3.4 Intracellular Volume 
Uptake of substrates was normalized to the amount of intracellular water volume. To 
determine total volume of the cell pellet, cells were incubated with 3H2O for 3 min at 
room temperature and then processed as described in section 2.3.3.2. To determine 
extracellular volume of the pellet, non-mediated uptake was extrapolated back to zero 
time to estimate the dpm present on the outside of the cells. Volume was then 
determined with the equation: 
Extracellular volume = dpmt=0/specific activity (dpm/µl) 
Intracellular volume was then defined as the difference between total volume and 
extracellular volume.  
2.3.3.5 Transport Data Analysis 
Mediated uptake, that is, the uptake of substrate for which the transporter is directly 
responsible, was defined as total uptake (in the absence of inhibitors) minus non-
mediated uptake (in the presence of inhibitors) in pmol/µl of intracellular water volume. 
Using GraphPad Prism software the Michaelis-Menten equation: Y=Vmax*X/(Km+X), 
where X was the concentration of substrate, was used to fit each curve and derive 
kinetic parameters. 
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CHAPTER THREE 
 
NUCLEOSIDE AND NUCLEOBASE TRANSPORTERS OF PRIMARY HUMAN CARDIAC 
MICROVASCULAR ENDOTHELIAL CELLS: CHARACTERIZATION OF A NOVEL TRANSPORTER1 
  
 
 
 
 
 
 
 
 
 
 
1A version of this chapter has been published: 
Bone, DBJ and Hammond JR. Nucleoside and nucleobase transporters of primary human 
cardiac microvascular endothelial cells: Characterization of a novel nucleobase 
transporter. Am J Physiol Heart Circ Physiol. Dec; 293(6):H3325-32. Epub: 2007 Oct 5. 
doi:10.1152/ajpheart.01006.2007
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3.1 Introduction 
The transmembrane flux of hydrophilic nucleosides and nucleobases is mediated by 
integral membrane proteins, including equilibrative nucleoside transporters (SLC29; 
ENTs) and concentrative nucleoside transporters (SLC28; CNTs) (4; 17). These nucleoside 
transporters (NTs) have roles in salvaging endogenous nucleosides, such as adenosine, 
and have been exploited for cancer chemotherapy and treatments for viral infection 
(21). The CNTs are Na+-dependent transporters that facilitate movement of nucleosides 
against their concentration gradient. Three members of the CNT family have been 
cloned, each with distinct substrate specificity. CNT1 transports adenosine and 
pyrimidine nucleosides, CNT2 transports purine nucleosides and uridine, and CNT3 is 
broadly selective for both purine and pyrimidine nucleosides (27). The ENTs, on the 
other hand, are Na+-independent facilitative diffusion transporters that rely on the 
concentration gradient of the substrate and thus are capable of mediating both influx 
and efflux of nucleosides. The two classical ENTs have been identified as being sensitive 
(ENT1) or insensitive (ENT2) to the nucleoside analog nitrobenzylmercaptopurine 
riboside (NBMPR) (36). ENT2 is also able to transport nucleobases like hypoxanthine 
(26). Recently, two more ENT family members have been identified: ENT3 is associated 
with intracellular acidic environments (19), and ENT4 was initially discovered as a 
monoamine transporter in the brain (15).  
The purine nucleoside adenosine is an important compound in the vasculature. Acting 
through a variety of G-protein-coupled receptors, adenosine mediates physiological 
actions such as, among others, vasodilation, bradycardia, and inhibition of platelet 
50 
 
aggregation (33). NTs play a role in regulating adenosine levels in the vasculature by 
facilitating its removal from the extracellular environment (23). In fact, cardiovascular 
drugs like dipyridamole inhibit NTs, thereby extending the lifespan of adenosine in the 
vasculature (30). Analogs of NBMPR (38) and dipyridamole (22) are now being designed 
and tested for the potential to act as cardioprotective agents, thus highlighting the 
importance of vascular NTs as potential therapeutic targets.  
Investigations of NTs in the vasculature have primarily utilized models derived from the 
macrovasculature, with a particular focus on umbilical vein endothelial cells, due to the 
ease of obtaining the source tissue. However, the majority of exchange between the 
blood and peripheral tissues occurs in the microvasculature, in which microvascular 
endothelial cells (MVECs) are responsible for the regulation of this exchange. It has been 
shown that endothelial cells in the heart are responsible for the uptake of up to 65% of 
free adenosine (12). Therefore, changes in the ability of MVECs to transport or 
metabolize adenosine can have profound effects on the cardiovasculature and 
surrounding tissues.  
Here, we describe the nucleoside and nucleobase transport capabilities of primary 
human cardiac MVECs.  
 
3.2 MATERIALS AND METHODS  
3.2.1 Materials.  
2-[8-3H]chloroadenosine (4-7 Ci/mmol), [2,8-3H]hypoxanthine (24-35 Ci/mmol), [2,8-
3H]adenine (50 Ci/mmol), [3H] NBMPR (5.5 Ci/mmol), and [3H]water (1 mCi/g) were 
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purchased from Moravek Biochemicals (Brea, CA). Nonradiolabeled 2-chloroadenosine, 
hypoxanthine, NBMPR, nitrobenzylthioguanine riboside, dipyridamole {2,6-
bis(diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d] pyrimidine}, and all other 
nucleosides and nucleobases were obtained from Sigma-Aldrich (St. Louis, MO). Dilazep 
{N,N'-bis[3-(3,4,5-trimethoxybenzoyloxy)propyl] homopiperazine} was from Asta Werke 
(Frankfurt, Germany), and draflazine {2-(aminocarbonyl)-4-amino-2,6-dichlorophenyl-4-
[5,5-bis(4-fluorophenyl)-pentyl]-1-piperazineacetamide 2HCl} was provided by Janssen 
Research Foundation (Beerse, Belgium).   
3.2.2 Cell culture.  
Culture of primary human cardiac MVECs is described in Chapter Two. HMEC-1 cells 
were obtained from the Center for Disease Control (Atlanta, GA) and cultured in MCDB-
131 medium supplemented with 10 % fetal bovine serum (FBS), 100 U/ml penicillin G, 
100 µg/ml streptomycin sulfate, 10 ng/ml epidermal growth factor, and 1 µg/ml 
hydrocortisone. HMEC-1 cells were used between passage 15-40. Some studies required 
the use of additional cell types, and all media and culture reagents were from Invitrogen 
(Burlington, ON). All cells were cultured and harvested as described in Chapter Two. 
Primary rat MVECs were isolated as previously described (3) and cultured in M199 
medium containing 10% FBS, 100 U/ml penicillin G, 100 µg/ml streptomycin sulfate, 0.25 
µg/ml amphotericin B, 2 mM L-glutamine, 0.025 U/ml heparin, and 75 µg/ml endothelial 
cell growth supplement. Nucleoside transporter-deficient PK15 cell line (PK15NTD) and 
PK15NTD-human ENT2 (hENT2) cells were a generous gift from Dr. Ming Tse (Johns 
Hopkins University) and were cultured in MEM containing 10% bovine growth serum 
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with penicillin G (100 U/ml), streptomycin sulfate (100 mg/ml), nonessential amino acids 
(0.1 mM), and sodium pyruvate (1 mM). G418 (300 µg/ml) was added to the culture 
medium of the PK15NTD-human ENT2 cells to maintain a selection pressure on the 
stable transfection. UMR-108 and HEK-293 cells were a gift from Dr. Peter Chidiac 
(Department of Physiology and Pharmacology, University of Western Ontario). UMR-108 
cells were cultured in α-MEM with 10% FBS, penicillin G (100 U/ml), and streptomycin 
sulfate (100 mg/ml). HEK-293 cells were cultured in MEM with 10% FBS and 10 µg/ml 
gentamicin. Madin-Darby canine kidney cells were cultured in MEM with 10% FBS and 
penicillin G (100 U/ml) and streptomycin sulfate (100 µg/ml). Cells were collected by 
centrifugation, and pellets were washed in either PBS or a Na+-free buffer [NMG (in 
mM): 140 N-methyl-D-glucamine, 5 KCl, 4.2 KH2PO4, 0.36 K2HPO4, 10 HEPES, 1.3 
CaCl2·2H2O, and 0.5 MgCl2·6H2O; pH 7.4] and resuspended in the same buffer as 
required for immediate use. In some cases, cells were depleted of ATP by sequential 
incubation at 37°C with rotenone and 2-deoxyglucose as described previously (3). 
3.2.3 Substrate efflux assay.  
ATP-depleted cells were loaded with 100 µM [3H]hypoxanthine for 10 min. Cells were 
collected by brief centrifugation and resuspended in buffer ± 1 mM adenine. One ml 
aliquots were taken at desired time points and centrifuged through a mixture of silicone 
and light mineral oil (21:4 v/v) to terminate efflux. Remaining [3H] activity in the pellet 
was determined and expressed as pmol/106 cells.  
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3.2.4 Data analysis and statistics.  
Data are presented as means ± SEM. Curves were fitted with the use of Graphpad Prism 
4.03 software. Where appropriate, statistical analysis was performed using a two-tailed 
Student's t-test with P < 0.05 considered significant. Ki values were determined with the 
Cheng-Prusoff relationship (10).  
 
3.3RESULTS  
3.3.1 [3H]NBMPR binding.  
Specific [3H]NBMPR binding to human cardiac MVECs revealed 53,000 ± 6,000 ENT1 
sites/cell with a Kd of 0.031 ± 0.003 nM (Figure 3.1). A second population of low-affinity 
(Kd > 5 nM) binding sites was also present.  
3.3.2 2-[3H]Chloroadenosine uptake.  
A time course profile showed that human cardiac MVECs accumulated 10 µM 2-
[3H]chloroadenosine with an initial rate of 1.6 ± 0.5 pmol/µl/s. Incubation of cells with 
50 nM NBMPR to block ENT1-mediated uptake resulted in a rate of uptake that was not 
significantly different from that seen in the presence of 10 µM dipyridamole and NBMPR 
(Figure 3.2A). Furthermore, when uptake buffer was changed from NMG (–Na+) to PBS 
(+Na+), there was no change in initial rate of uptake or maximal intracellular 
accumulation (Figure 3.2B). Uptake of increasing concentrations of 2-
[3H]chloroadenosine demonstrated a Km of 42 ± 19 µM and a Vmax of 3.4 ± 1.0 pmol/µl/s 
(Figure 3.2C). Inhibition of 10 µM 2-[3H]chloroadenosine was examined with the classical 
ENT inhibitors NBMPR, dipyridamole, draflazine, and dilazep. All four compounds (Figure 
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3.3) displayed high-affinity inhibition with no indication of an inhibitor-insensitive (ENT2) 
component to the uptake. The lack of ENT2 was especially evident from the monophasic 
NBMPR inhibition curve. Ki values derived from these data are listed in Table 3.1. 
3.3.3 [3H]hypoxanthine uptake.  
Human cardiac MVECs were able to accumulate [3H]hypoxanthine under Na+-free 
conditions despite an apparent lack of ENT2 activity. Uptake was insensitive to 
dipyridamole; however, the addition of 1 mM adenine was able to block uptake (Figure 
3.4A). As with 2-[3H]chloroadenosine, Na+ had no effect on the uptake of 
[3H]hypoxanthine (Figure 3.4B). ATP depletion of the cells before exposure to 5 µM 
[3H]hypoxanthine reduced the extrapolated maximum intracellular accumulation from 
39 ± 18 to 4.1 ± 0.2 pmol/µl (Figure 3.4C). Consequently, subsequent experiments were 
performed under ATP-depleted conditions to minimize the effects of intracellular 
metabolism. With the use of a 15-s time point to estimate initial rate, the Vmax of 
[3H]hypoxanthine influx was determined as 1.6 ± 0.3 pmol/µl/s with a Km of 96 ± 37 µM 
(Figure 3.4D). Additional nucleobases were tested for the ability to inhibit 5 µM 
[3H]hypoxanthine uptake. Adenine was the most effective, with a Ki of 19 ± 7 µM. 
Guanine produced significant inhibition of 17 ± 4% at a concentration of 1 µM (Figure 
3.5A). Higher concentrations of guanine could not be achieved because of low solubility 
in assay buffers at physiological pH. Pyrimidines were much less effective, with thymine 
producing inhibition only at 1 mM (59 ± 6%) and cytosine and uracil had no effect at 1 
mM concentrations. 
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The chemotherapeutic thiopurine analogs 6-mercaptopurine (6-MP) and 6-thioguanine 
(6-TG) and the pyrimidine analog 5-fluorouracil (5-FU) were also examined. Both 6-MP 
and 6-TG were able to inhibit 5 µM [3H]hypoxanthine uptake with an IC50 of 37 ± 11 µM 
and 20 ± 2 µM, respectively (Figure 3.5B). As with other pyrimidines, 5-FU had no effect 
on [3H]hypoxanthine uptake (data not shown).  
To confirm that the dipyridamole-insensitive hypoxanthine uptake mechanism was 
nucleobase selective, the nucleosides adenosine and uridine were tested. Adenosine 
had an extrapolated IC50 value of 1.3 ± 0.9 mM (Figure 3.5A), and uridine had no effect.  
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Figure 3.1. 3H-labeled nitrobenzylmercaptopurine riboside (NBMPR) binding to human 
cardiac microvascular endothelial cells (MVECs).  
Human cardiac MVECs were incubated with increasing concentrations of [3H]NBMPR in 
the presence (nonspecific) or absence (total) of 10 µM nitrobenzylthioguanine riboside 
(NBTGR) for 45 min. Cells were collected on glass fiber filters, and cell-associated 3H 
content was determined. Specific binding was determined as total bound minus 
nonspecific bound (n = 5). 
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Figure 3.2. 2-[3H]chloroadenosine uptake characteristics of human cardiac MVECs.  
A: time course of 2-[3H]chloroadenosine uptake. Human cardiac MVECs were incubated 
with 10 µM 2-[3H]chloroadenosine for the times indicated. Some cell lots were 
preincubated with 50 nM NBMPR to inhibit only equilibrative nucleoside transporter 1 
(ENT1). Total uptake (no inhibitors) minus ENT1 inhibited uptake represents ENT2-
mediated uptake. Nonmediated uptake was determined with cells preincubated with 10 
µM NBMPR and 10 µM dipyridamole (n = 5). B: Effect of sodium (Na+) on 2-
[3H]chloroadenosine uptake. Uptake was performed as in A) in either sodium free (-Na+) 
or sodium replete (+Na+) conditions (n = 5). C: concentration-dependent uptake of 2-
[3H]chloroadenosine. Cells were incubated with increasing concentrations of 2-
[3H]chloroadenosine for 7 s. Transporter-mediated uptake is presented as pmol/µl/s and 
was defined as total uptake minus nonmediated uptake (n = 4). 
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Figure 3.3. Inhibition of 2-[3H]chloroadenosine uptake.  
Cells were incubated with increasing concentrations of inhibitor for 15 min before 
uptake of 10 µM 2-[3H]chloroadenosine for 15 s. Uptake in the absence of any inhibitor 
was defined as 100%, and totally inhibited cells (10 µM NBMPR + 10 µM dipyridamole) 
was defined as 0% (n = 4). Ki values are reported in Table 1. DY, dipyridamole. 
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Figure 3.4. [3H]hypoxanthine uptake characteristics of human cardiac MVECs (hMVECs). 
A: [3H]hypoxanthine time course. Cells were incubated with 5 µM [3H]hypoxanthine for 
the times indicated. Some cells were preincubated with 10 µM DY to inhibit any ENT2 
that may be present in the cells. To completely block uptake, cells were coincubated 
with 1 mM adenine (n = 5). B: Effect of sodium on [3H]hypoxanthine uptake. Uptake was 
performed as in A) in the absence (-Na+) or presence (+Na+) of sodium (n = 5). C: ATP-
depleted [3H]hypoxanthine time course. Uptake was performed identical to A, except 
that cells were depleted of ATP before assay (n = 6). D: concentration-dependent 
[3H]hypoxanthine uptake. ATP-depleted cells were incubated with increasing 
concentrations of [3H]hypoxanthine for 15 s. Transporter-mediated uptake is presented 
and was defined as uptake in the absence of any inhibitor minus uptake in the presence 
of 1 mM adenine (n = 4). 
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Figure 3.5. Inhibition of [3H]hypoxanthine uptake.  
A: Inhibition of [3H]hypoxanthine uptake by nucleobases and nucleosides. Cells were 
coincubated with 5 µM [3H]hypoxanthine and indicated purine for 60 s. Uptake in the 
absence of inhibitor was defined as 100%, and totally inhibited uptake (1 mM adenine) 
was defined as 0% (n = 3). B: Inhibition of [3H]hypoxanthine uptake by pyrimidine 
nucleobases. Assays were conducted in the same manner as A (n = 3). C: Inhibition of 
[3H]hypoxanthine uptake by purine and pyrimidine nucleobase analogs. 6-MP, 6-
mercaptopurine; 6-TG, 6-thioguanine; 5-FU, 5-flurouracil. Assays were conducted in the 
same manner as A (n = 3). Ki values are reported in Table 1. 
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Table 3.1 Ki values for inhibition of uptake by hMVECs 2-chloroadenosine and 
hypoxanthine 
 Ki 
2-chloroadenosine uptake 
NBMPR 0.5 ± 0.2 nM 
Dipyridamole  14 ± 8 nM 
Dilazep  0.4 ± 0.1 nM 
Draflazine  0.9 ± 0.2 nM 
Hypoxanthine uptake 
Adenine 19 ± 7 µM 
Guanine >1 µM 
Cytosine  No effect 
Thymine >1 mM 
Uracil  No effect 
6-MP 37 ± 11 µM 
6-TG 20 ± 2  µM 
5-FU  No effect 
Adenosine  1.2 ± 0.8 mM 
Uridine  No effect 
Ki values were determined with the Cheng-Prusoff relationship from IC50 values obtained from 
data presented in Figs. 3 and 5. (n ≥ 3). NBMPR, nitrobenzylmercaptopurine riboside; 6-MP, 6-
mercaptopurine; 6-TG, 6-thioguanine; 5-FU, 5-fluorouracil.  
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3.3.4 Nucleobase transport in other cell types.  
The identification of Na+-independent [3H]hypoxanthine transport in human cardiac 
MVECs, by a mechanism other than ENT2, led to the examination of other cell types for 
evidence of a similar dipyridamole-insensitive nucleobase transport system. Established 
cell lines from human (U2OS and HEK-293), rat (UMR-108), pig (PK15NTD), and dog 
(Madin-Darby canine kidney) were examined along with primary rat skeletal muscle 
MVECs. Figure 3.6 shows the time course profiles for dipyridamole-insensitive 
hypoxanthine uptake by these cells. All cells tested displayed evidence of dipyridamole-
insensitive nucleobase transport with the exception of HEK-293 cells.  
PK15NTD cells were chosen for further characterization of this nucleobase transporter. 
These cells do not have ENT1 or ENT2 (10; 32), thereby eliminating any contribution 
from other nucleoside/nucleobase transporters to the results obtained. 
[3H]hypoxanthine uptake by PK15NTD cells was concentration dependent with a similar 
Km (122 ± 31 pmol/µl) to the human cardiac MVEC in ATP-depleted conditions and a Vmax 
of 7.0 ± 0.6 pmol/µl/s (Figure 3.7A). There was no effect of pH on [3H]hypoxanthine 
uptake, and the thiopurines 6-MP and 6-TG displayed Ki values (21 ± 5 and 19 ± 1 µM, 
respectively) similar to those for human cardiac MVECs (data not shown). [3H]adenine 
was tested as a transport substrate with unlabeled hypoxanthine as the inhibitor (Figure 
3.7B). Hypoxanthine at 150 µM was able to produce ~20% inhibition of 500 nM 
[3H]adenine uptake under ATP-depleted conditions. The use of unlabeled 1 mM adenine 
was required for total inhibition. 
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Figure 3.6. Dipyridamole-insensitive [3H]hypoxanthine uptake in various cell types. Cells 
were incubated with 5 µM [3H]hypoxanthine for the times indicated. Cell lots were 
preincubated with 10 µM DY to inhibit any ENT2. To completely block uptake, cells were 
coincubated with 1 mM adenine (n = 2). UMR, UMR-108 cells; NTD, nucleoside 
transporter deficient PK15 cells (PK15NTD); MDCK, Madin-Darby canine kidney cells; 
rMVEC, rat skeletal muscle MVECs; HEK, HEK-293 cells. 
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Figure 3.7. PK15NTD cells as a model for nucleobase transport.  
A: concentration dependent uptake of [3H]hypoxanthine under ATP-depleted 
conditions. Cells were incubated with increasing concentrations of [3H]hypoxanthine for 
15 s. Transporter-mediated uptake is presented and was defined as uptake in the 
absence of any inhibitor minus uptake in the presence of 1 mM unlabeled adenine (n = 
3). B: Initial rate of 5 µM [3H]hypoxanthine was determined in NMG at varying pH. (n = 
4). C: Inhibition of [3H]hypoxanthine uptake by 6-MP and 6-TG (n = 3) D: [3H]adenine 
uptake time course. ATP-depleted cells were incubated with 500 nM [3H]adenine in the 
presence or absence of 150 µM hypoxanthine or 1 mM adenine (n = 2). 
69 
 
70 
 
[3H]hypoxanthine uptake in the presence or absence of dipyridamole was also examined 
in PK15NTD cells that had been previously transfected with human ENT2. Accumulation 
of 5 µM [3H]hypoxanthine in ATP-depleted conditions reached a maximum intracellular 
concentration of 3.8 ± 0.03 pmol/µl; however, in the presence of dipyridamole, the 
amount of [3H]hypoxanthine that accumulated in the cell rose to 18 ± 4 pmol/µl. 
Blocking ENT1 with NBMPR in the human cardiac MVECs (no ENT2) did not have an 
effect on [3H]hypoxanthine accumulation (Figure 3.8).  
3.3.5 Characterization of HMEC-1 Cells 
In the interest of having a MVEC cell model that was more economical than the primary 
human cells, HMEC-1 cells were tested as a suitable replacement. HMEC-1 cells bound 
[3H]NBMPR with two apparent populations, similar to the primary human cardiac 
MVECs. The high affinity binding had 76,000 ± 14,000 sites with a Kd of 0.03 ± 0.01 nM 
(Figure 3.9A). The low affinity binding was not always rational, and thus was probably an 
artifact of the binding assay. 
The time course of 10 µM 2-[3H]chloroadenosine uptake in the presence or absence of 
50 nM NBMPR showed a lack of NBMPR-insensitive uptake much like the primary 
human cardiac MVECs (Figure 3.9B). Inhibition of 10 µM 2-[3H]chloroadenosine by 
NBMPR was also monophasic and had a Ki of 0.098 ± 0.011 nM (Figure 3.9C) 
Finally, the time course of 5 µM [3H]hypoxanthine uptake was also similar to the primary 
human MVECs with uptake being insensitive to dipyridamole but could be inhibited by 1 
mM adenine (Figure 3.9D). 
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3.3.6 Decynium-22 and [3H]Adenine Km/Vmax 
A report by Hoque and colleagues (18) suggested that the compound decynium-22 (D-
22) was capable of inhibiting purine nucleobase uptake. Indeed, in PK15NTD cells, D-22 
inhibited hypoxanthine uptake with a Ki of 202 ± 156 nM. Similarly, D-22 inhibited 5 µM 
adenine uptake with an IC50 of 1.01  0.59 M (Figure 3.10A). Using D-22 to define non-
mediated uptake, concentration-dependent uptake of [3H]adenine was observed for 
concentrations of [3H]adenine up to 150 µM. Higher concentrations of [3H]adenine 
appeared to actually inhibit the transport mechanism. A curve was fit to the data up to 
150 µM to generate a Km of 36  10 M and a Vmax of 8.2  0.8 pmol/µl/s (Figure 3.10B). 
3.3.7 [3H]Hypoxanthine Efflux 
ATP-depleted PK15NTD cells were preloaded with 100 µM [3H]hypoxanthine for 10 
minutes, then transferred to buffer with or without 1 mM adenine. [3H]hypoxanthine 
was released from cells by an adenine sensitive mechanism as illustrated by a significant 
increase in efflux half-time from 0.9 ± 0.3 min in the absence of 1 mM adenine to 4.8 ± 
0.9 min in the presence of 1 mM adenine (Figure 3.11). 
3.3.8 Candidates for the identity of ENBT1 
The purine selective dipyridamole-insensitive nucleobase transporter ENBT1 identified 
in this chapter was done so through functional and pharmacological analyses only. The 
molecular identity of the transporter is still unresolved. Some potential candidates were 
identified and tested. 
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3.3.8.1 The unnamed human protein product hUPP1 
Through collaboration with Dr. Imogen Coe at York University (Toronto, Canada), a gene 
product for a potential new transporter was identified. Known only as unnamed protein 
product (Genbank Accession: BAC86869), this protein was predicted to be a member of 
the Major Facilitator Superfamily (MFS) which contains all transporters that rely on the 
concentration gradient of their substrate for transport. Stable expression of GFP-hUPP1 
in HEK cells was confirmed by fluorescent microscopy, however there was no gain of 
dipyridamole-insensitive [3H]hypoxanthine uptake (Figure 3.12). 
3.3.8.2 Organic Cation Transporter as a possible candidate for ENBT1 
The compound D-22 used in section 3.3.6 as an inhibitor of ENBT1 is a known organic 
cation transporter (OCT) inhibitor (31). OCTs have been shown to transport nucleobase 
analogues, therefore we tested one nucleobase analogue substrate, acyclovir, and one 
non-nucleobase substrate, metformin (11; 35). At a concentration of 1 mM, acyclovir 
inhibited the uptake of 5 µM [3H]hypoxanthine by 36 ± 7 %, however 1 mM metformin 
had no effect (Figure 3.13).  
73 
 
0 
 
Figure 3.8. Complex effects of nucleoside and nucleobase transporter coexpression and 
inhibition.  
A: PK15NTD [3H]hypoxanthine uptake ± dipyridamole (DY). ATP-depleted PK15NTD cells 
were incubated with 5 µM [3H]hypoxanthine for the times indicated in the presence or 
absence of 5 µM DY (n = 3). B: PK15NTD-human ENT2 (hENT2) [3H]hypoxanthine uptake 
± DY. ATP-depleted PK15NTD-human ENT2 cells were incubated with 5 µM 
[3H]hypoxanthine for the times indicated in the presence or absence of 5 µM DY (n = 2). 
C: hMVEC [3H]hypoxanthine uptake ± NBMPR. Cells were incubated in 100 µM 
[3H]hypoxanthine in the presence or absence of 50 nM NBMPR (n = 4). 
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Figure 3.9. Characterization of HMEC-1 cells.  
A) Cells were harvested, resuspendend in PBS and subjected to [3H]NBMPR binding as 
described in the methods. ENT1 sites per cell was determined by subtracting [3H]NBMPR 
binding in the presence of NBTGR (non-specific binding) from total binding. Data are 
means ± SEM of four independent experiments performed in duplicate. B) Cells were 
harvested, resuspended in NMG buffer and subjected to 2-[3H]chloroadenosine uptake 
as described in the methods. Solid squares represent uptake of 10 µM 2-
[3H]chloroadenosine in the absence of inhibitors (total uptake). Half-solid circles with 
dashed line represent uptake in the presence of 50 nM NBMPR (+NBMPR), or the 
contribution of NBMPR-insensitive ENT2 mediated uptake. Open circles with the dotted 
line represent uptake in the presence of both 5 µM NBMPR and 5 µM dipyridamole 
(non-mediated uptake). ENT1 mediated uptake is the difference between ENT2 
mediated uptake (+NBMPR minus non-mediated) and total mediated uptake (total 
minus non-mediated). Only ENT1 mediated 2-chloroadenosine transport was present in 
these cells. Data are means ± SEM of seven independent experiments. C) Cells were 
incubated with increasing concentrations of NBMPR for 15 min before analysis of the 
uptake of 10 µM 2-[3H]chloroadenosine for 15 s. Uptake in the absence of any inhibitor 
was defined as 100%, and totally inhibited cells (10 µM NBMPR + 10 µM dipyridamole) 
was defined as 0% (n = 3).D) Cells were harvested, resuspended in NMG, ATP-depleted, 
and subjected to [3H]hypoxanthine uptake as described in the methods. Solid squares 
represent uptake of 5 µM [3H]hypoxanthine in the absence of any inhibitors (total 
uptake). Half-solid circles with dashed line represent uptake in the presence of 5 µM 
dipyridamole (+DY), or the contribution of the dipyridamole-insensitive nucleobase 
transporter. Open circles with the dotted line represent uptake in the presence of both 
5 µM dipyridamole and 1 mM adenine (+DY and adenine; non-mediated uptake). Data 
are means ± SEM of three independent experiments. 
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Figure 3.10. Decynium-22 and [3H]adenine Km/Vmax.  
A) PK15NTD cells were preincubated with increasing concentrations of decynium-22 (D-
22) for 15 min followed by exposure to 5 µM [3H]adenine (solid squares) or 50 µM 
[3H]hypoxanthine (open squares) for 20 s (n = 4). B) PK-15 NTD cells were ATP-depleted 
as described and preincubated with 10 µM D-22 (non-mediated) or DMSO (total) for 15 
minutes before exposure to increasing concentrations of [3H]adenine for 15 s (n = 5).  
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Figure 3.11. [3H]hypoxanthine efflux. PK15NTD cells were ATP-depleted and loaded with 
100 µM [3H]hypoxanthine for 10 min. Cells were collected by brief centrifugation and 
resuspended in buffer ± 1 mM adenine. Aliquots of cells were taken at the indicated 
time points and centrifuged through oil as described in the methods section 3.2.3 (n = 
3). 
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Figure 3.12. GFP-hUPP1 does not increase hypoxanthine uptake in HEK cells. 
HEK cells (A) or HEK cells stably transfected with GFP-hUPP1 (B) were depleted of ATP 
and subjected to uptake of 5 µM [3H]hypoxanthine over time. C) Total uptake of 5 µM 
[3H]hypoxanthine of HEK cells (solid squares) and GFP-hUPP1 cells (open squares, dotted 
line). D) Uptake of 5 µM [3H]hypoxanthine in the presence of 10 µM dipyridamole, 
representing any uptake that is mediated by ENBT1. No significant uptake was observed 
in HEK cells or GFP-hUPP1 cells. E) ENT2 mediated [3H]hypoxanthine uptake as 
determined by subtracting uptake in the presence of dipyridamole from total uptake. 
Uptake data is mean ± SEM of 4 independent experiments. 
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Figure 3.13. OCT substrate acyclovir but not metformin can inhibit hypoxanthine uptake. 
A) 1 mM acyclovir (solid bar) or metformin (open bar) was co-incubated with 5 µM 
[3H]hypoxanthine for 60 s. Control (or 100%) was defined as accumulation of 5 µM 
[3H]hypoxanthine after 60 s incubation in the absence of any inhibitor. *P<0.05 
compared to 100%. Data are mean ± SEM of 4 independent experiments performed in 
duplicate.  
B) Chemical structures of acyclovir (nucleobase analogue) and metformin (non-
nucleobase). 
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3.4 DISCUSSION  
The microvasculature forms a barrier between the circulation and peripheral tissues and 
is responsible for mediating nutrient exchange between these two compartments. 
MVEC regulation of nucleosides via NTs can have profound effects on the cardiovascular 
actions of adenosine, warranting further investigation of NTs as potential therapeutic 
targets (23).  
3.4.1 Characterization of Nucleoside Transport in Human Cardiac Microvascular 
Endothelial Cells. 
Human cardiac MVECs have both high- and low-affinity binding sites for the ENT1-
selective probe NBMPR. The Kd of the high-affinity site is consistent with reported values 
for ENT1 (19). Our group, in rat skeletal muscle MVECs (3), and others (7) have reported 
the presence of the low-affinity population of NBMPR binding sites, which may be a 
result of [3H]NBMPR binding to intracellular ENT1 proteins. The high-affinity maximum 
binding capacity of ∼53,000 ENT1 sites/cell likely represents the transporters associated 
with the plasma membrane.  
2-Chloroadenosine is an established substrate of NTs and was chosen to limit the effects 
of intracellular metabolism on the measurement of transport kinetics (6; 20). Na+-
independent uptake of 2-chloroadenosine in the presence or absence of a low 
concentration of NBMPR (50 nM) to inhibit ENT1 revealed no significant contribution of 
the NBMPR-insensitive ENT2 to the overall uptake. In addition, NBMPR, dilazep, 
draflazine, and dipyridamole all produced monophasic inhibition curves for inhibiting 2-
chloroadenosine uptake (pseudo Hill coefficients were approximately –1) with Ki values 
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typical of ENT1 inhibition (36). Numerous endothelial cell models express a combination 
of ENT1 and ENT2, including primary rat MVECs (3), human umbilical vein endothelial 
cells (2), primary mouse MVECs (see Chapter 5), and EVC 304 cells (26). In this regard, 
human MVECs, which demonstrate only ENT1 function, appear to be an exception. 
3.4.2 Identification of a Novel Nucleobase Transporter in Human Cardiac Microvascular 
Endothelial Cells. 
Although human cardiac MVECs had no functional ENT2, they were still able to 
accumulate hypoxanthine under Na+-free conditions. Uptake was insensitive to 
dipyridamole; however, other purine nucleobases were capable of blocking influx. There 
was no significant change in uptake in the presence of Na+, thus ruling out the ascorbic 
acid transport system. An increase in H+ had no effect, and uptake was not inhibited by 
monoamines; thus this hypoxanthine transporter is not the recently identified ENT4 
(14). The apparent Km of hypoxanthine uptake (96 ± 37 µM) was threefold lower, and 
the Ki of adenine inhibition of hypoxanthine uptake (19 ± 7 µM) reported in this study 
was ∼140 times lower than previously reported for human ENT2 (26). Together, these 
data support that hypoxanthine uptake in human cardiac MVECs was mediated by a 
transport system distinct from ENT2. Further characterization showed that the transport 
system as purine nucleobase selective. The only pyrimidine tested that could inhibit 
hypoxanthine uptake was thymidine at nonphysiological concentrations (>1 mM). The 
nucleoside adenosine also inhibited uptake at high concentrations (IC50 > 1 mM), but this 
may be the result of adenosine metabolism releasing adenine. 
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The chemotherapeutic purine nucleobase analogs 6-MP and 6-TG demonstrated an 
affinity for the nucleobase transport system, whereas the pyrimidine analog 5-FU did 
not. The Ki determined for 6-MP and 6-TG inhibition of hypoxanthine uptake (∼20–30 
µM) were similar to reported values of therapeutic concentrations found within cells 
(13). This has relevance in the role that the vasculature plays in delivering 
chemotherapeutic agents to the intended target such that if this nucleobase transport 
system is blocked or down-regulated the chemotherapeutic purine nucleobase analogs 
would be less able to gain access to their intracellular site of cytotoxic action.  
3.4.3 Physiological Importance of Nucleobase Transport 
The ability of a cell to mediate the transmembrane flux of nucleobases is important, as 
evidenced by the existence of at least two distinct transport systems for nucleobases in 
many cell types. Regulation of intracellular levels of nucleobases, such as hypoxanthine, 
may be critical during periods of physiological stress, including hypoxia or ischemia. 
During hypoxia or ischemia in the heart, the breakdown of ATP in cardiomyocytes results 
in an increase in adenosine, which is released to the interstitial space via NTs (16). The 
surrounding endothelium then accumulates this extracellular adenosine. Adenosine 
kinase becomes saturated with the excess adenosine therefore shifting the metabolism 
to inosine via adenosine deaminase. Subsequent metabolism by purine nucleoside 
phosphorylase produces hypoxanthine as an intermediate to the final product of uric 
acid (33). It is in the production of hypoxanthine that the role of MVEC nucleobase 
transporters may hold importance. Because hypoxanthine is metabolized to xanthine by 
xanthine oxidase, reactive oxygen species (ROS) are produced (25). Links have been 
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established between xanthine oxidase-derived ROS and endothelial dysfunction (5; 29). 
Therefore, having a system capable of regulating hypoxanthine levels, before xanthine 
oxidase-mediated metabolism of hypoxanthine were to occur, may prevent or reduce 
ROS-induced endothelial dysfunction.  
The molecular identity of this distinctive dipyridamole-insensitive, purine-selective 
nucleobase transporter is presently not known. Despite this lack of identity, we have 
named the transporter equilibrative nucleobase transporter 1 (ENBT1). There is some 
evidence in the literature that similar transporters may exist (28; 32), and we have been 
able to identify its presence through function in several cell types from various species. 
Preliminary data from our laboratory have suggested that mouse MVECs are more 
similar to human cardiac MVECs than rat MVECs with respect to their nucleoside and 
nucleobase transport properties. However, rat MVECs appear to have less of the 
dipyridamole-insensitive [3H]hypoxanthine transporter and instead use ENT2 as the 
primary nucleobase transport system. This needs to be considered when using rat as a 
model for human extrapolation studies.  
Of the cells tested, only HEK-293 cells appeared to be deficient in ENBT1. Thus HEK-293 
cells may prove useful to the heterologous expression of candidate genes for ENBT1. In 
contrast, PK15NTD cells, which lack ENTs, have very high levels of ENBT1. Thus PK15NTD 
cells may provide a useful model to study dipyridamole-insensitive hypoxanthine 
transport. The lack of ENTs in these cells allows for the transfection of a NT of interest 
for the study of interactions between nucleoside and nucleobase transporters, as we 
have shown with the PK15NTD-human ENT2 cell line. HMEC-1 are an immortalized cell 
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line created from human dermal microvascular endothelial cells that were transfected 
with the simian virus 40 large T antigen, that are generally accepted to be a suitable 
model for the study of microvascular endothelial cells (1). Given that HMEC-1 cells 
appear to have identical transport characteristics as the primary human MVECs, we 
conclude that at the general level of nucleoside and nucleobase transport that these 
cells are a suitable substitute for primary human cells. However, it remains to be seen if 
HMEC-1 cells will respond in a similar manner when exposed to stimuli that elicit 
physiological responses.  
The 4.5-fold enhancement of hypoxanthine accumulation in the presence of 
dipyridamole in PK15NTD-human ENT2 cells (see Fig. 3.8) may be the result of 
intracellular trapping of hypoxanthine metabolites, or perhaps hypoxanthine itself, that 
normally are substrates for ENT2. It is possible for ENT2-preferring nucleosides, like 
inosine (36), to be formed from hypoxanthine by purine nucleoside phosphorylase when 
normal physiological conditions are changed to allow the enzyme to catalyze the 
preferred reaction of nucleoside synthesis (8). Thus nucleobases can be used to 
replenish depleted nucleoside and nucleotide stores, using ENBT1 as a salvage pathway. 
Cells that lack ENT2, like human MVECs, or ones that have their existing ENT2 
transporters blocked will see an enhancement of this salvage pathway, possibly leading 
to improved cellular function during periods of physiological stress.  
Decynium-22 is a known inhibitor of organic cation transporters and has been shown to 
inhibit the purine nucleobase uptake in PK15NTD cells by others (18; 31). We too have 
shown that D-22 works as an inhibitor in our hands. Before this discovery, the only 
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inhibitor of ENBT1 was adenine, which was not suitable for determining the uptake 
kinetics of adenine itself. The use of D-22 allowed a Km/Vmax profile for adenine to be 
generated, however the reason that transport rates returned to zero at high 
concentrations remains unresolved (Figure 3.10B). Since PK15NTD cells lack nucleoside 
transporters, it was unlikely that a nucleoside metabolite was being transported out of 
the cells. A more likely explanation would be an inability of D-22 to completely inhibit 
the transporter at very high concentrations of substrate. 
Despite the overlap of D-22 and nucleobase analogues with ENBT1 and OCTs, the non-
nucleobase OCT substrate metformin was unable to inhibit hypoxanthine mediated 
uptake. Like the ENT family, there are multiple OCTs and metformin is transported by 
OCT1 and OCT3 (9; 24; 34; 37). The lack of inhibition in this study lowers the likelihood 
that ENBT1 is actually an OCT, however there is still the possibility that ENBT1 resembles 
an OCT in some genetic or structural manner. 
The ability to move substrates bi-directionally across the plasma membrane is a defining 
feature of equilibrative transporters. ENBT1 is truly equilibrative, as hypoxanthine was 
transported out of PK15NTD cells in an adenine sensitive manner (Figure 3.11). This 
evidence supports the hypothesis that ENBT1 is capable of regulating intracellular 
nucleobase concentrations that may impact on ROS production. In an ischemic event, as 
hypoxanthine accumulates in the endothelial cell as a result of adenosine metabolism 
through the deaminase pathway, the concentration gradient of hypoxanthine would be 
from the intracellular compartment out. Transport of hypoxanthine out of the cell 
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through ENBT1 would reduce the amount of substrate available for xanthine oxidase 
and ROS production when oxygen returns. 
In summary, we have characterized the nucleoside and nucleobase transporters of 
primary human cardiac MVECs. Human cardiac MVECs rely solely on ENT1 for nucleoside 
transport, and we have identified a novel nucleobase transport system, which we have 
named ENBT1. ENBT1 is present in a variety of different cell types in combination with 
ENT2; however, this combination varies between species and cell types. We recommend 
that future studies involving nucleoside or nucleobase regulation in the 
microvasculature be conducted in mouse models if human models are unavailable. The 
role of nucleoside and nucleobase transporters in the vasculature is important and 
complex. Regulation of extracellular adenosine levels, either through ENT expression or 
pharmacological intervention, will impact cardiovascular function. Considering the 
vasodilatory effects of adenosine, ENT regulation of purine levels can impact perfusion 
and thus nutrient exchange between the microvasculature and surrounding tissues (23). 
Control of nucleobase levels by ENT2 or ENBT1 will have implications in nutrient salvage, 
chemotherapy, and ROS production during hypoxia or ischemia.  
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CHAPTER FOUR 
REGULATION OF HUMAN MICROVASCULAR ENDOTHELIAL CELL PURINE TRANSPORTERS. 
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4.1 Introduction 
In human microvascular endothelial cells, transmembrane flux of nucleosides and 
nucleobases is controlled by equilibrative nucleoside transporter 1 (ENT1) and 
equilibrative nucleobase transporter 1 (ENBT1) respectively (4). In mice, there is an 
additional small, but measurable, contribution to both nucleoside and nucleobase 
transport by equilibrative nucleoside transporter 2 (ENT2) (4). These transporters act as 
important regulators of intracellular concentrations of their substrates, and influence 
the interaction of these compounds with receptors on the plasma membrane. Thus, 
alteration of the expression and/or function of purine transporters can have far reaching 
consequences for the microvascular endothelium. 
Regulation of nucleoside and nucleobase transporters in the context of hypoxia and 
ischemia is an under-appreciated field. As described in Chapter One, hypoxia/ischemia 
results in increased extracellular adenosine, a substrate of ENT1 (and ENT2). 
Extracellular adenosine is known to promote protection of surrounding tissue during 
hypoxia/ischemia. Intracellular adenosine metabolism produces hypoxanthine, a 
substrate of ENBT1 (and ENT2), and reactive oxygen species (ROS). Therefore, 
understanding the function of transporters during hypoxia/ischemia may contribute to 
the understanding of pathologies such as ischemia-reperfusion injury.  
It has been shown previously that ENT1 can be transcriptionally regulated by hypoxia 
inducible factor 1 alpha (HIF-1α) in human, mouse, and rat cell lines representing 
epithelial, endothelial, cardiomyocyte, and carcinoma cells (9; 15; 25), but not in 
primary microvascular endothelial cells (MVECs). One gene target of HIF-1α is vascular 
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endothelial growth factor (VEGF). Interestingly, adenosine is also capable of promoting 
VEGF production. However, the potential interaction between VEGF and 
nucleoside/nucleobase transporters has not yet been investigated.  
Surprisingly, the effect of adenosine receptor activation/inhibition on nucleoside 
transport is poorly understood. Some attempts have been made to study the 
interaction, however the results are not readily interpretable (16; 33). Instead, there has 
been more success on studying downstream effector proteins including protein kinase A 
(PKA) (13; 27) and protein kinase C (PKC) (10; 12; 14; 18; 21). An additional kinase, 
protein kinase CKII (CKII), has also been implicated in nucleoside transport regulation 
(Figure 4.1) (6; 14; 41). The factors linking these studies together are 1) most are in 
immortalized cell lines, 2) several are from rodent cell lines, and 3) nucleobase transport 
was not addressed.  
The effects of ROS on nucleoside and nucleobase transport function have not been 
directly addressed. Endothelial cells produce nitric oxide (NO), which can react with the 
free radical superoxide to produce the reactive nitrogen species (RNS) peroxynitrite 
(ONOO-). Peroxynitrite, a very powerful oxidant, has been shown to reduce the function 
of other transport proteins, as well as prevent adenosine accumulation in rat astrocytes 
(42). However, ENT1 mediated transport of adenosine following peroxynitrite exposure 
was not properly addressed in that study.  
While the effect of ROS and RNS on transporter function is not well studied, there have 
been efforts to understand the effects of hypoxia on ENT1. It has been previously shown 
that ENT1 was transcriptionally regulated by HIF-1α in a number of cell lines following 
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chronic hypoxia (9; 15; 25). Short term hypoxia (2 hr or less) had no effect on ENT1 
expression. The impact of ischemia, however, has not been addressed, nor has the 
model of primary MVECs been reported. 
 
4.2 Materials and Methods 
4.2.1 Materials 
2-[3H]Chloroadenosine, [2,8-3H]hypoxanthine (28.7 Ci/mmol), [3H]NBMPR (23.8 
Ci/mmol), and [3H]water (1mCi/ml) were purchased from Moravek Biochemicals (Brea, 
CA). Non-radiolabeled, 2-chloroadenosine, hypoxanthine, NBMPR, 
nitrobenzylthioguanine riboside (NBTGR), and adenine were from Sigma-Aldrich. Human 
recombinant VEGF-165 was purchased from Cell Signaling Technology (Danvers, MA). 
Sunitinib malate (N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-
3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioate 
salt), ZM323881 (5-((7-Benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol 
hydrochloride), CGS21680 (4-[2-[[6-Amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-
purin-2-yl]amino]ethyl]benzene propanoic acid hydrochloride), NECA (1-(6-Amino-9H-
purin-9-yl)-1-deoxy-N-ethyl-β-D-ribofuranuronamide), forskolin, sp-cAMP, KT5270 
((9R,10S,12S)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-][1,6]benzodiazocine-10-carboxylic acid, hexyl 
ester), 8-CPT-2Me-cAMP(8-(4-Chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic 
monophosphate sodium salt),  PMA (phorbol 12-myristate 13-acetate), Gö6983 (3-[1-[3-
(Dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-
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dione), Gö6976 ( 5,6,7,13-Tetrahydro-13- methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-
c]carbazole-12-propanenitrile), and TBB (4,5,6,7-tetrabromobenzotriazole) were 
obtained from Tocris Bioscience (Ellisville, MO).4α-PMA and BFA (γ,4-Dihydroxy-2-(6-
hydroxy-1-heptenyl)-4-cyclopentanecrotonic acid λ-lactone) were from Sigma. Tert-
butyl hydroperoxide (TBHP), menadione, and cobalt chloride (CoCl2) were from Sigma-
Aldrich. 3-Morpholinosydnonimine hydrochloride (SIN-1) was from BIOMOL Research 
Laboratories (Plymouth Meeting, PA) and manganese(III) tetrakis(1-methyl-4-
pyridyl)porphyrin (MnTMPyP) was from Calbiochem (Mississauga, ON). One percent 
oxygen gas was from Praxair (London, ON).  
4.2.2 Vascular Endothelial Growth Factor Treatment 
Confluent cells were washed with PBS and fed with EBM-2 medium or MCDB 131 
medium for MVECs and HMEC-1 cells respectively, without serum or other growth 
factors plus the indicated concentration of human recombinant VEGF or PBS and 
cultured for 24 hr. In cases where treatment time was less than 24 hr, cells were 
cultured in basal medium without serum until VEGF was added. The total time in serum 
free medium was always 24 hr. When required, cells were pretreated with 1 µM 
sunitinib (non-selective VEGF receptor inhibitor) or 1 µM ZM323881 (VEGFR2 selective 
inhibitor) for 1 hr before the addition of VEGF.  
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Figure 4.1. Putative intracellular phosphorylation sites on human ENT1. 
Amino acid sequence and predicted topology of human ENT1 with highlighted residues 
predicted to be phosphorylated by receptor tyrosine kinases (RTK), protein kinase C 
(PKC), protein kinase CKII (CKII), or protein kinase A (PKA). Residues were predicted 
using NetPhos 2.0 web based software (http://www.cbs.dtu.dk/services/NetPhos/) (3). 
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4.2.3 Protein Kinase Modulation 
Serum starved cells were harvested and resuspended in HBSS. Cells were then treated 
with 100 µM forskolin or 1 µM of the direct PKA activator sp-cAMP and incubated at 
37°C for 15 min. When used, inhibitors were added to the cells 15 min at 37°C before 
the addition of forskolin or sp-cAMP. Treated cells were then used for substrate uptake 
assays as described in Chapter 2. Alternatively, cells were then treated with the PKC 
activator PMA for 15 min at 37°C. Inhibitors were added to the cells 15 min at 37°C 
before the addition of PMA.  
To test the contribution of CKII to transporter regulation, cells were washed and fed 
with medium containing 10 µM TBB or DMSO and incubated at 37°C for 24 to 48 hr prior 
to uptake assays. 
4.2.4 Adenosine Receptor Agonists  
For uptake assays, cells were harvested, resuspended in buffer and treated with the 
indicated concentration of agonist or antagonist for the time mentioned at 37°C. 
Following incubation, cells were harvested and subjected to substrate uptake assays.  
4.2.5 Treatment with a Reactive Oxygen Species Generator 
Menadione, an intracellular superoxide generator, was dissolved in 100% ethanol and 
prepared fresh each day. Cells were washed with warm HBSS and fed with warmed 
HBSS containing vehicle (control) or 100 µM menadione. In some cases, 100 µM 
MnTMPyP, a superoxide dismutase mimetic dissolved in ddH2O, was also added to cells 
at the same time as menadione, or to cells alone. Cells were incubated at 37°C for 30 
min before harvesting and subsequent uptake studies (as described in Chapter 2). 
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4.2.6 Simulated Hypoxia and Ischemia  
4.2.6.1 Cobalt Chloride Treatment 
Cobalt chloride (CoCl2) is an established stabilizer of HIF-1α (35). Confluent cells were 
washed with PBS and fed with medium containing 100 µM CoCl2 and incubated at 37°C 
for the time indicated before harvesting for substrate uptake assays. 
4.2.6.2 Simulated Ischemia 
Based on a method developed by Meldrum and colleagues(29), primary mouse cells 
were harvested and resuspended in fresh complete medium. Cell suspensions were 
placed in a 37°C 5%CO2-95% air humidified atmosphere for 1 hr to equilibrate. Following 
equilibration, a cell lot was centrifuged briefly and all medium was aspirated off with the 
exception of enough to keep the pellet covered. The pellet was resuspended by flicking 
the tube. Simulated ischemia was initiated by the layering of mineral oil over the 
concentrated cell suspension, creating a gas exchange barrier. Mineral oil overlayed 
cells were placed back in the atmosphere described above for 2 hr. Control cells were 
left in the complete medium with no overlay. Cells were gently mixed every 30 min. 
Following treatment, cells were washed with PBS, centrifuged, and supernatant was 
aspirated. This procedure was repeated three times to ensure no mineral oil was 
remaining. Cells were then resuspended in a final volume appropriate for substrate 
uptake assays. 
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4.3 RESULTS 
4.3.1 Regulation of transport by VEGF 
4.3.1.1 VEGF protects against serum starvation cell death in primary but not 
immortalized microvascular endothelial cells.  
Primary human cardiac microvascular endothelial cells (MVEC) and immortalized cell 
line HMEC-1 were treated with human recombinant VEGF165 for 24 hr at 
concentrations ranging from 0.1 to 25 ng/ml. A dose-dependent increase in cell 
concentration, as determined by cell counting, was observed with MVECs cells but not 
HMEC-1 cells (Figure 4.2).  
4.3.1.2 VEGF reduces [3H]NBMPR binding sites in microvascular endothelial cells. 
Treatment with VEGF for 24 hr in serum free medium resulted in a dose-dependent 
decrease in the number of [3H]NBMPR binding sites, representative of ENT1 protein, to 
a maximum of 66 ± 4 % of control at a concentration of 25 ng/ml in MVECs (Figure 
4.3A). HMEC-1 cells also had reduced [3H]NBMPR binding sites after VEGF treatment, 
however this effect was achieved at a lower concentration of 1 ng/ml. The magnitude of 
drop was similar to MVECs at 65 ± 9 % of control (Figure 4.3B). 
4.3.1.3 The reduction in [3H]NBMPR binding is temporally different between MVEC and 
HMEC-1 cells. 
Primary MVECs and immortalized HMEC-1 cells were treated with 25 ng/ml and 1 ng/ml 
VEGF, respectively, over a range of different times. The number of [3H]NBMPR binding 
sites in MVECs was unaffected up to 2 hr of treatment. However, after 4 hr of 
treatment, [3H]NBMPR binding was reduced to 69 ± 9 % of control and remained 
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depressed at the same level at both 6 and 24 hr (Figure 4.4A). In contrast, the number of 
[3H]NBMPR sites in HMEC-1 remained at control levels until 24 hr (Figure 4.4B). 
4.3.1.4 VEGF reduction in [3H]NBMPR binding sites in MVECs may be mediated by 
VEGFR2.  
Primary MVECs were pretreated with the non-selective VEGF receptor antagonist 
sunitinib malate or the VEGFR2 selective antagonist ZM323881 at a concentration 1 µM 
for 15 min. Following pretreatment, 25 ng/ml VEGF was added to culture medium and 
cells were incubated for an additional 24 hr. The VEGFR2 inhibitor ZM332881 was able 
to prevent a VEGF mediated reduction in [3H]NBMPR Bmax. Sunitinib malate failed to 
prevent a VEGF induced reduction in [3H]NBMPR binding sites, however sunitinib alone 
also significantly reduced [3H]NBMPR Bmax (Figure 4.5). Both ZM323881 and sunitinib 
were able to directly inhibit [3H]NBMPR binding at high concentrations (10µM), however 
there was no significant inhibition of [3H]NBMPR binding at the 1µM concentration used 
for both compounds in the [3H]NBMPR binding assay (Figure 4.6). 
4.3.1.5 Nucleobase, but not nucleoside transport is increased by VEGF. 
In contrast to the findings that VEGF was capable of reducing the number of [3H]NBMPR 
binding sites in both primary MVECs and HMEC-1 cells, the transport of 2-
[3H]chloroadenosine by ENT1 was not affected by 24 hr VEGF treatment of either cell 
type. Interestingly, the Vmax of [
3H]hypoxanthine uptake indicating an increase in the 
activity of the purine selective nucleobase transporter ENBT1 was significantly increased 
in HMEC-1 cells to from 4.3 ± 0.3 to 6.0 ± 0.6 pmol/µl/s (n = 4). The primary MVEC 
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[3H]hypoxanthine uptake Vmax was also increased from, 7.8 ± 1.7 to 11.8 ± 2.5 pmol/µl/s, 
however this did not reach statistical significance in this data set (Figure 4.7). 
4.3.2 Regulation by PKC 
Treatment of serum starved hMVECs with 100 nM PMA for 15 min resulted in a 35 ± 6 % 
decrease in ENT1 mediated uptake of 10 µM 2-[3H]chloroadenosine compared to 
control. In contrast PMA had no effect on ENBT1 mediated uptake of 50 µM 
[3H]hypoxanthine (Figure 4.8A). The effect of PMA on ENT1 was inhibited by the 
compound Go6983 which is a non- specific PKC inhibitor, but was not affected by 
Go6976 which is selective for the alpha and beta isoforms of PKC. The inactive PMA 
analogue 4α-PMA had no effect on ENT1 mediated transport (Figure 4.8B) 
Kinetic analysis of ENT1 transport of 2-[3H]chloroadenosine after 100 nM PMA 
treatment revealed a 74 ± 11 % decrease in Vmax and an 81 ± 9 % decrease in Km 
compared to control (Figure 4.8C). 
Treatment with 100 nM PMA in serum free medium for 24 hr was also performed. 
Uptake of 10 µM 2-[3H]chloroadenosine by ENT1 was increased to 180 ± 33 % of control 
(n=4). Additionally, uptake of 50 µM [3H]hypoxanthine by ENBT1 dramatically increased 
to 279 ± 39 % of control (Figure 4.8D). 
4.3.3 Regulation by CKII 
Treatment with 10 µM TBB in serum free medium for 24 hr, resulted in a substantial 
decrease in 10 µM 2-[3H]chloroadenosine uptake to 21 ± 6 % of control. Additionally, 
there was a significant decrease in 50 µM [3H]hypoxanthine uptake to 52 ± 11 % of 
control (Figure 4.9). 
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Figure 4.2 VEGF enhances cell concentration in primary MVECs but not immortalized 
HMEC-1 cells. 
Primary hMVECs or immortalized HMEC-1 cells were washed with PBS and then cultured 
with serum free medium containing vehicle or the indicated concentration of VEGF for 
24 h (shaded boxes). Cells were harvested and resuspended in buffer and counted by 
using either a hemocyotmeter or TC-10 automated cell counter. Cell concentration in 
cells/ml of VEGF treated cells was taken as a percentage of control cells. *P<0.05 one 
sample t-test compared to 100%, n ≥ 3. Data are means ± SEM. 
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Figure 4.3. VEGF decreased [3H]NBMPR binding Bmax in both hMVECs and HMEC-1 cells. 
Confluent primary hMVECs or immortalized HMEC-1 cells were washed with PBS and 
then fed with serum free medium containing vehicle or the indicated concentration of 
VEGF for 24 h. Cells were harvested and resuspended in PBS and subjected to 
[3H]NBMPR binding as described in the methods. A) Primary MVECs had a significant 
decrease in [3H]NBMPR binding Bmax compared to 66 ± 4 % of control at 25 ng/ml 
(*P<0.05, one sample t-test vs 100%, n = 3). B) HMEC-1 cells had a significant decrease 
in [3H]NBMPR binding sites to 65 ± 9 % of control at 1 ng/ml VEGF (n ≥ 4). 
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Figure 4.4. The reduction in [3H]NBMPR binding was temporally different between 
MVEC and HMEC-1 cells. 
A) Primary MVECs were incubated with 25 ng/ml VEGF for the times indicated and 
[3H]NBMPR binding was measured. A significant decrease to 69 ± 9 % of control was 
obtained after 4 hr and did not change at 6 or 24 hr of treatment (*P<0.05 one sample, 
two-tailed t-test vs 100%, n ≥ 3). 
B) HMEC-1 cells were incubated with 1 ng/ml VEGF for the times indicated and 
[3H]NBMPR binding was measured. A significant decrease to 65 % of control was seen at 
24 hr of treatment (*P<0.05 one sample, two-tailed t-test vs 100%, n ≥ 3). 
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Figure 4.5. VEGF reduction in [3H]NBMPR Bmax was mediated by VEGF receptor VEGFR2. 
Primary MVECs were pretreated with or without 1 µM of the non-selective VEGFR 
inhibitor sunitinib (A) or the VEGFR2 selective inhibitor ZM323881 (B) for 15 min prior to 
the addition of 25 ng/ml VEGF in serum free medium. In parallel, cells were treated with 
inhibitors only (C). Cells were incubated for 24 hr followed by the determination of 
[3H]NBMPR Bmax. Changes in Bmax were compared to serum free control in the absence 
of VEGF or inhibitors. Data is mean ± SEM of 9 experiments performed in duplicate. 
*P<0.05 two-tailed, one sample t-test vs 100%. #P<0.05 two-tailed t-test. 
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Figure 4.6. Sunitinib inhibition of [3H]NBMPR binding does not correspond to Bmax 
decreases. 
Primary hMVECs were co-incubated with 0.15 nM [3H]NBMPR and increasing 
concentrations of sunitinib (closed squares) or ZM323881 (open squares) for 45 min at 
room temperature. Specific bound [3H]NBMPR in the presence of a VEGFR inhibitor was 
taken as a percentage of specific bound [3H]NBMPR in the absence of any inhibitor. 
The vertical dotted line represents the concentration of sunitinib and ZM323881 that 
were used to inhibit the effects of 24 hr treatment with 25 ng/ml VEGF as described by 
Figure 4.5. 
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Figure 4.7. Nucleobase transport, but not nucleoside transport, is increased by VEGF.  
Primary MVECs and immortalized HMEC-1 cells were treated with 25 ng/ml VEGF for 24 
hr. ENT1 mediated transport of 2-[3H]chloroadenosine was unchanged in MVECs (A) or 
HMEC-1 cells (B). The Vmax of ENBT1 mediated transport of [
3H]hypoxanthine was 
increased in both MVECs (C) and HMEC-1 cells (D) The increase in Vmax  in HMEC-1 cells 
reached statistical significance. (P<0.05 two-tailed t-test, n = 4). 
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Figure 4.8. Nucleoside and nucleobase transport are differentially regulated by PKC. 
A) Serum starved cells were harvested and treated with PMA for 15 min at 37°C in HBSS 
prior to analysis of 10 µM 2-[3H]chloroadenosine(ENT1) and 50 µM [3H]hypoxanthine 
(ENBT1) uptake. *P<0.05 two-tailed, one sample t-test vs 100%. #P<0.05 two-tailed t-
test. Data are means ± SEM of four independent experiments performed in duplicate. 
B) Serum starved cells were harvested and pretreated with the broad spectrum PKC 
inhibitor Go6983 or the PKC-α/β selective inhibitor Go6976 for 15 min prior to the 
addition of PMA. Some cells were treated with 100 nM 4α-PMA, an inactive analogue of 
PMA. Mediated uptake of 10µM 2-[3H]chloroadenosine after 5 sec was then 
determined. *P<0.05 two-tailed, one sample t-test vs 100%. #P<0.05 two-tailed t-test. 
Data are means ± SEM of at least 4 independent experiments performed in duplicate. C) 
Serum starved cells were treated with 100 nM PMA (open squares, dotted line) for 15 
min prior to 2-[3H]chloroadenosine uptake. PKC activation resulted in a 74 ± 11 % 
decrease in Vmax and an 81 ± 9 % decrease in Km compared to control (P<0.05 two-tailed, 
one sample t-test vs 100%, n = 3). D) Cells were treated with 100 nM PMA for 24 hr in 
serum free medium. Cells were then harvested and subjected to 10 µM 2-
[3H]chloroadenosine uptake (ENT1) and 50 µM [3H]hypoxanthine uptake (ENBT1). Data 
are means ± SEM of three independent experiments performed in duplicate. *P<0.05 
two-tailed, one sample t-test vs 100%. 
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Figure 4.9. Inhibition of CKII decreases nucleoside and nucleobase uptake. 
Primary hMVECs were treated with or without 10 µM TBB in serum free medium for 24 
hrs. Treated cells were then harvested and subjected to uptake assay of 10 µM 2-
[3H]chloradenosine (ENT1) or 50 µM [3H]hypoxanthine. Data is mean ± SEM of three 
independent experiments performed in duplicate. *P<0.05 two-tailed, one sample t-test 
vs 100%. 
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4.3.4 Regulation by PKA 
ENT1 mediated transport of 10 µM 2-[3H]chloroadenosine was decreased by both 
forskolin and sp-cAMP, whereas ENBT1 mediated transport of [3H]hypoxanthine was 
unaffected. The adenylate cyclase activator forskolin decreased ENT1 function by 40 ± 
11 % of control, and the cAMP analogue sp-cAMP reduced ENT1 by 56 ± 13 % of control 
(Figure 4.10A) 
The PKA inhibitor KT5720 was unable to inhibit the decrease in ENT1 function caused by 
forskolin or sp-cAMP. In fact, KT5720 caused a concentration-dependent enhancement 
of the effects of both forskolin and sp-cAMP (Figure 4.10B). When tested against 
[3H]NBMPR binding, KT5720 inhibited specific binding with a Ki of 70 ± 17 nM (Figure 
4.10C). 
Both adenosine A2A and A2B receptors are known to couple to Gs proteins which 
stimulate the production of cAMP through the activation of adenylate cyclase. However, 
treatment with the A2A selective agonist CGS21680 or the non selective agonist NECA 
did not have any effect on ENT1 (Figure 4.11) 
4.3.5 Effect of ROS on nucleoside and nucleobase transporter function. 
HMEC-1 cells were treated with the intracellular superoxide generator menadione as 
described in section 4.2.5. Both ENT1 and ENBT1 Vmax was significantly reduced by 
menadione to 46 ± 3 and 28 ± 9 percent of control respectively. The superoxide 
dismutase mimetic MnTMPyP could not prevent the reduction in ENT1 Vmax, however 
MnTMPyP significantly diminished the effect of menadione on the reduced Vmax of 
[3H]hypoxanthine uptake by ENBT1 (Figure 4.12). 
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Figure 4.10. Effect of cAMP on nucleoside and nucleobase transporter function. 
A) Cells were serum starved for 24 hrs, harvested and treated with 100 µM forskolin, 1 
µM sp-cAMP, or 10 mM 8CPT-2Me-cAMP for 15 min at 37°C in HBSS followed by 
analysis uptake of 10 µM 2-[3H]chloroadenosine(ENT1) and 50 µM [3H]hypoxanthine 
(ENBT1). Data are mean ± SEM of at least 3 experiments performed in duplicate. 
*P<0.05 two-tailed, one sample t-test vs 100%, n ≥ 3. #P<0.05 two-tailed t-test 
compared to ENT1. 
B) Cells were pretreated with the PKA inhibitor KT5720 for 15 min at 37°C in HBSS prior 
to the addition of 100 µM forskolin (solid bars) or 1 µM sp-cAMP (open bars) for an 
additional 15 min at 37°C. Data are mean ± SEM of three experiments performed in 
duplicate. *P<0.05 two-tailed, one sample t-test vs 100%. 
C) Primary human MVECs were harvested and incubated with 0.15 nM [3H]NBMPR and 
increasing concentrations of KT5720 for 45 min at room temperature. Using the Cheng-
Prusoff equation, KT5720 was found to have a Ki of 70 ± 17 nM. Data are means ± SEM 
of three independent experiments performed in duplicate. 
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Figure 4.11. Adenosine A2 receptor agonism does not alter ENT1 function. 
Primary MEVCs were treated with 300 nM of the A2A selective agonist CGS21680 or 10 
µM of the non-selective A2 agonist NECA for 2 hrs in HBSS at 37°C. Cells were then 
harvested and subjected to analysis of 2-[3H]chloroadenosine uptake. Data are mean ± 
SEM of six independent experiments.  
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Figure 4.12. Intracellular superoxide production by menadione reduced ENBT1 but not 
ENT1 function. 
HMEC-1 cells were treated with 100 µM menadione in HBSS at 37°C for 30 min ± 100 
µM MnTMPyP. A) The Vmax of 2-[
3H]chloroadenosine uptake by ENT1 was significantly 
reduced to 45 ± 2 % of control. MnTMPyP had no effect on menadione treated cells or 
on its own. 
B) The Vmax of [
3H]hypoxanthine uptake by ENBT1 was significantly reduced to 25 ± 7 % 
of control. Co-treatment with MnTMPyP was able to limit the reduction in Vmax to 68 ± 6 
% of control. As with ENT1, MnTMPyP had no effect on ENBT1 transport alone. 
Panels C) and D) show the effects of menadione ± MnTMPyP on Vmax and Km parameters 
as percent of control. Effects of MnTMPyP alone are excluded for clarity. *P<0.05, two-
tailed one sample t-test vs 100%, n ≥ 3. #P<0.05 one way ANOVA with a Tukey-Kramer 
post hoc test, n ≥ 4. 
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4.3.6. Simulated Ischemia  
Treatment with the HIF-1α stabilizer CoCl2 had no effect on ENT1 or ENBT1 in primary 
hMVECs (Figure 4.13 A-B). The mineral oil overlay to simulate ischemia had no 
significant effect on 2-[3H]chloroadenosine transport with Vmax of 2.0 ± 0.4 pmol/µl/s 
and 2.0 ± 0.2 pmol/µl/s for control and ischemia respectively. However, mineral oil 
overlay dramatically reduced [3H]hypoxanthine uptake by ENBT1 to levels that 
resembled non-mediated uptake (Figure 4.13 C-D). 
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Figure 4.13 Effects of hypoxia and ischemia on nucleoside and nucleobase transport. 
A & B) Primary MVECs were treated with 100 µM CoCl2 for 2 hrs at 37°C in complete 
medium. 2-[3H]chloroadenosine (A) and [3H]hypoxanthine (B) uptake assays were 
performed. Data are mean ± SEM of four experiments. 
C&D) Cells were subjected to mineral oil overlay as described in Section 4.2.3.2.  
2-[3H]chloroadenosine uptake by ENT1 was not significantly affected (C) however, 
[3H]hypoxanthine uptake by ENBT1 (D) was abolished following 2 hrs of mineral-oil 
overlay ischemia. Data are mean ± SEM of four experiments. 
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4.4 Discussion 
This chapter addressed the regulation of purine transporters in the context of 
hypoxia/ischemia. This included the generation and effects of ROS as well as 
physiological molecules, receptors, and kinases that have been shown to be important 
in both the normal vasculature, as well as during times of vascular stress. 
4.4.1 Regulation of Transport by VEGF 
This is the first study to demonstrate that VEGF is a regulator of purine transporters in 
microvascular endothelial cells. VEGF acts through a family of transmembrane receptor 
tyrosine kinases (RTKs). A recent study by Vega et al., demonstrated that transforming 
growth factor beta 1, another molecule that signals through a family of RTKs, limits the 
expression of ENT1 in human umbilical vein endothelial cells (44). While the model is 
different, the overlap in signaling pathways between TGF-β and VEGF receptors 
supports our finding that VEGF has the potential to regulate ENT1. In silico analysis of 
the ENT1 protein revealed a potential RTK phosphorylation consensus sequence at Tyr-2 
of intracellular N-terminal, suggesting a possible direct link between RTK activation and 
ENT1 post-translational regulation.   
It is widely accepted that changes in [3H]NBMPR binding are mirrored by similar changes 
in substrate transport, i.e. a decrease in [3H]NBMPR binding would result in decreased 
transport. However, in the current study, we found that there was no decrease in 
nucleoside transport despite a decrease in [3H]NBMPR binding of about 35%. The 
decrease in [3H]NBMPR binding could be a result of a conformational change elicited by 
phosphorylation of the transporter by VEGFR2 that alters the [3H]NBMPR binding site 
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that does not impact the substrate translocation site. The physiological relevance of this 
effect remains to be elucidated.  
We observed a difference between the primary hMVECs and the immortalized HMEC-1 
cells in the response to VEGF-165 treatment. This was despite the fact that HMEC-1 cells 
have a comparable number of ENT1 sites per cell to hMVECs and show a complete lack 
of functional ENT2 (5). The HMEC-1 cell line is a well established endothelial cell model 
created from human dermal microvascular endothelial cells that were transfected with 
the simian virus 40 large T antigen (1). This cell line is reported to maintain many of the 
characteristics of the original microvascular endothelial cells, and is capable of 
producing VEGF (17).  
The observation that the nucleoside transporter ENT1, as measured by [3H]NBMPR 
binding, is reduced by VEGF while cell numbers increased is counter-intuitive. In fact, 
ENT1 expression has been shown to increase during cell proliferation (7). This finding 
suggests that the VEGF cell proliferation and ENT1 regulation pathways are divergent. 
This also suggests, therefore, that ENT1 regulation by VEGF signaling is of greater 
importance than regulation via normal cell cycle progression. The VEGFR2 selective 
antagonist ZM323881 was able to prevent a VEGF-mediated decrease in ENT1, 
suggesting that it is the VEGFR2 receptor responsible for this effect. These data are 
consistent with VEGF pharmacology as the VEGF-165 used in this study is the most 
common form of the protein produced and the VEGFR2 receptor is believed to be the 
receptor subtype that mediates the biological effect of VEGF-165 (49). However, 
VEGFR2 may not be the only RTK capable of regulating ENT1 expression. The drug 
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sunitinib is capable of inhibiting a wide variety of RTKs including platelet derived growth 
factor receptor (PDGFR),  stem cell grown factor receptor (KIT), and fms-like tyrosine 
kinase receptor-3 (FLT3) (30; 31). Given that inhibition [3H]NBMPR binding and 
reduction of [3H]NBMPR binding sites after 24 hr treatment of sunitinib do not co-relate 
(Figures 4.5,4.6), it is possible that the sunitinib effect is receptor mediated.  
When viewed in a physiological context, VEGF release and signaling is most likely to 
occur during periods of hypoxia/ischemia. During hypoxia, adenosine levels increase as a 
result of increased ATP breakdown. Adenosine is a known stimulator of VEGF 
production (11). Additionally, the VEGF gene contains a hypoxia response element, and 
therefore is directly regulated by oxygen tension (19). Thus, a VEGF signal in endothelial 
cells causing a decrease in ENT1 protein may be acting to potentiate the protective 
actions of adenosine by reducing the amount taken up into the endothelium. Reduced 
intracellular adenosine accumulation in the endothelium could also be a protective 
mechanism against ischemia-reperfusion injury. Adenosine metabolism to hypoxanthine 
provides substrate for xanthine oxidase to produce reactive oxygen species upon re-
oxygenation. Less adenosine in the cell means less hypoxanthine and therefore less ROS. 
The other main observation of this study is the VEGF mediated increase in the function 
of the hypoxanthine transporter ENBT1 in HMEC-1 cells, with a trending towards a 
similar increase in MVECs. This increase would compliment an endothelial protective 
function for VEGF, as more ENBT1 would result in enhanced removal of hypoxanthine 
from the cells and thus another way to limit ROS production.  
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There is also potential application of the presented results to cancer treatment. It is well 
known that solid tumours are hypoxic and rely on VEGF to generate new blood vessels 
to supply the tumour with blood (22; 26; 48). Given that VEGF increases ENBT1 function, 
therapies involving nucleobase analogues that are potential substrates for ENBT1, like 6-
mercaptopurine or 6-thioguanine (5), may more effectively cross the endothelial barrier 
and reach the tumour cells. 
4.4.2 Regulation by Protein Kinase C 
Regulation of ENT1 by PKC is a widely studied phenomenon. However, the effect on 
ENT1 function, and by which PKC isoform, is still disputed. In human MCF7 and HeLa 
cancer cell lines, short term PMA treatment (10 min) caused an increase in uptake that 
was mediated through PKC-δ or -ε, whereas chronic treatment (24 hr) caused a 
decrease in uptake (12). In mouse HL-1 cardiomyocytes acute PMA (10 min) also caused 
an increase in ENT1 mediated transport (10). However, in human umbilical vein 
endothelial cells, PMA treatment (30 min) resulted in decreased ENT1 activity (34). In 
rat cardiac fibroblasts, PKC-ζ has been implicated in the down-regulation of ENT1 in 
response to elevated glucose (21), and PKC-ε down-regulation by chronic hypoxia (18 
hr) has also been linked to decreased ENT1 activity (9). In Figure 4.8, activation and 
inhibition of PKC with PMA and Go6983, respectively, supports a role for PKC-δ/ε, 
however the effects on ENT1 are the opposite of that observed in MCF7 and HeLa cells 
as well as the mouse HL-1 cardiomyocyte cell line.  
The role of PKC in the regulation of ENBT1 is much more complex. Acute PMA treatment 
of serum starved cells had no effect on ENBT1 function; however chronic PMA exposure 
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resulted in a significant increase in the uptake of 50 µM hypoxanthine. These data 
suggest that PKC has no direct effect on ENBT1 function, rather that ENBT1 is regulated 
by another protein that is the target of PKC phosphorylation. Alternatively, ENBT1 may 
be constitutively phosphorylated and the decrease in PKC activity caused by chronic 
PMA treatment leads to a decreased ENBT1 phosphorylation state. Recent evidence in 
human umbilical vein endothelial cells showed that PKC inhibition led to increased nitric 
oxide (NO) production (40), perhaps a similar mechanism occurs in MVECs and is 
responsible for the [3H]hypoxanthine uptake increase. However, since the uptake assay 
was performed in ATP-replete conditions to allow cellular regulation events to function 
properly, the increase in [3H]hypoxanthine uptake could be an artifact of altered 
metabolism. That is, with ATP present, nucleobase scavaging enzymes, such as 
hypoxanthine-guanine phosphoribotransferase are capable of producing [3H]nucleotides 
from [3H]hypoxanthine, trapping the [3H]label inside the cell, and thus artificially 
increasing the apparent rate of [3H]hypoxanthine uptake. 
4.4.3 Regulation by CKII 
In agreement with the study by Bone et al.,(6) CKII inhibition by TBB resulted in 
decreased ENT1 transport activity. However, this was not achieved under the same 
conditions as that study, instead, the decrease was observed after 24 hr in serum free 
medium, compared to 48 hr in complete medium as described by Bone (6). Differences 
in cell model and culture medium could contribute to the temporal differences observed 
between the two studies. The cells used by Bone were nucleoside transporter deficient 
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cells stably expressing recombinant human ENT1 (6) compared to the primary MVECs 
used presently. 
4.4.4 Regulation by Protein Kinase A 
The in silico analysis of ENT1 predicted potential PKA phosphorylation sites (Figure 4.1), 
therefore the effects of PKA activators were investigated on nucleoside and nucleobase 
transport. Forskolin, an adenylate cyclase activator and therefore an indirect PKA 
activator, and the cAMP analogue sp-cAMP, a direct PKA activator, both led to a 
decrease in ENT1 mediated uptake but had no effect on ENBT1 mediated nucleobase 
uptake. The decrease in ENT1 mediated uptake is in agreement with a study by Sen et 
al., who showed that forskolin was able to decrease ENT1 uptake by 30% in mouse 
Neuro-2a cells (39). It has also been shown that active PKA is required for ethanol 
mediated inhibition of adenosine uptake in neuronal cells (13). However a difficulty 
arose when trying to confirm PKA as the protein responsible for the ENT1 down-
regulation. The cAMP analogue 8-CPT-2Me-cAMP, a direct activator of another cAMP 
binding protein Epac-1, is a direct inhibitor of ENT1 (46). Additionally, the commonly 
used PKA inhibitor H89 is a direct ENT1 inhibitor as well (23). Thus a different PKA 
inhibitor, KT5720 was used, however it also turned out to be a direct, high affinity 
inhibitor of ENT1 as shown by the ability to inhibit [3H]NBMPR binding with a Ki of 70 
nM.  
Adenosine A2 receptors stimulate adenylate cyclase activity and thus activate PKA when 
presented with an agonist. Therefore, it was expected that the adenosine A2A agonist 
CGS21680 or the non-selective A2 agonist NECA would produce the same effect as 
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forskolin and sp-cAMP. However, this was not the case as adenosine receptor agonism 
had no effect on 2-[3H]chloroadenosine uptake (Figure 4.11). Primary human MVECs are 
expected to express the adenosine A2A receptor (38) therefore the lack of response 
could be a lack of sufficient cAMP production to effectively activate PKA. Another 
possibility could be that cAMP, forskolin, or sp-cAMP directly interact with ENT1 to 
prevent [3H]NBMPR binding. The presence of potential PKA phosphorylation sites on 
ENT1 suggests that PKA is responsible for the decrease in ENT1 function, but without a 
PKA inhibitor that does not directly interfere with ENT1 function this phenomenon could 
not be properly addressed.  
4.4.5 Effects of ROS on Purine Transporters 
The superoxide generator menadione had differential effects on ENT1 and ENBT1 
transport of nucleosides and nucleobases, respectively. Menadione reduced the Vmax of 
both ENT1 and ENBT1 mediated uptake (Figure 4.12). The superoxide dismutase 
mimetic, MnTMPyP reduced the effect of menadione on ENBT1 uptake but not ENT1. 
Therefore, ENBT1 transport function is sensitive to the presence of superoxide, and thus 
most likely selectively oxidized on a residue important to transport function. Oxidation 
of sulphydryl groups, especially those found on cysteine residues, is typically the cause 
of modifications that lead to protein dysfunction (2; 8; 36). Modification of cysteine 
residues has been shown to inhibit function of a number of different transporter types 
(24; 43; 45).  
Unfortunately, it cannot be determined using menadione if ENT1 is also sensitive to 
superoxide modification. Since MnTMPyP could not reverse the effects of menadione, 
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direct inhibition of ENT1 by menadione is the probable outcome. Direct inhibition of 
ENT1 by menadione is supported by the fact that antibiotics containing quinone, the 
same class of chemical as menadione, reduced nucleoside uptake via ENT1 (32). 
4.4.6 Effects of Simulated Hypoxia and Ischemia on Purine Transporters 
CoCl2 stabilizes HIF-1α in the presence of normal oxygen concentrations, thus making it 
an easier tool to study the impact of HIF-1α (and by extension hypoxia) on your gene of 
interest (35). The mineral-oil overlay model has been shown to reduce oxygen 
concentrations to which the cells are exposed (28; 29). The lack of effect of CoCl2 after 2 
hr indicates that stabilization of HIF-1α does not impact ENT1 or ENBT1 in the short 
term (Figure 4.13). It was previously shown that ENT1 responds to actual hypoxia after 8 
hr in HUVEC cells (15), and thus these data are not totally unexpected. The loss of 
ENBT1 function, with no effect on ENT1 after 2 hr of ischemia, suggests that another 
mechanism other than low oxygen is mediating this effect. In vivo, ischemia-reperfusion 
is known to produce ROS (20; 37; 47), and may be produced in culture leading to 
oxidation of ENBT1. However, another possibility could be an increase in intracellular 
hypoxanthine, as a result of increase adenosine metabolism, that establishes a 
concentration gradient favouring efflux. However, in this model of ischemia, it could be 
argued that the resuspension of cells in buffer and washing away of the mineral oil is the 
reperfusion step. This would allow both efflux and metabolism of any endogenous 
hypoxanthine, generating superoxide and establishing the proper conditions for uptake. 
Thus, taken with the data generated with menadione treatment, these data suggest that 
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ENBT1 is indeed sensitive to the presence of ROS, to the point of complete loss of 
function.   
 4.4.7 Conclusions 
Primary human MVECs were used to study the roles of VEGF, intracellular kinases, 
adenosine receptors, reactive oxygen species, and ischemia on purine transport. These 
studies were successful in identifying VEGF as a novel regulator of purine transporters 
through VEGFR2.  Additionally, intracellular kinases PKC and CKII are capable of altering 
transport function. The intracellular kinase PKA may also play a role in the regulation of 
ENT1, however more work is needed to confirm a PKA interaction and rule out a direct 
cAMP interaction with the transporter. 
These data suggest that the microvascular purine transporters ENT1 and ENBT1 may be 
altered in the pathophysiology of hypoxia/ischemia and oxidative stress. Intracellular 
superoxide, generated by menadione, produced dramatic decreases in transporter Vmax. 
ROS may also be a contributing factor to the down-regulation of ENBT1 during ischemia, 
with ENT1 being less sensitive to oxidative insult. Further ROS dose response studies are 
needed to clarify the mechanism of regulation.  
These alterations may contribute to endothelial dysfunction, especially the down-
regulation of ENBT1, which would trap the superoxide producing hypoxanthine inside 
endothelial cells. Fortunately, these transporters are also regulated by proteins that are 
targets of pharmacological manipulation and thus interventions could be devised to 
prevent or reduce the impact they have on endothelial cell oxidative stress. 
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CHAPTER FIVE 
MICROVASCULAR ENDOTHELIAL CELLS ISOLATED FROM MICE: TRANSPORTER 
CHARACTERIZATION AND REGULATION, SUBSTRATE METABOLISM, AND 
CONSEQUENCES OF ENT1 KNOCKOUT1 
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5.1 INTRODUCTION 
All mammalian cells express at least one form of equilibrative transporter responsible 
for the cellular uptake and release of endogenous nucleosides such as adenosine. The 
predominant transporters are equilibrative nucleoside transporter subtypes 1 (ENT1; 
SLC29A1) and 2 (ENT2; SLC29A2) (4). The inhibition of ENTs has been shown to enhance 
the cardioprotective (28) and neuroprotective (17) actions of adenosine. These 
transporters are also responsible for the cellular uptake of cytotoxic nucleoside analogs 
used to treat cancer and viral infections (35).  
An ENT1-null (ENT1−/−) mouse model has been generated by Choi and colleagues (12). 
The ENT1−/− mice are phenotypically normal with the only difference from wild-type 
(WT) littermates being a slight (<10%) decrease in body weight and some differences in 
their behavioral characteristics. The ENT1-null mice are less sensitive to the intoxicating 
effects of ethanol compared with their WT littermates (12), and they also display less 
anxiety-like behavior (11). It has been noted that there is less tonic A1 adenosine 
receptor signaling in the brains of ENT1−/− mice (12), reflecting either reduced 
extracellular adenosine levels or a decreased sensitivity of the receptor to adenosine, 
suggesting that ENT1 plays an important role in modulating the interaction of adenosine 
with its concomitant receptors in the central nervous system.  
In addition to its regulatory activities in the nervous system, adenosine is well 
established as an endogenous cardioprotective agent via interactions with 
cardiomyocytes and is also a potent vasodilator through actions on vascular smooth 
muscle and endothelial cells (23). The availability of ENT1−/− mice will now allow an in-
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depth examination of the role of ENT1 (and the effects of its absence) in adenosine 
metabolism and bioactivity in the various cell types that constitute the cardiovascular 
system under both normal and pathophysiological conditions. We have recently 
published the results of a study based on cardiomyocytes isolated from WT and ENT1−/− 
mice (31). The present study extends this work to an examination of the impact of ENT1 
loss on the nucleoside flux and metabolism in microvascular endothelial cells (MVECs).  
Previous studies from our laboratory have established that rat MVECs express high 
levels of both ENT1 and ENT2 (3), whereas human MVECs express predominantly the 
ENT1 subtype of nucleoside transporter (7). MVECs are considered to be the major site 
of accumulation and metabolism of the adenosine released into the interstitial space by 
myocytes during periods of high energy demand in heart and skeletal muscle (15); 
therefore, in the absence of biological compensation, one might expect the loss of ENT1 
to have dramatic effects on the vascular actions of adenosine.  
In this communication, we describe the nucleoside and nucleobase transport profile of 
MVECs derived from skeletal muscle of ENT1−/− mice and their WT littermate controls.  
 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
8-2-[3H]chloroadenosine(4–7 Ci/mmol), 2,8-[3H]hypoxanthine (24–35 Ci/mmol), 
[3H]nitrobenzylmercaptopurine riboside (NBMPR) (5.5 Ci/mmol), and [3H]water (1 
mCi/g) were purchased from Moravek Biochemicals (Brea, CA). Nonradiolabeled 2-
chloroadenosine, hypoxanthine, NBMPR, nitrobenzylthioguanine riboside, dipyridamole 
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{2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d]pyrimidine}, collagenase, 
trypsin, BSA, tert-butyl hydroperoxide (TBHP), menadione, and cobalt chloride (CoCl2) 
were obtained from Sigma-Aldrich (St. Louis, MO). All cell culture media, fetal bovine 
serum (FBS), culture grade Dulbecco's PBS, trypsin-EDTA, antibiotic/antimycotic 
(penicillin, streptomycin, and amphotericin B), and heparin were purchased from 
GIBCO/BRL (Burlington, ON, Canada). Endothelial cell growth supplement (ECGS) was 
supplied by Beckton Dickinson (Oakville, ON, Canada). Rabbit polyclonal anti-adenosine 
deaminase (ADA), goat polyclonal anti-ENT3, rabbit polyclonal anti-adenosine receptor 
A3, and donkey anti-goat horseradish peroxidase conjugated antibodies were all from 
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-adenosine receptor 
A2a and rabbit-anti mouse horseradish peroxidase-conjugated and mouse anti-rabbit 
horseradish peroxidase-conjugated antibodies were from Abcam (Cambridge, MA).  
5.2.2 ENT1−/− mouse model 
ENT1−/− mice were generated in the laboratory of Dr. Doo-Sup Choi as described 
previously (12); ENT1−/− mice were backcrossed with outbred WT C57BL/6 mice to 
generate ENT1−/+ mice. Only ENT1−/+ mice were crossed (producing ENT1+/+, ENT1+/−, and 
ENT1−/− offspring) to establish a breeding colony at the University of Western Ontario. 
Genotyping was done using isolated genomic DNA and standard PCR as previously 
described (11). All aspects of this study were conducted in accordance with the policies 
and guidelines set forth by the Canadian Council on Animal Care and were approved by 
the Animal Use Committee of the University of Western Ontario.  
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5.2.3 MVEC isolation/culture 
MVECs were isolated as described previously for rats (3), based on the affinity of their α-
d-(+)galactosyl residues for isolectin B4 from Bandeiraea simplicifolia (BSI-B4; Sigma) 
bound to magnetic microbeads (Dynabeads, M-450 Epoxy, Dynal, Lake Success, NY). The 
extensor digitorum longus muscles of female mice were removed from the hindlimbs 
under anesthesia by pentobarbital sodium (42 mg/kg ip). After careful removal and 
disposal of tissue containing larger blood vessels, the isolated muscle was sliced into 
∼0.5-mm pieces and digested for 30–45 min in 0.84 mg/ml collagenase, 0.12 mg/ml 
trypsin and dispase, and 1.62 mg/ml BSA in 50 ml Krebs-Ringer solution containing (in 
mM) 127 NaCl, 4.6 KCl, 1.1 MgSO4, 1.2 KH2PO4, 8.3 d-glucose, 24.8 NaHCO3, 2 pyruvate, 
11.4 creatinine, 20 taurine, 5 d-ribose, 2 l-asparginine, 2 l-glutamine, 1 l-arginine, and 
0.5 uric acid in a 37°C water-jacketed organ bath bubbled with 95% O2-5% CO2. The 
enzymatic digest was filtered through 100-μm nylon mesh to remove undigested 
fragments, and the dissociated cells were collected by centrifugation and washed in 
37°C DMEM-F12 media. Cells were then resuspended with ∼1 × 106 BSI-B4 coated 
Dynabeads (in DMEM-F12 media) and rotated on a spindle for 10–15 min. Endothelial 
cells bound to the magnetic beads were collected using a magnetic particle collector 
(MPC-1, Dynal), washed twice, and transferred to six-well plates in DMEM-F12 media 
supplemented with 20% FBS, 100 U/ml penicillin G, 100 μg/ml streptomycin sulfate, 
0.25 μg/ml amphotericin B, 2 mM l-glutamine, 0.025 IU/ml heparin, and 125 μg/ml ECGS 
and cultured at 37°C in a 5% CO2-95% room air humidified atmosphere. The media was 
changed routinely every 3 to 4 days, and the cells were passaged using 0.05% trypsin in 
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0.53 mM EDTA upon reaching confluence. After passage 3, the FBS and ECGS levels 
were reduced to 10% and 75 μg/ml, respectively. The endothelial cell phenotype was 
confirmed by the presence of von Willebrand factor VIII and BSI-B4 antigens as 
described previously (3). The cultures were typically found to contain >95% endothelial 
cells. In general, five passages were required to obtain sufficient cells to undertake the 
transport assays described herein.  
In preparation for experimental assays, MVECs (passage 5–15) were trypsinized for 5 
min at 37°C and then diluted with DMEM-F12 media + 10% FBS and collected by 
centrifugation. The cells were washed once by resuspension/centrifugation in PBS 
containing (in mM) 137 NaCl, 6.3 Na2HPO4, 2.7 KCl, 1.5 KH2PO4, 0.9 CaCl2·2H2O, and 0.5 
MgCl2·6H2O (pH 7.4) or a modified Na
+-free PBS containing N-methyl-d-glucamine 
(NMG) buffer consisting of (in mM) 140 NMG, 10 HEPES, 5 KCl, 4.2 KHCO3, 0.44 KH2PO4, 
0.36 K2HPO4, 1.3 CaCl2·2H2O, and 0.5 MgCl2·6H2O (pH 7.4) as appropriate to the assay 
and then resuspended in the same buffer for immediate use as described in [3H]NBMPR 
binding and [3H]substrate uptake. In some cases, the cells were depleted of ATP by 
sequential incubation at 37°C with rotenone and 2-deoxyglucose as described previously 
(3).  
5.2.4 Analysis of [3H]hypoxanthine metabolites in MVECs 
[3H]Hypoxanthine can be phosphorylated to inosine 5′-monophosphate by 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) or oxidized to xanthine via 
xanthine oxidase. To determine whether the ENT1−/− MVECs metabolized hypoxanthine 
differently than WT cells, we assessed the [3H]metabolites arising from incubating cells 
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for 20 min with 100 μM *3H]hypoxanthine. The cells were harvested as described in 
MVEC isolation/culture, ATP depleted, and then incubated for 15 min in the presence 
and absence of 5 μM dipyridamole before exposure to *3H]hypoxanthine for 20 min at 
room temperature. After incubation with [3H]hypoxanthine, the cells were centrifuged 
through oil as described in [3H]substrate uptake, and the cell pellet was digested with 
7% perchloric acid for ∼16 h. The acid soluble extract was removed and neutralized with 
an equal volume of 1 M potassium hydroxide and then centrifuged (10,000 g for 10 min) 
to remove insoluble precipitate. Extracts were stored at −20°C until required.  
The separation of purine nucleobases, nucleosides, and nucleotides was performed 
using two one-dimensional thin-layer chromatography methods modified from Metz et 
al. (25) (6 min 0.5 M LiCl, 10 min 1.0 M LiCl, and remainder in 1.5 M LiCl, all at pH 4.0 
and included 0.1 M EDTA; condition 1) and Shimizu et al. (33) (n-butanol:ethyl 
acetate:methanol:ammonium hydroxide; 7:4:3:4, vol:vol; condition 2). Plastic-backed 
PEI-cellulose F TLC plates (EMD Chemicals or Merck) were loaded with 10-μl aliquots of 
neutralized extract and developed using the two solvent conditions in parallel. Purine 
metabolite locations were determined under UV light, and the Rf values were calculated 
and compared with standards for identification. The plates were then cut into 5-mm 
strips for liquid scintillation analysis of [3H] content using Beckman Ready Protein+ 
scintillation fluid.  
Neither solvent system on its own was capable of separating all the purine metabolites 
of interest. The organic solvent (condition 2) was able to retard all nucleotides at the 
loading point on the plate and could clearly isolate adenosine and xanthine. However, 
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the hypoxanthine and inosine spots overlapped. The LiCl gradient (condition 1), on the 
other hand, could isolate inosine effectively but produced a blended hypoxanthine-
adenosine spot. Thus the amount of hypoxanthine was determined from the equation: 
dpm hypoxanthine = dpm hypoxanthine/adenosine (condition 1) − dpm adenosine 
(condition 2). Since xanthine oxidase removes the tritium at the two position of 2,8-
[3H]hypoxanthine to give 8-[3H]xanthine, the dpm values associated with xanthine were 
doubled to compensate for this.  
5.2.5 Reverse-transcriptase polymerase chain reaction 
Total RNA was isolated from the WT and ENT1−/− MVECs using the phenol-chloroform 
extraction. First-strand DNA template was generated using 5 μg (MVECs) of DNaseI 
(Invitrogen, Carlsbad, CA)-treated total RNA and the Superscript First Strand Synthesis 
System for RT-PCR using oligo d(T) primers (Invitrogen).  
RT-PCR amplifications were performed using Platinum Taq DNA polymerase (Invitrogen) 
in a Thermocycler PE 480 (Perkin Elmer, Norwalk, CT) using an oil-overlaid 50-μl reaction 
mixture in 500-μl thin-walled reaction tubes. Reaction conditions included a 2-min 94°C 
initial activation, followed by 25, 30, or 35 cycles of 30 s at 94°C, 30 s at 55°C, and 30 s at 
72°C. Preliminary experiments determined the number of cycles of PCR that were 
required to obtain a visible product on agarose gels for each of the transcripts while 
remaining on the log-linear portion of the cycle number versus product formation 
curves. PCR products were resolved by electrophoresis on 2% agarose gels against the 
O'GeneRuler 50-bp DNA ladder mix (Fermentas, Burlington, ON, Canada). Based on 
qualitative PCR, ENT1, ENT3, ADA, and the adenosine receptor A2a and A3 genes were 
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chosen for quantitative real-time PCR analysis using a Roche LightCycler (Roche Applied 
Sciences, Mississauga, ON, Canada). β-Actin was chosen as a reference control. All 
primers used were the same as those for qualitative PCR. Standard curves for all 
transcripts were generated using the same cDNA preparation at concentrations ranging 
from 10−7 to 10−12 M. The PCR was conducted using 1 μl of WT or knockout (KO) cDNA 
and SYBR Green Jumpstart Taq ReadyMix capillary formulation (Sigma). PCR conditions 
were as follows: initial denaturing at 94°C for 30 s, followed by 40 cycles of 94°C for 0 s, 
55°C for 5 s, 72°C for 17 s, and 78°C for 1 s. The melting curve analysis of products at the 
end of the reaction revealed single products from each primer pair. At least three 
individual reactions were performed using two different cDNA preparations.  
Primer sequences and expected sizes are summarized in Table 5.1 for ENT1; ENT2; 
ENT3; ENT4; concentrative nucleoside transporter subtypes 1 (CNT1), 2 (CNT2), and 3 
(CNT3); adenosine kinase; ADA; adenine phosphoribotransferase; hypoxanthine-guanine 
phosphoribotransferase; purine nucleoside phosphorylase; xanthine oxidase; A1, A2a, 
A2b, and A3 adenosine receptors; and β-actin.  
5.2.6 Immunoblots 
Extensor digitorum longus muscles were isolated from age- and sex-matched mice and 
quickly placed in ice-cold lysis buffer containing 20 mM Tris·HCl, 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, and 1 μg/ml leupeptin (pH 7.5), supplemented with 1 
mM phenylmethylsulfonyl fluoride just before use (Cell Signaling Technology, Pickering, 
ON, Canada). Total protein from tissue lysates (100 μg for ADA and ENT3; and 200 μg for 
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adenosine receptor A2a and A3) was subjected to SDS-PAGE and transferred to 
polyvinylidene difluoride membranes. Membranes were incubated overnight (≥12 h) at 
4°C with one of the following primary antibody dilutions: ADA, 1:1,000; ENT3, 1:400; 
adenosine receptor A2a, 1:1,000; or adenosine receptor A3, 1:200. Secondary antibodies 
were used at dilutions of 1:10,000, 1:1,000, 1:4,000, and 1:1,000 for ADA, ENT3, A2a, and 
A3, respectively, and incubated with membranes for 1 h at room temperature. Detection 
was performed using LumiGLO chemiluminescent substrate (Cell Signaling Technology) 
and the VersaDoc Imaging System (Bio-Rad). After exposure, the membranes were 
stripped (200 mM glycine, 1% Tween-20, and 0.1% SDS; pH 2.2) and then probed for 
GAPDH using a 1:1,000 dilution of primary antibody for 2 h at room temperature. The 
secondary antibody was used at dilutions of 1:2,000 for ADA and ENT3 and 1:4,000 for 
adenosine receptor A2a to account for the double amount of protein used. Densitometry 
was performed using ImageJ software (http://rsbweb.nih.gov/ij/index.html). In all cases, 
the major protein detected by each antibody reflected the expected size of the product 
based on manufacturers' specifications and previously published data using these 
antibodies (10; 27). 
5.2.7 Treatment with Reactive Oxygen Species Generators 
Reactive oxygen species (ROS) generators were made fresh each day. TBHP was diluted 
in ddH2O from a concentrated stock. Menadione was dissolved in 100% ethanol. In all 
cases, confluent cells were washed with warm PBS and fed with warmed complete 
medium containing vehicle (control) or the indicated concentration of ROS generator. 
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Cells were placed back into the 37°C CO2 incubator for the desired time before 
harvesting and subsequent uptake studies (as described in Chapter 2). 
5.2.8 Simulated Ischemia and Hypoxia 
5.2.8.1 Cobalt Chloride Treatment 
Cobalt chloride (CoCl2) is an established stabilizer of HIF-1α (30). Confluent cells were 
washed with PBS and covered with medium containing 100 µM CoCl2 and incubated at 
37°C for the time indicated before harvesting for uptake. 
5.2.8.2 Simulated Ischemia 
Based on a method developed by Meldrum and colleagues (24), primary mouse cells 
were harvested and resuspened in fresh complete medium. Cell suspensions were 
placed in a 37°C 5%CO2-95% air humidified atmosphere for 1 hour to equilibrate. 
Following equilibration, a cell lot was centrifuged briefly and all medium was aspirated 
off with the exception of enough to keep the pellet covered. The pellet was 
resuspended by flicking the tube. Simulated ischemia was initiated by the layering of 
mineral oil over the medium, creating a gas exchange barrier. Mineral oil overlayed cells 
were placed back in the atmosphere described above for 2 hr. Control cells were left in 
the complete medium with no overlay. Cells were gently mixed every 30 minutes. 
Following treatment, cells were washed with PBS, centrifuged, and supernatant was 
aspirated. This procedure was repeated three times to ensure no mineral oil was 
remaining. Cells were then resuspended in a final volume appropriate for substrate 
uptake assay. 
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5.2.8.3 Hypoxia 
For true low oxygen exposure, culture flasks were place in Hypoxia Chambers (Billips-
Rothenberg, Del Mar, CA). Chambers were flushed with 1% O2 for 5 min and expelled air 
was measured with an O2 detector to confirm low oxygen levels. Chambers were then 
sealed and placed in a 37°C incubator for the desired time. Following hypoxia, flasks 
were removed from the chambers and harvested for uptake.  
 
5.3 RESULTS 
5.3.1 MVECs from ENT1-/- Lack [3H]NBMPR Binding 
The gross phenotype of the ENT1−/− mice was similar to that reported previously by Choi 
and colleagues (12). The ENT1−/− mice had a consistently lower body weight. They were 
also notably easier to handle than WT mice (less distress because of handling), likely 
reflecting the anxiolytic phenotype reported previously (11). Quantitative RT-PCR 
confirmed the loss of the full-length ENT1 transcript in the ENT1−/− mice (Figure 5.2). 
MVECs from the ENT1−/− mice had no detectable high-affinity binding sites for the ENT1-
selective radioligand probe [3H]NBMPR (Figure 5.1), confirming the specificity of this 
radioligand for the ENT1 protein. WT mouse MVECs had 150,000 ± 27,000 [3H]NBMPR 
sites/cell with an affinity of 0.09 ± 0.02 nM, which is typical of NBMPR binding to ENT1. 
5.3.2 Compensatory Changes in Purinergic Genes in ENT1-/- MVECs 
We found no evidence for Na+-dependent CNT1, CNT2, and CNT3, and we confirmed 
that MVECs do not express the A1 adenosine receptor subtype (19). No changes were 
observed in the expression of the ENT2 subtype of plasma membrane-located 
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nucleoside transporters in ENT1−/− mice compared with littermate controls (Figure 5.2A), 
nor was the ENT4 transcript detected in either the WT or ENT1−/− cells. Furthermore, no 
significant differences were noted in the expression of adenosine kinase, xanthine 
oxidase, HGPRT, adenine phosphoribotransferase, purine nucleoside phosphorylase, or 
A2B adenosine receptors in the ENT1
−/− MVECs compared with WT controls (Figure 5.2A). 
However, MVECs from ENT1−/− mice showed significant increases of 15 ± 3- and 11 ± 2-
fold, respectively, in the expression of mRNA transcripts for ADA and A2a adenosine 
receptors, relative to WT littermate controls (Figure 5.2B). There was a trend toward a 
decrease in adenosine A3 receptor transcript in the ENT1
−/− mice, but this did not reach 
statistical significance and there was no corresponding change in A3 receptor protein 
levels (Figure 5.3). Likewise, there was a small but significant increase in ENT3 transcript 
(Figure 5.2B), which was also not paralleled by an increase in ENT3 protein in skeletal 
muscle (Figure 5.3). Attempts to measure ADA and A2a adenosine receptor protein levels 
in the MVECs proved to be problematic. However, significant increases in ADA (2.1-fold) 
and adenosine A2a receptor (2.4-fold) protein was evident by immunoblotting using the 
skeletal muscle tissue of ENT1−/− mice from which the MVECs were derived, relative to 
WT mice (Figure 5.3). 
5.3.3 Nucleoside and Nucleobase Transport Function in WT and ENT1-/- MVECs 
In terms of the ability to accumulate [3H]substrates associated with ENT activity, the WT 
MVECs accumulated both [3H]formycin B (Figure 5.4) and 2-[3H]chloroadenosine (Figure 
5.5) via two distinct Na+-independent dipyridamole-sensitive processes (Table 5.2). The 
majority (∼90%) of the substrate uptake in WT MVECs was inhibited by 50 nM NBMPR 
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and hence was mediated by ENT1. The remainder of the uptake was inhibited by 
dipyridamole, but not NBMPR, and hence was mediated by ENT2. The uptake of 
[3H]formycin B (Figure 5.4) and 2-[3H]chloroadenosine (Figure 5.5) by MVECs was 
reduced dramatically in the cells derived from the ENT1−/− mice (Table 5.2). The initial 
rate of uptake of 10 μM *3H]formycin B in the ENT1−/− MVECs was 0.07 ± 0.01 pmol/μl/s, 
which is not significantly different from the rate of ENT2-mediated formycin B uptake by 
WT mMVECs (0.06 ± 0.01 pmol/μl/s) (Figure 5.4). When 2-[3H]chloroadenosine was used 
as a substrate, it was evident that in WT MVECs, ENT1 accounted for the majority of 
nucleoside transport, with ENT2 providing a very small component of the total. In  
ENT1-/- MVECs, only ENT2 mediated transport was present. Interestingly, the Vmax of 2-
chloroadenosine uptake in the ENT1−/− mice (0.19 ± 0.07 pmol/μl/s) was actually 
significantly lower than the Vmax of ENT2-mediated 2-chloroadenosine uptake in the WT 
mice (1.2 ± 0.5 pmol/μl/s) (Figure 5.5). 
To further assess the ENT2-mediated component in the MVECs, the uptake of 
[3H]hypoxanthine was examined after depleting the cells of ATP to reduce trapping of 
[3H]hypoxanthine metabolites. ENT2 differs from ENT1 in that it accepts nucleobases, 
such as hypoxanthine, as substrates in addition to purine and pyrimidine nucleosides. It 
was apparent from the initial time course studies using 10 μM hypoxanthine that mouse 
MVECs readily accumulated hypoxanthine via a saturable system that was relatively 
insensitive to dipyridamole but that was inhibited by adenine (Figure 5.6). These data 
suggest that hypoxanthine was being accumulated via an ENT-independent transport 
process. When adenine (1 mM) is used to define the nonmediated uptake component, 
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the WT mouse MVECs accumulated hypoxanthine with Km and Vmax estimates of 125 ± 
29 μM and 16.5 ± 3.8 pmol/μl/s, respectively, while ENT1−/− cells had similar Km and Vmax 
values of 123 ± 28 μM and 11.6 ± 2.1 pmolμl/s, respectively (Figure 5.7). 
Interestingly, the apparent rate of [3H]hypoxanthine influx tended to increase when cells 
from WT mice were incubated with the ENT blocker dipyridamole before the uptake 
measurements, particularly at higher (>100 μM) concentrations of hypoxanthine (Figure 
5.7). In contrast, dipyridamole had no effect on hypoxanthine uptake by ENT1−/− MVECs. 
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Figure 5.1. MVECs from ENT1-/- lack [3H]NBMPR binding.  
MVECs isolated from either wild-type (WT) or equilibrative nucleoside transporter 
subtype-1 (ENT1) knockout (KO) (ENT1-/-) littermates were exposed to a range of 
concentrations of [3H]nitrobenzylmercaptopurine riboside (NBMPR) (abscissa) in the 
absence (total binding) or presence (nonspecific binding) of 10 µM 
nitrobenzylthioguanine riboside. Specific binding (ordinate) was calculated as the 
difference between total and nonspecific binding. Each point is the mean ± SEM of 5 
experiments performed in duplicate. 
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Table 5.1 RT-PCR primers 
Primers used for the amplification of each of the indicated genes are shown along with 
the expected product size and the number of cycles used in the PCR reactions. The cycle 
number was selected based on the lowest number that revealed a product up to a 
maximum of 35 cycles in the qualitative reverse-transcriptase PCR reactions. ENT, 
equilibrative nucleoside transporter; CNT, concentrative nucleoside transporter.
Gene Primer 5’-3’ Product Size 
(bp) 
# of cycles 
ENT1 CAAGTATTTCACAAACCGCCTGGAC 
GAAACGAGTTGAGGCAGGTGAAGAC 
196 25 
ENT2 GACCTCTGCTCTTGGATACTTCAT 
GACAACAAAGACTGAAGGTTTTCC 
288 35 
ENT3 CCCTCCCTGCTGTTCCTGGT 
CATGGGGAAGGAGCCTGTGA 
245 30 
ENT4 ATTGGCGGCTGTGCTCCTAAA 
TGCCGTGCTCTCTCCAGTCAT 
279 35 
CNT1 GCAGCTGTTTGAGTGGATCA 
ACCACACAGGTGATGACGAA 
120 35 
CNT2 ATTTGTGGCCTACCAGCAAC 
GCCTCCCAGTGTGATTCCTA 
169 35 
CNT3 TGTGCGATAAGCTTCCACAG 
CAAGTTTTGTTGGCCCAGTT 
243 35 
Adenosine Kinase TGGAGCGGAACTGGGTGTTGG 
GGAAGAGCCTGCGCCTTTTTGG 
300 30 
Adenosine Deaminase GAAGGCAAAGGAGGGCGTGGTCTA 
GATGTCCACAGCCTCACGCACAAC 
423 25 
Adenine Phosphoribosyltransferase CAAGATCGACTACATCGCAGGTCT 
GCTCACACACTCCACCACTTCAG 
297 25 
Hypoxanthine-Guanine 
Phosphoribosyltransferase 
CATTGTGGCCCTCTGTGTGCTCAA 
CGAGAGGTCCTTTTCACCAGCAAGC 
326 25 
Purine nucleoside phosphorylase GCCGACTGGTGTTTGGATTGCTG 
TCGTTGCTCCCCCATTTGTTTCC 
358 25 
Xanthine Oxidase TGCCTGCTTGACCCCCATCTG 
CCTCCACAGCACCCACCATCC 
299 30 
A1 adenosine receptor ATCCCTCTCCGGTACAAGACAGT 
ACTCAGGTTGTTCCAGCCAAAC 
119 35 
A2A adenosine receptor CCGAATTCCACTCCGGTACA 
CAGTTGTTCCAGCCCAGCAT 
119 35 
A2B adenosine receptor TCTTCCTCGCCTGCTTCGT 
CCAGTGACCAAACCTTTATACCTGA 
120 35 
A3 adenosine receptor ACTTCTATGCCTGCCTTTTCATGT 
AACCGTTCTATATCTGACTGTCAGCTT 
128 35 
β-actin GTGACGTTGACATCCGTAAA 
CTCAGGAGGAGCAATGATCT 
148 25 
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Figure 5.2. Analysis of purine transporter/metabolic enzyme gene expression in MVECs. 
A: qualitative reverse-transcriptase PCR: PCR reactions were conducted using the 
primers shown in Table 5.1, and the products were resolved on 2% agarose gels. The 
same PCR conditions were used for each primer pair in both the WT and ENT1-/- 
samples, and all amplifications shown on each gel set were done in parallel using the 
same WT and KO cDNA preparations. The first lane on each gel set represents the DNA 
ladder (bp sizes as labeled). Set 1: ENT1, ENT2, ENT3, and β-actin (the vertical bar 
indicates where a blank section of the gel image was removed between the ENT3 and β-
actin lanes); set 2: adenosine A2A receptor, adenosine A2B receptor, A3 receptor, and β-
actin; and set 3: adenosine kinase (ADK), adenosine deaminase (ADA), adenine 
phosphoribosyltransferase (APRT), hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT), purine nucleoside phosphorylase (PNP), xanthine oxidase (XO), and β-actin. All 
products were of the expected size. B: quantitative real-time PCR: apparent differences 
in gene expression between the WT and ENT1-/- MVECs, as noted in the studies shown in 
A, were confirmed by real-time PCR. Crossing point (CP) values, obtained from SYBR 
green I fluorescence signals, were used to compute the concentrations of ENT3, ADA, 
and adenosine A2A and A3 receptor transcripts, relative to β-actin. β-Actin CP values 
were 19.3 ± 0.6 and 18.8 ± 0.7 for the WT and ENT1-/- samples, respectively. The gene-
to-β-actin ratios derived from each independent experiment were then averaged to 
obtain the data shown. Each bar is the mean ± SEM of 3 separate amplification runs 
from 2 independent mRNA isolations (n = 6). *P<0.05, significant difference in 
expression between the WT and ENT1-/- cells (Student’s t-test). C: data from B plotted as 
the relative change between the WT and ENT1-/- mice. 
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Figure 5.3. ADA and A2A are upregulated at the protein level.  
Proteins extracted from the extensor digitorum longus muscles of WT and ENT1-/- mice 
were separated by electrophoresis and immunoblotted, in parallel, with antibodies to 
GAPDH (37 kDa), ADA (50 kDa), adenosine A2A receptor (45 kDa), adenosine A3 receptor 
(43 kDa), and ENT3 (52 kDa).Representative immunoblots are shown in A. The results 
(mean ± SEM) of densitometry analysis of 3 independent experiments with adenosine 
receptor A2A and ADA are shown in B as a ratio relative to GAPDH. *P<0.05, significant 
difference in expression between the WT and ENT1-/- muscle (Student’s t-test). 
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Figure 5.4. Formycin B uptake by ENT2 is unchanged in MVECs from ENT1-/- mice.  
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated with 10 µM 
[3H]formycin B (FB) in the absence (Total, ▪) or presence of 50 nM NBMPR (+NBMPR; 
selective inhibition of ENT1-mediated uptake, □) or 10 µM dipyridamole/NBMPR (+DY; 
complete inhibition of transporter-mediated uptake, ●) for the times indicated. Uptake 
is represented as picomoles of [3H]FB accumulated per microliters of intracellular water. 
Each point is the mean ± SEM from 4 experiments. 
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Figure 5.5. Uptake of 2-[3H]chloroadenosine by ENT2 is reduced in MVECS from ENT1-/- 
mice.  
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated for 5 or 15 s, 
respectively, with the indicated concentrations of 2-[3H]chloroadenosine. Parallel assays 
were conducted in the absence (total influx) and presence of either 50 nM NBMPR 
(NBMPR-resistant influx) or 10 µM DY/NBMPR (nonmediated uptake) as described in 
Figure 5.4 for [3H]FB uptake. The total transporter-mediated uptake of substrate was 
calculated as the total influx minus the nonmediated component. The ENT2-mediated 
uptake was calculated as the NBMPR-resistant uptake minus the nonmediated 
component, and the ENT1-mediated uptake was estimated as the difference between 
the total uptake and that seen in the presence of NBMPR. Results are plotted as 
picomoles of 2-[3H]chloroadenosine accumulated per microliter of cell water per second 
(Vi, ordinate) against the concentration of 2-[3H]chloroadenosine used (abcissa). Each 
point is the mean ± SEM from 5 experiments. The transporter kinetic constants derived 
from these data are shown in Table 5.2. 
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Figure 5.6. Uptake of [3H]hypoxanthine was mediated by a dipyridamole-insensitive 
transporter.  
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated with 5 µM 
[3H]hypoxanthine in the absence (Total) or presence of 10 µM DY (inhibition of ENT2-
mediated uptake) or 1 mM adenine for the times indicated. Uptake is represented as 
picomoles of [3H]hypoxanthine accumulated per microliter of intracellular water (in 
µM). Each point is the mean ± SEM from 4 experiments. 
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Figure 5.7. Dipyridamole enchanced [3H]hypoxanthine uptake in WT, but not ENT1-/- 
MVECS.  
MVECs isolated from either WT (A) or ENT1-/- (B) mice were incubated for 10 s with the 
indicated concentrations of [3H]hypoxanthine (abcissa). Parallel assays were conducted 
in the absence and presence of 1 mM adenine with or without the inclusion of 10 µM DY 
as described in Figure 5.6. Results are plotted as the transporter-mediated uptake of 
substrate (in pmol per µl of cell water accumulated per s; Vi, ordinate) after subtraction 
of the adenine-insensitive component. Each point is the mean ± SEM from 5 
experiments. The transporter kinetic constants derived from these data are shown in 
Table 5.2. 
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5.3.4 Purine Metabolism in ENT1-/- MVECs 
We examined the [3H]metabolite profile of WT and ENT1−/− MVECs after exposure to 
[3H]hypoxanthine under the conditions that we used for the uptake assays (Figure 5.8). 
ENT1−/− MVECs had significantly higher intracellular levels of [3H]hypoxanthine than did 
the WT MVECs after exposure to 100 μM *3H]hypoxanthine for 20 min. [3H]inosine levels 
showed a trend toward being increased in ENT1−/− MVECs; however, this difference was 
not significant unless dipyridamole was present to block the remaining ENT2-mediated 
efflux. The difference between the WT and ENT1−/− MVECs was also attenuated in the 
presence of the ENT blocker dipyridamole. 
5.3.5 Effects of Free Radical Generators on Purine Transport in Mouse MVECs 
The hydroxy radical producing TBHP had no effect on ENT1, ENT2 or ENBT1 in primary 
mouse MVECs following 100 µM treatment for 30 minutes (Figure 5.9). Following 
treatment with the intracellular ROS generator menadione, the Vmax of ENT1 mediated 
2-[3H]choloroadenosine uptake dropped significantly from 15.6 ± 2.7 pmol/µl/s to 4.9 ± 
2.1 pmol/µl/s. The Vmax of ENT2 also appeared to drop, however the small amount of 
ENT2 present in mMVECs resulted in high background that prevented statistical analysis. 
[3H]Hypoxanthine mediated uptake via ENBT1 was not affected by menadione 
treatment, however the small amount of ENT2 mediated [3H]hypoxanthine uptake that 
was present in control cells appeared to be abolished in menadione treated cells (Figure 
5.10). 
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Table 5.2 Kinetic parameters for the transporter-mediated uptake of 2-chloroadenosine 
and hypoxanthine by MVECs isolated from WT and ENT1-/- mice. 
 
 
 
WT 
  
ENT1 -/- 
 Total ENT1 ENT2  Total ENT1 ENT2 
2-Chloroadenosine        
 
Vmax (pmol/μl/s) 
 
18 ± 3 
 
24 ± 5 
 
1.2 ± 0.5 
  
- 
 
nd * 
 
0.19 ± 0.06 * 
 
Km (μM) 
 
84 ± 17 
 
147 ± 44 
 
9 ± 3 
  
- 
 
nd * 
 
13 ± 6 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Total DY 
-insensitive 
ENT2  Total DY 
-insensitive 
ENT2 
 
Hypoxanthine 
Vmax (pmol/μl/s) 
 
 
12 ± 2 
 
 
17 ± 4 
 
 
nd 
  
 
10 ± 2 
 
 
12 ± 2 
 
 
nd 
 
Km (μM) 
 
84 ± 20 
 
126 ± 29 
 
nd 
  
96 ± 29 
 
131 ± 32 
 
nd 
Values are means ± SEM; n = 5 WT and 5 ENT1-/- mice. MVECs, microvascular 
endothelial cells; WT, wild-type; ENT1-/-, ENT knockout; DY, dipyridamole; ND, no 
transport activity detected. *P<0.05, significant difference between WT and ENT1-/- 
(Student’s t-test).
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Figure 5.8. [3H]Metabolite profile in WT and ENT1-/- MVECs.  
MVECs isolated from WT and ENT1-/- mice were depleted of ATP and incubated with 100 
µM [3H]hypoxanthine in the absence and presence of 10 µM DY for 20 min. Acid extracts 
of cell pellets were neutralized with 1 M KOH, and aliquots were subjected to thin-layer 
chromatography as described in section 5.2.4. A repeated-measures ANOVA was 
performed within each metabolite group. *P<0.05 compared with WT -ATP condition; 
†P <0.05 compared with WT -ATP +DY condition. 
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5.3.6 Effects of Ischemia and Hypoxia on Purine Transporters 
Treatment with the HIF-1α stabilizer CoCl2 resulted in a significant decrease in mENBT1 
Vmax of [
3H]hypoxanthine uptake to 21 ± 10% of control. 2-[3H]Chloroadenosine uptake 
by mENT1 was not affected (Figure 5.11A-B). Exposure of cells to a simulated ischemic 
environment by mineral oil overlay caused significant reduction in ENBT1 Vmax in 
primary mouse MVECs. (Figure 5.11C). When cells were exposed to true hypoxia of 1% 
O2 ENBT1 Vmax of [
3H]hypoxanthine uptake increased significantly from 9.5 ± 2.2 
pmol/µl/s to 31.4 ± 5.1 pmol/µl/s in MVECs (Figure 5.11D). 
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Figure 5.9. TBHP had no effect on purine transport. 
Primary mouse MVECs were treated with 100 µM TBHP for 30 minutes at 37°C. Uptake 
of 2-[3H]chloroadenosine(A and B) and [3H]hypoxanthine (C and D) was determined as 
described in Chapter 2. Data are means ± SEM of 6 (A and B) or 5 independent 
experiments (C and D). 
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Figure 5.10. Menadione reduced the Vmax of ENT1 mediated 2-chloroadenosine uptake. 
Primary mouse MVECs were treated with 100 µM menadione for 30 minutes at 37°C 
prior to uptake of 2-[3H]chloroadenosine (A and B) and [3H]hypoxanthine (C and D).  A) 
Uptake of 2-[3H]chloroadenosine by ENT1 following menadione treatment (open 
squares, dotted line) had a Vmax of 4.9 ± 2.1 pmol/µl/s compared to the Vmax of control 
cells (solid squares, solid line) of 15.6 ± 2.7 pmol/µl/s. Data are mean ± SEM of three 
independent experiments, P<0.05 by two-tailed t-test. B) ENT2 mediated uptake of  
2-[3H]chloroadenosine also appeared to decrease following menadione treatment but 
high variability prevented statistical analysis (n=3). C) ENBT1 mediated uptake of 
[3H]hypoxanthine was not affected by menadione treatment (n=3). D) ENT2 mediated 
uptake of [3H]hypoxanthine was abolished (n=3). 
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Figure 5.11. Hypoxanthine uptake can be altered by both ischemia and hypoxia in 
mouse MVECs. 
Primary mouse MVECs were treated with 100 µM CoCl2 for 2 hr at 37°C. ENT1 and 
ENBT1 uptake of 2-[3H]chloroadenosine and [3H]hypoxanthine, respectively, (A and B) 
was determined. Only ENBT1 function was altered. The Vmax of CoCl2 treated cells (open 
squares, dotted line) decreased to 21 ± 10% of control (solid squares, solid line). Data 
are means ± SEM of 4 independent experiments for each substrate. C) MVECs were 
subjected to simulated ischemia by mineral oil overlay. The Vmax of ENBT1 mediated 
uptake of [3H]hypoxanthine dropped from 23 ± 6 pmol/µl/s to 5 ± 1 pmol/µl/s after 2 hr 
of simulated ischemia. P<0.05 two-tailed t-test, n = 4. D) Following exposure to 1% O2 
for 2 hr, uptake of [3H]hypoxanthine increased in primary mouse MVECs following 
hypoxia, with ENBT1 Vmax increasing from 9.5 ± 2.2 pmol/µl/s to 31.4 ± 5.1 pmol/µl/s, 
P<0.05 two-tailed t-test, n = 3.  
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5.4. DISCUSSION 
5.4.1 Compensatory Changes in ENT1-/- MVECs 
We performed both semi-quantitative and quantitative real-time PCR to determine 
which purinergic genes, if any, had altered transcript expression as a result of the 
genetic loss of ENT1. Statistical differences in PCR were followed up by western blotting. 
While there were significant changes in adenosine receptor A3 and ENT3 at the 
transcript level, the lack of correlation between changes in mRNA versus protein levels 
for these relatively low abundance transcripts may reflect posttranscriptional regulation 
of translation efficiency and protein processing. The significant increases in ADA and A2a 
transcripts were confirmed at the protein level as well. These adaptive changes can be 
rationalized, from a cell homeostasis perspective, if one assumes that the loss of ENT1 is 
leading to a reduced efflux of adenosine (arising from ATP metabolism) from the MVECs. 
This would result in an increased cytoplasmic adenosine and a decreased extracellular 
adenosine in the ENT1−/− compared with WT mice. The increase in ADA would lead to 
more adenosine metabolism to inosine, which may then be converted to either 
hypoxanthine or inosine monophosphate (2), thereby reducing intracellular adenosine. 
Adenosine has well-established vasodilatory (5) and anti-inflammatory activities (21), 
mediated in part via extracellular adenosine A2A receptors on vascular endothelial cells. 
Thus the increase in adenosine A2A receptor expression may be compensating for the 
lower levels of adenosine-mediated signaling in the ENT1−/− mice as a consequence of 
reduced extracellular adenosine concentrations. A previous study has also invoked 
lower extracellular adenosine levels as an explanation for the reduced A1 adenosine 
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receptor signaling observed in the brains of ENT1−/− mice (12). In contrast to our findings 
in MVECs, there does not appear to be a compensatory upregulation of adenosine A2a 
receptors in cardiomyocytes isolated from the ENT1−/− mice (31), suggesting that 
different cell types respond differently to changes in adenosine bioavailability. With the 
consideration that adenosine receptor expression varies between different tissues and 
therefore adenosine has differing physiological effects in each tissue, the compensatory 
changes that would result from altered adenosine levels might be expected to differ in 
different tissues and cell types.  
5.4.2 Alterations in Purine Transport Capacity 
The WT MVECs accumulated both [3H]formycin B (Figure 5.4) and 2-
[3H]chloroadenosine(Figure 5.5) via two distinct Na+-independent dipyridamole-
sensitive processes (Table 5.2). The majority (∼90%) of the substrate uptake in WT 
MVECs was inhibited by 50 nM NBMPR and hence was mediated by ENT1. The 
remainder of the uptake was inhibited by dipyridamole, but not NBMPR, and hence was 
mediated by ENT2. It is noteworthy that mouse MVECs are very different from rat 
MVECs where ENT2 mediates ∼50% of the total nucleoside uptake (3). Thus one would 
expect an ENT1-selective inhibitor such as NBMPR to have a much greater effect on 
nucleoside levels in the cardiovasculature of mouse compared with its effects in rat. The 
lack of change in ENT2 mediated [3H]formycin B uptake corresponds to the lack of 
change in ENT2 transcript levels. The interesting observation that the 2-
[3H]chloroadenosine Vmax for ENT2 was significantly decreased in ENT1
-/- knockout cells 
may be an artifact of the uptake procedure, as ENT2 mediated uptake is defined as  
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2-[3H]chloroadenosine uptake in the presence of 50 nM NBMPR, to inhibit ENT1 
transport function.  
Mouse MVECs appear to have a dipyridamole-insensitive nucleobase transporter very 
similar to the ENBT1 transporter described in detail in Chapter 3, and therefore quite 
possibly was the mouse ortholog of the human transporter. As such, ENBT1 was used to 
refer to the dipyridamole-insensitive hypoxanthine transporter in mMVECs. 
Hypoxanthine is a metabolite of adenosine metabolism and would be produced in the 
endothelial cells under conditions of high adenosine release from surrounding cells, 
such as would occur during tissue ischemia (2; 15; 16). This hypoxanthine is metabolized 
intracellularly by xanthine oxidase with the consequent production of reactive oxygen 
species. Reactive oxygen species are believed to play a role in mediating the endothelial 
dysfunction observed in various pathological conditions including diabetes and 
ischemia-reperfusion injury (6; 20; 32). Therefore, understanding how MVECs handle 
hypoxanthine is important in the overall evaluation of purine metabolism in the 
vasculature. It appears that both mouse and human MVECs, which have low or no ENT2, 
respectively, rely heavily on this nucleobase transporter for the transfer of nucleobases 
across the cell membrane. Rat MVECs, on the other hand, which express high levels of 
ENT2 (which can transport nucleobases), do not appear to express functional ENBT1. 
Further studies on this novel nucleobase transport system are needed. 
When studying ENBT1 transport kinetics in mouse MVECs, it was found that the ENT2 
blocker dipyridamole caused an apparent increase in Vmax in WT cells but had no effect 
in ENT1-/- cells (Figure 5.7). Given that part of the hypoxanthine uptake in the MVECs 
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would be due to the activity of ENT2, one should actually expect to see a small decrease 
in hypoxanthine uptake in the presence of dipyridamole. One interpretation of these 
data is that dipyridamole was blocking the efflux of a metabolite of hypoxanthine via 
ENT1. In normal cell metabolism, hypoxanthine is typically formed as a metabolite of 
inosine and is efficiently metabolized by xanthine oxidase to xanthine or by HGPRT to 
inosine monophosphate such that there is little free hypoxanthine in cells. However, 
under the experimental conditions used in this study, where cells are exposed to high 
concentrations of hypoxanthine, it is possible that the [3H]hypoxanthine is being 
metabolized to [3H]inosine via purine nucleoside phosphorylase (9). As noted above, 
inosine is a substrate for ENT2 and ENT1, both of which are blocked by dipyridamole. 
The WT MVECs, with their high level of expression of ENT1, would release the 
[3H]inosine formed in this way much more rapidly than would the ENT1-deficient cells 
and would thus be more sensitive to the effects of dipyridamole. To test this hypothesis, 
a [3H]metabolite profile was produced using a 1-D TLC method. The profile generated 
(Figure 5.8) supported the idea that [3H]hypoxanthine is being metabolized to 
[3H]inosine by nucleoside phosphorylase under these assay conditions and that this 
[3H]inosine is not released from ENT1−/− cells as effectively as it is from WT MVECs. 
These data also show that the ATP-depletion protocol used led to the expected 
reduction in the conversion of hypoxanthine to its phosphorylated metabolites. 
5.4.3 Impact of Ischemia and Hypoxia on Purine Transport in WT MVECs 
The oxidation of proteins is known to result in altered function. To determine how 
nucleoside and nucleobase transporters respond to the presence of increased ROS, 
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cultured primary cells were treated with extracellular (TBHP) or intracellular 
(menadione) ROS generators. Only menadione affected transport, and resulted in 
decreased transport capacity. This effect was similar to that observed in primary human 
MVECs in Chapter 4. Menadione (2-methyl-1,4-naphthoquinone) produces ROS 
intracellularly via metabolism by NAD(P)H:quinone oxidoreductase 1 in a redox cycling 
manner, directly generating superoxide anions(14). This is in contrast to TBHP, a 
peroxide, which forms hydroxyl radicals in the presence of iron via the Fenton reaction, 
or in the presence of superoxide anions by the Haber-Wells reaction. Peroxides are also 
detoxified to water and oxygen enzymatically by glutathione peroxidase (26). Thus, it is 
possible that the lack of effect of TBHP on purine transport could be at least three fold: 
1) the conditions were not suitable for hydroxyl radicals to be formed, 2) glutathione 
peroxidase removed all TBHP prior to radical formation, or 3) ENT1 and ENBT1 
transporters are not sensitive to oxidation by hydroxyl radicals.  
The superoxide anions produced by menadione are usually short lived and are 
converted into hydrogen peroxide by superoxide dismutase. However, in the presence 
of nitric oxide (NO) which is produced by endothelial nitric oxide synthase, the two 
radicals combine to form peroxynitrite (ONOO-), a much more potent oxidizing agent 
(34). Peroxynitrite has been shown to decrease the function of other transport proteins 
including the high affinity choline transporter, the human serotonin transporter(8), and 
the human dopamine transporter (29). Therefore it is possible that that the decrease in 
ENT1 and ENT2 function observed following mMVEC exposure to menadione was the 
result of peroxynitrite formation. 
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It has been previously established that ENT1 is a target of the HIF-1α transcription 
factor(1; 18). However the time required for a down-regulation was upwards of 8 hr 
(18). It was unknown if the nucleobase transporter ENBT1 was also a target. Initial 
experiments were conducted with the known HIF-1α stabilizer, CoCl2 (30). Treatment 
with 100 µM CoCl2 for 2 hr was only capable of reducing transport function of ENBT1, 
not ENT1. The treatment time used was much less than that known to cause HIF 
mediated ENT1 down-regulation but was chosen to reflect an acute ischemic event in 
the vasculature. In Chapter 4, it was shown that CoCl2 has no effect on human 
transporters. CoCl2 has also been shown to generate ROS in addition to HIF-1α 
stabilization, and the effects of CoCl2 are selectively blocked by the antioxidant ascorbic 
acid (vitamin C)(13). A major difference between the mouse and human MVEC medium 
was that the CoCl2 added to the human medium contained an additional 
supplementation of ascorbic acid (concentration unknown; proprietary information). 
Therefore, the lack of similar ENBT1 down-regulation in hMVECs may have been due to 
the protective presence of ascorbic acid. 
The nucleobase transporter ENBT1 was extremely sensitive to 2 hr of simulated 
ischemia with hypoxanthine uptake function being reduced by approximately 80%, 
similar to that of the human ENBT1 as shown in Chapter 4. The increase in Vmax of ENBT1 
mediated [3H]hypoxathine uptake after 2 hr of hypoxia (1% O2) suggests that ischemia 
and hypoxia cause differential effects in mouse MVECs. Since these assays were 
conducted in ATP-replete conditions as not to interfere with any regulatory processes, 
the most likely explanation for the apparent increased Vmax is due to increases in 
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[3H]hypoxanthine metabolism. Hypoxia is known to convert xanthine dehydrogenase to 
the hypoxanthine metabolizing xanthine oxidase. 
5.4.4 Conclusions 
The loss of ENT1 in the ENT1−/− mice leads to a dramatic reduction in the ability of 
MVECs to accumulate and release nucleosides such as adenosine. Despite this loss of 
nucleoside transport capacity, the ENT1−/− mice appear phenotypically normal under 
baseline conditions. There did not appear to be any compensatory upregulation of the 
other major plasma membrane nucleoside transporter ENT2 in the ENT1−/− mice, but 
there were increases in both ADA and A2A adenosine receptor expression in MVECs and 
the skeletal muscle tissue from which the cells were isolated. The consequent changes 
in adenosine metabolism and adenosine-mediated signaling via the A2A receptor likely 
compensate for decreased extracellular adenosine levels in the ENT1−/− mice and allow 
them to function normally under baseline conditions. However, given the widely 
acknowledged role of adenosine as a cardioprotectant in conditions of cardiovascular 
stress, it might be anticipated that the ENT1−/− mice will be less able to respond to 
cardiovascular stresses associated with conditions such as diabetes and ischemia-
reperfusion injury. Alternatively, a reduced uptake of extracellular adenosine might 
potentiate adenosine-receptor activation and subsequent cardioprotection, suggesting 
that ENT1−/− mice might be permanently preconditioned (22; 23) and thus protected 
from ischemic or hypoxic challenge. 
The studies in this chapter have provided the ground work for studying the role of 
purine transporters in oxidative stress in the microvasculature. Observations that the 
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hypoxanthine transporter, ENBT1 is affected by both intracellular ROS and ischemia 
point to ENBT1 being a contributing factor to endothelial dysfunction following an 
ischemic insult. Using the ENT1-/- MVECs will establish how ENT1 and thus adenosine 
transport contribute to the generation of ROS and the impact on ENBT1 function.
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CHAPTER SIX 
ADDITIONAL PHENOTYPES OF THE ENT1-/- MOUSE: FROM HYPOTENSION TO  
SPINAL HYPEROSTOSIS. 
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6.1 Introduction 
The equilibrative nucleoside transporter 1 (ENT1; SLC29A1) is the predominant 
nucleoside transporter expressed in mammalian cells. ENT1 is a sodium-independent, 
facilitative diffusion transporter that is responsible for the movement of hydrophilic 
nucleosides, like the purine adenosine, across biological membranes in a concentration 
dependent manner.  Pharmacological inhibition of ENT1 has been shown to increase 
local adenosine levels and promote the cardio- and neuro-protective actions of the 
nucleoside.  
An ENT1-/- mouse has been generated by Choi and his collaborators (4). ENT1-/- mice 
were viable but had a slightly lower body weight upon reaching maturity. The behaviour 
of the ENT1-/- mice is altered compared to their wild-type (WT) counterparts, especially 
in respect to increased ethanol consumption (4) and decreased anxiety (3).  
Work in our lab has explored changes at the cellular level in the microvascular 
endothelium (MVEC) and in cardiomyocytes. In MVECs, ENT1 loss results in an increase 
in both adenosine receptor A2A and adenosine deaminase transcript and protein(1). 
Cardiomyocytes from ENT1-/- mice are more resistant to ischemic insult(23). 
Despite the work that has already been done, a complete phenotype of the ENT1-/- 
mouse has not been described. In particular it is unknown what phenotypes manifest as 
the mouse ages. Here we report for the first time novel cardiovascular and skeletal 
phenotypes of the ENT1-/- mouse.  
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6.2 Materials and Methods 
6.2.1 Animals 
ENT1−/− mice were generated in the laboratory of Dr. Doo-Sup Choi as described 
previously(4); ENT1−/− mice were backcrossed with outbred WT C57BL/6 mice to 
generate ENT1−/+ mice. ENT1-/- had reduced reproductive viability, therefore only 
ENT1−/+ mice were crossed (producing ENT1+/+, ENT1+/−, and ENT1−/− offspring) to 
establish a breeding colony at the University of Western Ontario. Genotyping was done 
using isolated genomic DNA and standard PCR as previously described(1). All aspects of 
this study were conducted in accordance with the policies and guidelines set forth by 
the Canadian Council on Animal Care and were approved by the Animal Use Committee 
of the University of Western Ontario. 
6.2.2 Quantitative Real-Time PCR  
Female ENT1-/- and wild type mice were sacrificed simultaneously at 4 to 6 weeks of age.  
Whole heart, brain and kidney samples were extracted and placed in 10 ml guanidine 
thiocyanate (GTC) buffer (4.2M GTC, 25mM sodium citrate, 1mM EDTA, 0.7% (v/v) 2-
mercapto-ethanol, in distilled water; pH adjusted to 7.0) per gram of tissue. Tissue was 
homogenized using a Polytron® benchtop homogenizer. First-strand DNA template was 
generated using 5 μg (MVECs) of DNaseI (Invitrogen, Carlsbad, CA)-treated total RNA 
and the Superscript First Strand Synthesis System for RT-PCR using oligo d(T) primers 
(Invitrogen). Quantitative real-time PCR analysis was performed using a Roche 
LightCycler (Roche Applied Sciences, Mississauga, ON, Canada) as described in Chapter 
5, section 5.2.5. 
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6.2.3 Haemodynamics 
Heart rate and blood pressure were determined using the CODA-6 non-invasive tail-cuff 
machine (Kent Scientific) (8). Where needed, anaesthesia was induced using 
ketamine/xylazine at 80% of a 100/10 mg/kg dose. Anaesthetized animals were kept on 
a heated pad to prevent loss of body temperature. Animals were subjected to five 
acclimatization rounds (no data collection) followed by two separate acquisition cycles 
of 15 measurements each. There was a 60 second rest between acquisition cycles. The 
tail cuff deflated over a period of 20 seconds during data acquisition. 
6.2.4 High Performance Liquid Chromatography 
Three month old mice were anaesthetized with pentobarbital and blood was collected 
by cardiac puncture into a syringe containing 118 mM NaCl, 5mM KCl, 13.2mM EDTA, 
10µM 5-iodotubercidin, 100µM erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride 
(EHNA), and 10µM dilazep (21). Serum was isolated by centrifugation at 3000 x g for 10 
minutes at 4°C. Serum was applied to a 10 kDa cutoff ultra-filtration column and 
centrifuged at 14 000 x g for 15 minutes at 4°C. Filtrate was used for HPLC analysis(5). 
Filtered serum was analyzed on an Onxy monolithic C18 column with a slightly modified 
protocol established by Farthing D et al (5) in which adenosine was detected with a UV-
detector at 260nm and adenosine metabolites were detected at 250nm, instead of all 
compounds being detected at 250nm.  
6.2.5 Micro Computed Tomography (µCT) Imaging 
Formalin fixed or snap frozen whole mice and spines were imaged in collaboration with 
Dr. David Holdsworth at the Preclinical Imaging Research Centre at Robarts Research 
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Institute (London, ON) using the explore speCZT scanner (GE Healthcare Biosciences, 
London, Ontario, Canada).  Data were acquired with an x-ray tube voltage of 90 kV and a 
current of 40 mA.  In one continuous rotation, 900 views were obtained at an angular 
increment of 0.4o.  The scan time was 5 minutes. A calibrating phantom, consisting of a 
vial of water, air and a synthetic bone (SB3), was imaged together with the specimens.  
Images were acquired at isotropic voxel size of 50 m and reconstructed into 3D images, 
at the same voxel size, using a modified conebeam algorithm (6). The reconstructed 
data were expressed in Hounsfield units by calibrating the grey level values against 
those of water and air. 
6.2.6 Histology 
Spines and joints were dissected from WT and ENT1-/- mice of various ages and fixed in 
10% neutral buffered formalin. Samples were processed by The Molecular Pathology 
Laboratory at Robarts Research Institute (London, ON) and were decalcified before 
being embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E).  
6.2.7 Scanning Electron Microscopy  
A small section of spine isolated from an ENT1-/- mouse that included two verterbrae 
and their corresponding intervertebral space was sent to The Nanofabrication Facility at 
the University of Western Ontario. The sample was analyzed with a Leo (Zeiss) 1540XB 
scanning electron microscope (SEM).  
 
 
 
199 
 
6.3 Results 
6.3.1 Changes in Purinergic Genes in Organs 
Organs were chosen with respect to known adenosine physiology. ENT2 transcript levels 
were found to be significantly increased in the kidney and significantly decreased in the 
heart of ENT1-/- mice as compared to their wild type litter mates.  CNT2 expression was 
found to be significantly elevated in both kidney and brain tissue from ENT1-/- mice. 
Adenosine receptor A2A transcript levels were significantly higher in brain tissue of  
ENT1-/- mice and significantly lower in the heart as compared to the wild type.  There 
was no difference in A2A expression between wild type and ENT1
-/- kidney samples. 
Expression of adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and 
xanthine oxidase (XO) was compared between wild type and ENT1-/- kidney, brain and 
heart samples.  ADA transcript was present at a significantly higher level in kidney 
samples of ENT1-/- mice as compared to the wild type.  No significant differences in ADA 
expression were observed in brain or heart.  PNP expression was also significantly 
elevated in ENT1-/- kidneys compared to the wild type with no differences in expression 
of this gene in the brain or heart.  XO expression was shown to be significantly lower in 
ENT1-/- mouse brain tissue than in wild type brain tissue.  No significant differences in 
XO expression were found in kidney or heart samples (Figure 6.1).  
6.3.2 Haemodynamics 
The heart rate of awake WT mice was 680 ± 20 beats/minute and was significantly 
higher than the 590 ± 20 beats/minute heart rate of ENT1-/- mice (n=7; P<0.05 Student’s 
t-test) (Figure 6.2).  There was no strain-related difference in blood pressure between 
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awake animals. However, when the animals were anaesthetized, the heart rate for both 
WT and ENT1-/- mice was the same, 440 ± 20 and 430 ± 20 beats/minute respectively. To 
ensure animals were on an equal baseline, all subsequent measurements were 
performed on anaesthetized mice. In mice aged 2-3 months, WT mice had significantly 
higher blood pressure than their ENT1-/- counterparts, systolic: 131 ± 12 mm/Hg, 115 ± 5 
mm/Hg; diastolic: 99 ± 9 mm/Hg, 80 ± 6 mm/Hg; mean arterial pressure: 110 ± 10 
mm/Hg, 91 ± 5 mm/Hg respectively. Interestingly, mice aged >6 months did not. In fact 
there was a trend towards the reverse with older ENT1-/- mice having elevated blood 
pressure compared to their WT counterparts (Figure 6.2). 
6.3.3 Plasma Purines 
Free plasma adenosine in WT animals was 600 ± 100 ng/ml where as ENT1-/- animals 
had 2.75 fold higher levels at 1650 ± 370 ng/ml (Figure 6.3). 
6.3.4 Unexpected Paresis and Paralysis 
During the studies leading to the publication by Bone et al.  (2), a number of ENT1-/- 
mice were left to age without any intervention, simply for the sake of not wanting to 
sacrifice the poorly breeding genotype. When ENT1-/- mice reached an age of around 8 
months it was noted that they had decreased mobility in their hind limbs. Mice would 
live from anywhere between 12 and 16 months of age before their condition required 
euthanasia. Some mice requiring euthanasia had complete paralysis of their hind limbs. 
All mice had abnormal curved spines that were extremely rigid; freshly euthanized ENT1-
/- mice were unable to be laid out flat on their backs. Any ENT1-/- mouse to reach this 
age  
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Figure 6.1. Purinergic gene changes in other organs. 
Purinergic genes of interest were examined by quantitative real-time PCR. Solid bars 
represent wild-type (WT) mRNA levels while open bars represent ENT1-/- (KO) mRNA 
levels, normalized to β-actin. Statistical comparisons were made between WT and KO 
per gene per organ. No comparisons were made between genes or between organs. 
ENT2, equilibrative nucleoside transporter 2; CNT2, concentrative nucleoside 
transporter 2; ADA, adenosine deaminase; PNP, purine nucleoside phosphorylase; XO, 
xanthine oxidase; A2a, adenosine receptor 2A. *P<0.05 two-tailed t-test, n ≥ 3. 
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Figure 6.2. ENT1-/- mice have lower blood pressure than WT mice. 
Aged matched male mice were analyzed with a CODA-6 non-invasive tail-cuff machine 
as described in the methods. A) Heart rates of awake WT and ENT1-/- mice were 
determined. WT mice had an elevated mean heart rate of  680 ± 20 beats/minute 
compared to 590 ± 20 beats/minute heart rate of ENT1-/- mice (n=7; P<0.05 Student’s t-
test). There was no difference between the heart rate of anaesthetized animals at 440 ± 
20 and 430 ± 20 beats/minute for WT and ENT1-/- animals respectively.  B) Blood 
pressure of anaesthetized 2-3 month old male mice was determined.  C) Blood pressure 
was determined in anaesthetized WT and ENT1-/- mice older than 6 months. No 
statistical differences were observed however there was a trend towards increased 
pressure in the ENT1-/- mice. 
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Figure 6.3. Circulating plasma adenosine is elevated in ENT1-/- mice. 
Blood was obtained from age matched WT and ENT1-/- mice via cardiac puncture and 
processed for HPLC analysis as described in the methods. Adenosine levels were 
significantly elevated in ENT1-/- mice at 1650 ± 370 ng/ml compared to 600 ± 100 ng/ml 
in WT mice. There were no differences in xanthine or uric acid concentrations.
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developed these symptoms. A post-mortem analysis conducted on one male ENT1-/- 
mouse revealed the presence of hard, white deposits on the ventral side of the spine. 
These deposits were most numerous in the thoracic region however, they did extend 
into the lumbar spine. In the lumbar region, the lesions were much more organized and 
appeared to be localized in the intervertebral space (Figure 6.4). 
6.3.5 Histology 
Histological examination of formalin-fixed, decalcified, paraffin-embedded sections of 
spine confirmed the lesions were associated with the intervertebral spaces and were 
large, irregular accumulations of eosinophilic, amorphous material. In fact, the lesions 
appeared to have replaced the intervertebral discs in their entirety in the thoracic 
region. Some lesions were so large they would protrude into the spinal column and 
impinge on the spinal cord, leading to compression that most likely was the source of 
the paresis and paralysis observed. Lesions appeared to be specific to the ventral spine 
(Figure 6.5) 
Joints, including knees and shoulders were examined histologically for evidence of 
abnormal mineralization or mineral deposits between opposing bones. Interestingly, 
there was no indication of abnormal mineral being present in these areas (Appendix 4).  
6.3.6 µCT Scanning 
Since the lesions forming on the spine contained minerals similar to bone, µCT scanning 
was used to examine both whole mice and isolated spines preserved at fixed ages. Scans 
of a one year old ENT1-/- mouse confirmed the extensive mineral deposits were  
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Figure 6.4. ENT1-/- mice develop mineralized lesions on the spine. 
Spines from WT and ENT1-/- mice (KO) were removed and examined with a Nikon 
SMZ1500 microscope with digital camera. A) WT and KO thoracic spinal sections (as 
labelled) were compared side by side ventrally. Abnormal mineralization is highlighted 
by arrows. 1: vertebrae, 2: intervertebral disc, 3: rib. B) Ventral view of lumbar spines 
from WT and KO mice. Abnormal mineral is highlighted by arrow. 4: vertebrae, 5: 
intervertebral disc. 
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Figure 6.5. Histology of ENT1-/- spines reveals spinal cord impingement. 
Formalin fixed, decalcified spines were sectioned longitudinally and stained with H&E. 
Images were captured at 4x magnification, with dorsal orientation at the top of the 
image. Top images are sections of thoracic spine, bottom images are sections of lumbar 
spine. Images on the left are from a wild-type (WT) mouse and images on the right are 
from an ENT1-/- (KO) mouse. Yellow arrow identifies abnormal mineralization protruding 
into spinal column and resultant spinal cord compression. a: normal intervertebral disc, 
b: normal spinal cord, c: normal vertebra, 1: compressed spinal cord, 2: dorsal 
intervertebral disc, 4: ventral intervertebral disc, 5: vertebra. 
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localized to the spine and confined to the intervertebral spaces in a ventral specific 
manner (Figures 6.6A&C). A rostral to caudal view through the spinal column showed 
that some lesions did indeed intrude into the spinal column as first seen in histological 
sections (Figures 6.6B&D). A time course of lesion development and progression was 
also developed using µCT scanning. Spines from 2, 4, 5, and 6 month old WT and ENT1-/- 
mice were scanned and compared. Mineralized lesions could be seen in the 2 month old 
ENT1-/- mice (Figure 6.7A). A very distinct pattern of lesion development was observed, 
with the cervical spine being affected first. At the age of five months, lesions can be 
observed in the thoracic spine (Figure 6.7C). Very specific lesion formation was also 
observed at the first false rib (Figures 6.7C&D). 
In contrast to the histology and µCT performed on spines of 12 month old mice, these 
time course data suggest the abnormal mineralization begins to form on the outside of 
the spine and slowly progresses into the intervertebral space. 
6.3.7 Scanning Electron Microscopy  
High resolution, high magnification images of the mineral deposit found in the 
intervertebral space supported descriptions of the lesion from histological sections. The 
lesion appeared devoid of any biological material. Organization resembled that of 
angular crystals (Figure 6.8).  
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Figure 6.6. Micro computed tomography of ENT1-/- spines. 
Micro CT scans were performed and maximum intensity projections (MIP) images were 
made. A) Spine from a WT mouse age 12 months. a: anterior, d: dorsal, p: posterior, 
v:ventral. B) Rostral to caudal view showing individual vertebra and spinal column. C) 
Spine from age matched ENT1-/- mouse. Arrows highlight areas of abnormal 
mineralization. Orientation is the same as A). D) Rostral to caudal view of ENT1-/- spine. 
Arrow highlights mineral protrusion into spinal column. 
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Figure 6.7. Time course of lesion development in ENT1-/- mice. 
Spines from age matched WT and ENT1-/- mice (KO) were isolated and fixed in formalin. 
Micro CT scans were performed and MIP images were rendered at 100 µm resolution. 
A) WT (left) and KO (right) spines from 2 month old mice. B) 4 months old. C) 5 months 
old. D) 6 months old. In all cases arrows highlight areas of abnormal mineralization. 
These images are representative of µCT scans performed on at least three mice at each 
age point. 
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Figure 6.8 Scanning electron microscopy (SEM) images of mineral deposits in ENT1-/- 
intervertebral spaces. 
A sample of ENT1-/- spine that had a mineralized lesion in the intervertebral space was 
imaged by SEM. A representative area was chosen and images were captured at 4 
different magnifications: A) 500x, B) 758x, C) 1000x, D) 8660x.  
Note the lack of any cellular or other biological presence. Since the mineral deposits do 
not occur in WT mice, there are no images for comparison between the two strains.  
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6.4 Discussion 
We have characterized previously unreported age-related phenotypes of the ENT1-/- 
mouse. This study furthers our understanding of the physiological roles of ENT1 and 
adenosine, with particular focus on the local control of mineralization of paraspinal 
tissue. 
6.4.1 Altered gene expression 
Changes in gene expression in microvascular endothelial cells isolated from mouse 
skeletal muscle of ENT1-/- were presented in Chapter 5. Organs were chosen based on 
the overall cardiovascular aspect of this thesis (heart) and organs in which adenosine 
plays key physiological roles (brain, kidney, and heart). Of particular note are genes that 
differentially change depending on the organ. ENT2 drops significantly in KO hearts but 
rises significantly in KO kidneys. Adenosine receptor A2A rises significantly in the KO 
brain but drops significantly in the KO heart. Rose and colleagues also examined gene 
expression changes in the heart of ENT1-/- mice and found no statistical differences, 
however there was a trend towards decreased A2A mRNA as well (23). The only other 
reported gene change in the ENT1-/- mouse is an increase in adenosine receptor A1 
protein in the striatum (4). In other model, where human ENT1 was over-expressed in 
mouse neurons, there were no reported changes in gene expression (19). Clinically 
based work examining the lack of human ENT1 expression in cancer, have linked ENT1 
to response to nucleoside analogue chemotherapy (18; 25). Given that there are known 
polymorphisms in the ENT1 gene (14; 17), and that the lack of ENT1 affects the 
219 
 
expression of other genes that regulate adenosine bioactivity, more research is needed 
to study the role of ENT1 in human diseases of the heart, brain, and kidney. 
6.4.2 Altered cardiovascular function 
ENT1-/- mice had a lower awake heart rate than their WT counterparts. The CODA-6 
system has holding tubes for awake mice that limits mobility to obtain accurate 
readings. This environment would lead to stress and anxiety in the WT mouse, where as 
the ENT1-/- mouse is known to be less anxious in stressful situations(3). The normal 
heart rate for C57BL/6 mice that are trained for the tail-cuff apparatus ranges between 
600 and 620 bpm (11; 24), which is lower than the 680 bpm reported for the WT mice in 
this study and higher than the 590 bpm of the ENT1-/- mice (Figure 6.2). Therefore, it is 
proposed that anxiety in the WT mouse translated into a higher heart rate. This was 
supported by the equal heart rates in anaesthetized mice, and evidence that anxiety in 
mice results in elevated heart rates (7). 
To avoid the differences in anxiety between WT and ENT1-/- mice, blood pressure was 
measured in anaesthetized animals. ENT1-/- male mice aged 2-3 months had lower blood 
pressure than aged matched WT mice (Figure 6.2). Our group has previously reported 
that ENT1-/- mice have elevated adenosine receptor A2A protein expression in 
microvascular endothelial cells isolated from skeletal muscle(1). A2A receptor signaling is 
known to mediate vasodilation. In fact, the A2A
-/- mouse is hypertensive (16). Adding to 
the increased A2A expression previously reported, the current study showed that ENT1
-/- 
had an elevated adenosine concentration in plasma from whole blood collected by 
cardiac puncture (Figure 6.3). An increase in both the vasodilatory receptor and the 
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ligand could result in consistently decreased peripheral resistance, resulting in lower 
blood pressure in young mice. However, as these mice age, additional unknown factors 
contribute to a normalization of blood pressure. While it is known that blood pressure in 
mice increases as they age (8), the differential change between WT and ENT1-/- suggests 
an altered condition in the ENT1-/- animal. It could be possible that there is a progressive 
hardening of vessel walls, due to ectopic mineralization as seen with the soft tissue 
found around the intervertebral spaces of the ENT1-/- mice. There are links between 
adenosine, adenine nucleotides, and the calcification of arteries (12; 26). However, since 
there is no µCT evidence, either the calcification is extremely diffuse to be undetectable, 
or alternatively perhaps there is a gradual overcompensation of vasoconstrictor 
production that eventually takes over the initial vasodilatory signal. 
6.4.3 Abnormal mineral deposits in the spine 
The role of adenosine in the formation of abnormal mineral deposits is poorly 
understood. Abnormal calcification of vascular smooth muscle cells isolated from rat 
aorta is enhanced by a cAMP dependent mechanism that aids in the reduction of 
extracellular inorganic pyrophosphate (PPi) accumulation (20). Adenosine is capable of 
increasing cAMP levels via the adenosine A2A and A2B receptor subtypes. However, a 
very recent report by St. Hilarie et al., (26) suggests that adenosine is an inhibitor of 
calcification. In that study, human patients with a non-function mutation in the CD73 
enzyme that forms adenosine from AMP presented with abnormal vascular 
mineralization. Fibroblasts isolated from one patient spontaneously formed calcium 
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deposits in culture that was reversed by the addition of adenosine to the culture 
medium (26).  
A similar phenotype to our identified hypermineralization has been reported in mice 
lacking nucleotide pyrophosphatase phosphodiesterase-1 (NPP1; Enpp1-/-). NPP1 is 
responsible for the production of PPi via the metabolism of triphosphate nucleotides, 
like ATP, to monophosphate nucleotides. These Enpp1-/- mice, also known as tip-toe 
walking mice, spontaneously develop progressive ankylosing intervertebral and 
peripheral joint hyperostosis and articular cartilage calcification (10). However, our 
ENT1-/- mice do not appear to have any abnormal mineralization in other joints, 
suggesting a different mechanism.  
Interestingly, our spinal mineralization phenotype most closely resembles the human 
condition diffuse idiopathic skeletal hyperostosis (DISH). DISH affects about 25% of the 
male population over the age of 65, with a slightly lower occurrence in women (27).  
Resnick and Niwayama state that a diagnosis of DISH must meet the following criteria: 
1) the involvement of at least 4 contiguous vertebrae of the thoracic spine, 2) 
preservation of the intervertebral disc space (distinct from akylosing spondylitis), and 3) 
absence of apophyseal joints or sacroiliac inflammatory changes (22). Our phenotype 
clearly agrees with conditions 1 and 3. If examined solely on 12 months of age or older 
mice, then it would appear that condition 2 is not met. However, the µCT images of 
younger mice (Figure 6) would suggest that as the mineralization develops the 
intervertebral disc is intact. In reality, the severity of the mineral deposits in older mice 
is much more likely an extreme that would not be found in human patients because 
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humans will report their discomfort much sooner and more effectively than mice. Much 
like the phenotype of our ENT1-/- mice, DISH is asymptomatic until there is compression 
of surrounding tissues including the glottis resulting in dysphagia, or compression of the 
spinal cord producing neurological complications (28). The etiology of DISH is unknown. 
However in attempts to aid in the understanding of DISH, the Boxer dog has been 
identified as having an unusually high prevalence (41% compared to an average of 4% in 
other breeds) of DISH (15). Our lab had previously cloned the dog ENT1 gene (9), and 
given the DISH like phenotype in the ENT1-/- mouse there was interest in the ENT1 gene 
of the Boxer dog. In silico analysis of the ENT1 gene from mouse, human, Boxer dog, and 
Alsatian dog, revealed that the Boxer dog has an altered ENT1 gene resulting in a 
mutated protein missing 7 amino acids in a highly conserved region (Figure 6.9A).  When 
mapped to the proposed structure of ENT1, this deletion is predicted to be in the 
second extracellular loop (Figure 6.9B), a region identified to be important in transport 
function (13). Given the similarities between this condition and the hypermineralization 
phenotype of our ENT1-/- mice, we are currently pursuing the hypothesis that alterations 
in local adenosine concentrations as a result of the loss of ENT1 function contributes to 
the development of DISH.  
6.4.4 Conclusions 
In conclusion, the ENT1-/- mouse is a valuable model for the study of adenosine 
mediated regulation of vascular tone and is a possible novel model for the study of a 
common but poorly understood human disease. 
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Figure 6.9. Alterations in Boxer dog ENT1 protein. 
A) Alignment of ENT1 sequences (from Genbank). Letters are single character amino 
acid codes. Green colour indicates conserved, yellow indicated a unique residue, dashed 
line represents missing residues. 
B) Schematic of the proposed topology of dog ENT1 with missing amino acids identified 
in red and unique amino acids in yellow. Additional species specific differences are not 
shown.
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CHAPTER SEVEN 
GENERAL DISCUSSION 
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7.1 Review of Research Questions 
In Chapter 2 research questions were identified that would be addressed in this thesis. 
Study of nucleoside transporters in the microvasculature had been neglected, with the 
majority of studies using the macrovascular HUVECs as a model. The understanding of 
nucleobase transport was even sparser. 
Choosing primary human MVECs as a model, questions regarding the expression and 
function of nucleoside and nucleobase transporters were addressed. This work included 
identifying what transporters existed in this cell type to mediated nucleoside and 
nucleobase transport, as well as the molecular mechanisms in place that regulated the 
function of these transporters.  
An ENT1-/- mouse was also studied to understand how ENT1 contributes to purine 
handling in the microvasculature. Through culturing primary mouse MVECs, it was 
possible to address questions about compensatory mechanisms that exist to respond to 
the missing nucleoside transporter ENT1. The whole animal was also studied to 
determine the impact of the loss of ENT1 on cardiovascular physiology. 
 
7.2 Picking an Appropriate Model: Differences in species and cell type 
The idea that differences exist between species and cell types is not new. In fact there 
are already several examples in the nucleoside transporter field that highlight this. It has 
long been known that the pharmacology of ENT1 is species-dependent with inhibitor 
affinities displaying a rank order of human being the most sensitive, rat being least 
sensitive, and mouse falling in the middle (8). Additionally, the mouse ENT1 gene has 
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multiple splice variants that affect transporter regulation and expression that do not 
appear to exist in humans (9; 17).  
7.2.1 Differences in expression of nucleoside and nucleobase between species. 
It has been previously shown that primary MVECs isolated from rat skeletal muscle 
express ENT1 and ENT2 in approximately equal amounts (1). In these cells ENT2 was the 
nucleobase transporter of note and mediated both the uptake and release of 
hypoxanthine (16). However, as shown in Chapter 3, primary human cardiac MVECs did 
not display any functional ENT2. Additionally, it was discovered that a novel purine-
selective nucleobase transporter, ENBT1, was the transporter responsible for the uptake 
and release of hypoxanthine. In Chapter 5, primary mouse skeletal muscle MVECs were 
found to be different from both human cardiac and rat skeletal muscle. Mouse MVECs 
expressed both ENT1 and ENT2, however the contribution of ENT2 to nucleoside uptake 
was minimal. A mouse orthologue of ENBT1 was also discovered and was the 
predominant nucleobase transporter. The relative expression of ENT1, ENT2, and ENBT1 
with respect to species is highlighted in Table 7.1. 
7.2.2 Impact of cell type. 
In Chapter 4 regulation of ENT1 and ENBT1 was examined in primary human MVECs and 
in some cases the immortalized endothelial cell line HMEC-1.  
The effect of PKC activation and down-regulation in MVECs on ENT1 (Figure 4.8) was the 
opposite of reported effects in cancer cells (4), but similar to HUVECs (13). The effect of 
the CKII inhibitor TBB was similar to a recombinant expression model (3), but different 
from a dominant negative model (18). Adenosine A2 receptor agonists had no effect on 
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ENT1 in MVECs whereas it has been shown previously that both receptors can affect 
ENT1 and ENT2 in HUVECs (6). There was even temporal and concentration differences 
in the response to VEGF between MVECs and HMEC-1 cells within this work (Figures 4.3 
and 4.4).  
7.2.3 Species differences and cell types: conclusions. 
It is clear that the choice of species and cell type is critical to the proper interpretation 
of data. Based on rat MVECs it was predicted that human MVECs would express ENT2 as 
both a nucleoside and nucleobase transporter. If human or mouse MVECs were not 
actually studied, then the discovery of ENBT1 would not have occurred and the 
realization that rat is not an appropriate model of nucleoside/nucleobase transport 
would not have been made. Mouse, although closer to human MVECs than rat, is still 
not an ideal model; however, mice have the advantage of providing genetically modified 
models to study gene function.  
The variation seen in response in different cell types when studying transporter 
regulation reinforces the importance of proper model selection and highlights the need 
to be careful when extrapolating results to another model. 
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Table 7.1. Relative expression of nucleoside and nucleobase transporters in primary 
MVECs from different species 
 
 
 
 
 
 
 
In human primary MVECs only ENT1 and ENBT1 are expressed for nucleoside and 
nucleobase transport respectively. In mouse, there is some detectable ENT2 expression, 
however the contribution to either nucleoside or nucleobase transport is minimal, 
hence the 3:1 ratio of symbols (this ratio is representative and not meant to be an 
absolute measure of expression levels). In rat MVECs there is approximately equal ENT1 
and ENT2 distribution.  
-: no expression  
n.d.: not determined (1; 16) 
 
Species Tissue ENT1 ENT2 ENBT1 
Human Cardiac + - * 
Mouse Skeletal muscle +++ + *** 
Rat Skeletal muscle + + n.d. 
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 7.3 Physiological Relevance 
7.3.1 Discovery of a novel purine nucleobase transporter: A change in dogma. 
Following the cloning and molecular characterization of ENT1 and ENT2, it was generally 
accepted that ENT1 was the primary sodium-independent nucleoside transporter and 
ENT2 was the sole sodium-independent nucleobase transporter (23). However, it is clear 
from the data presented in this thesis that this dogma is in need of revision.  
The existence of ENBT1, the dipyridamole-insensitive purine selective nucleobase 
transporter changes the understanding of purine transport in mammalian cells. 
Understanding that ENT2 most likely is not the transporter mediating uptake or release 
of nucleobases and nucleobase analogues will change our views on cardiovascular 
physiology, chemotherapy in cancer and other conditions, and possibly other areas of 
physiology and pharmacology that are not yet appreciated. Figure 7.1 contrasts the old 
and new understanding of nucleoside and nucleobase transport in mammalian cells. 
7.3.1.1 Future Directions: The Genetic Identity of ENBT1 
Characterization of ENBT1, as presented in Chapter 3, has laid the ground work for 
understanding how the transporter functions. However, without knowing the genetic, 
and therefore, molecular identity of ENBT1, these studies are limited in progression. 
Expression studies using PCR and western blotting techniques are impossible without 
this knowledge. Additionally, structure-function studies that would provide better 
understanding of substrate recognition and inhibitor sensitivities, and even allow for the 
rational design of nucleobase analogues that could be used in chemotherapies, are not 
possible without knowing the genetic identity of ENBT1. 
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With the sequencing of the human genome complete, the gene that encodes ENBT1 is 
known, it just needs to be found. A group in Japan has ruled out that ENBT1 is a member 
of the SLC23 family, or sodium-dependent ascorbate transporters (see Chapter 1). Since 
ENT2 has a similar substrate profile to ENBT1, and the amino acids in ENT2 that help 
confer the ability to transport nucleobases is known, genome searches for similar 
regions may prove to be a good starting point. 
In an alternative approach, further examination of the OCT family of transporters can be 
performed. Chapter 3 tested a potential candidate, hUPP1, without success. As well, 
substrates of OCT1 and OCT3 were tested as potential inhibitors of [3H]hypoxanthine 
uptake, with mixed results. Despite these outcomes, there is still enough potential in an 
OCT to justify a different approach. Expression of recombinant OCTs in HEK cells (which 
lack functional ENBT1) can be used in gain of function experiments to better test the 
possibility that an OCT is ENBT1.  
7.3.2 ENBT1 and Ischemia-Reperfusion injury of MVECs 
The generation of ROS from purine metabolism in endothelial cells during reperfusion 
after ischemia is an established phenomenon (12). There is also evidence that ROS 
generated in this manner contributes to endothelial dysfunction (7; 15; 22). The 
sensitivity of the hypoxanthine transporter ENBT1 to superoxide produced 
intracellularly by menadione may contribute to increased ROS production and overall 
endothelial dysfunction through oxidative stress. Figure 7.2 proposes a model of how 
ENBT1 contributes to ROS production and endothelial dysfunction.    
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Figure 7.1. Changes in nucleoside and nucleobase transporter dogma. 
Following the cloning of ENT1 and ENT2 it was generally accepted that ENT1 was the 
primary Na-independent nucleoside transporter and ENT2 was the sole nucleobase 
transporter that could also contribute to nucleoside transport. The top panel depicts 
that view. Inhibitors of transport, NBMPR and dipyridamole, are connected to their 
targets with red arrows. 
The bottom panel depicts the current view of nucleoside and nucleobase transport in 
primary human MVECs based on discoveries presented in this thesis. In place of ENT2, 
ENBT1 is the sole nucleobase transporter, and is selective for purine nucleobases. 
ENBT1 is also insensitive to dipyridamole inhibiton.  
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Figure 7.2. ENBT1 and ischemia-reperfusion injury of the microvascular endothelium. 
The following schematic is a proposed model of how ENBT1 may contribute to injury of 
the endothelium following ischemia-reperfusion. 
During ischemia, adenosine released by surrounding cardiomyocytes accumulates in the 
MVECs, via uptake by ENT1. Adenosine kinase is inactivated by ATP depletion and thus 
the excess adenosine is metabolized to hypoxanthine. Without oxygen, the metabolism 
of hypoxanthine cannot continue. ENBT1 mediates the efflux of hypoxanthine.  
Upon reperfusion, the return of oxygen allows xanthine oxidase to metabolize 
hypoxanthine to xanthine and xanthine to uric acid, producing ROS in the process. The 
ROS produced attacks ENBT1, leading to decreased hypoxanthine efflux. 
The resulting lack of ENBT1 function promotes increased hypoxanthine metabolism and 
an increase in ROS, contributing to increased cellular oxidative stress, injury, and 
possible endothelial dysfunction. 
Notes: Inhibitory effect of ROS on ENBT1 is depicted by red arrow with diamond tip. The 
non-functional or reduced function ENBT1 is depicted with as a red arrowless box with a 
yellow starburst to suggest oxidative modification by ROS. 
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7.3.2.1 Future Directions: ENT1, ENBT1, and ROS production 
In Chapter 4, it was found that the intracellular superoxide generator menadione 
reduced hypoxanthine uptake by a process that could be blocked by a superoxide 
dismutase mimetic (Figure 4.12). While it would seem that this effect was mediated by 
superoxide, no measurement of ROS was made.  
Measuring ROS production, by use of fluorescent dyes, would strengthen the proposed 
mechanism of reduced hypoxanthine uptake by menadione. As well, measurement of 
ROS would allow the investigation of the role of ENBT1 and hypoxanthine transport on 
the intracellular production of superoxide by hypoxanthine metabolism.  
ROS measurement would also be useful after the mineral oil-overlay ischemia treatment 
to determine a possible mechanism of action as the effects of ischemia are similar to 
that of menadione treatment (Figure 4.13).  
Other oxidants should also be tested on the ability to affect ENT1 and ENBT1 function. 
As superoxide is rapidly converted to hydrogen peroxide or can react with NO to form 
peroxynitrite, there is potential that there are additional mechanisms of oxidative stress 
that could affect transport function (5; 11; 15). In fact, one recent study claimed that the 
peroxynitrite donor SIN-1 reduced adenosine uptake in rat astrocytes (19). However, the 
conditions of that study resulted in total adenosine accumulation rather than ENT1 
mediated transport and the effects of SIN-1 on adenosine metabolism were not 
addressed. Treatment of cells with stable peroxides, like tert-butyl hydroperoxide, or 
with the peroxynitrite donor SIN-1 is needed to complete the profile of oxidative stress 
on transporter function. 
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7.3.3 New roles of ENT1 in disease 
The ENT1-/- mouse has identified the contribution of ENT1 to the regulation of blood 
pressure (Figure 6.2) and control of mineralization of tissues in the spine (Figures 6.4-
6.6).  
The link between ENT1 and blood pressure is not surprising, given that the ENT1 
substrate adenosine is a potent vasodilator (2). However, the hypotension phenotype 
raises the possibility that ENT1 may be a suitable target for the treatment of 
hypertension. It may also be possible that enhanced ENT1 function contributes to the 
development of hypertension, by limiting the exposure of adenosine to the vascular 
lumen (10).  
The hind limb paralysis and abnormal spinal mineralization observed in ENT1-/- mice was 
a serendipitous discovery. The connection between ENT1 and mineralization, especially 
in such a specific manner, is not immediately clear. However, the resemblance of the 
ENT1-/- mice to human patients with the condition DISH is exciting (14; 21). The cause of 
DISH is currently unknown and there is no treatment option besides surgery. DISH is the 
second most common form of arthritis, and the ENT1-/- mouse may prove to be an 
excellent model to better understand this disease (20; 21).  
7.3.3.1 Future Directions: The Role of ENT1 in Disease 
Chapters 5 and 6 examined the role of ENT1 in MVECs and whole animals using ENT1-/- 
mice. While some changes in gene expression in MVECs were found, the impact of ENT1 
to hypoxia, ischemia-reperfusion, and oxidative stress could not be completely 
addressed due to difficulty in culturing ENT1-/- MVECs. Once the culturing process has 
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been properly adjusted, data can be generated to complement the wild-type responses 
observed in Chapter 5. 
The ENT1-/- mouse had two interesting phenotypes, hypotension in young mice, and 
abnormal mineralization in the spine, as discussed in Chapter 6. 
The hypotension phenotype was determined with a tail-cuff system. Confirmation of the 
phenotype should be performed using telemetry to obtain more natural measurements 
of the course of a day. The potential of ENT1 in the treatment of hypertension can be 
studied using isolated blood vessels and myograph systems.  
The abnormal mineralization observed in the spine resembles the human condition 
DISH. The mechanism behind the lack of ENT1 and abnormal mineralization has yet to 
be determined. Altered gene expression that may contribute to the formation or 
deposit of mineral in the ENT1-/- will be determined using quantitative PCR. Blood 
chemistry analysis will be performed to identify possible changes in calcium or 
phosphorous levels. Additionally, the specific tissue affected is currently unknown. More 
in depth histological analyses need to be performed using mice at a variety of age 
points. Samples from boxer dogs, who display a high rate of DISH, as well as from 
diagnosed humans, for the study of ENT1 function will also help form a link between the 
nucleoside transporter and the disease. 
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7.4 Closing Remarks 
The discoveries presented in this thesis strengthen the need to understand nucleoside 
and nucleobase transporters, their expression, function, and regulation. It is evident 
that these transporters are important in the microvasculature as well as overall 
cardiovascular function, and even long term health.  
Better understanding of ENT1 and ENBT1 at the molecular level will improve the 
effectiveness of using these transporters as pharmacological targets in cardiovascular 
disease, cancer, and surprisingly, pathological mineralization in the spine. 
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Appendix 1: Copyright permission for Chapter 3 
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Appendix 2: Copyright permission for Chapter 5 
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Appendix 3: Ethics approval for usage of animals 
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Appendix 4: Lack of mineralization in other joints 
 
Unlike the spine from ENT1-/- animals (KO), joints such as knees and shoulders appear to 
lack any abnormal mineralization.  
251 
 
 
Curriculum Vitae 
Derek Benjamin James Bone, B.M.Sc(Hon.) 
 
 
Contact Info 
Department of Physiology and Pharmacology 
The University of Western Ontario, London, Ontario, Canada  
 
Education 
2007-current: Ph.D. candidate, Department of Physiology and Pharmacology, Schulich 
School of Medicine and Dentistry, The University of Western Ontario (Supervisor: Dr. 
James R. Hammond) 
 
2005-2007: M.Sc. candidate, rolled into Ph.D. program January 2007. 
 
2005: B.M.Sc. (Hon.) – Pharmacology and Toxicology, The University of Western 
Ontario 
 
Publications 
5. Bone, DBJ, Choi, DS, Coe, IR, and Hammond, JR. Nucleoside/nucleobase 
transport and metabolism by microvascular endothelial cells isolated from ENT1 
-/- mice. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H847-56. Epub 2010 
Jun 11. 
 
4. Robillard, KR., Bone, DBJ., Park, JS., and Hammond, JR. Characterization of a 
novel alternative splice variant of the mouse equilibrative nucleoside transporter 
1: mENT111. Mol Pharmacol. 74(1):264-273. Epub: April 15, 2008. 
 
3.  Robillard, KR.1, Bone, DBJ.1, and Hammond, JR. Hypoxanthine uptake and release 
by equilibrative nucleoside transporter 2 (ENT2) of rat microvascular endothelial 
cells. Microvasc Res. 75(3):351-357. Epub: 2007 Oct 18. 1Equal contribution. 
 
2.  Bone, DBJ and Hammond JR. Nucleoside and nucleobase transporters of primary 
human cardiac microvascular endothelial cells: Characterization of a novel 
nucleobase transporter. Am J Physiol Heart Circ Physiol. Dec; 293(6):H3325-32. 
Epub: 2007 Oct 5.  
 
1.  Bone, DBJ, Robillard, KR., Stolk, M, and Hammond, JR. Differential regulation of 
mouse equilibrative nucleoside transporter 1 (mENT1) splice variants by protein 
kinase CK2. Mol Membr Biol. 2007 Jul-Aug; 24(4):294-303 
 
 
 
 
252 
 
 
Conference Abstracts 
7. Bone, DBJ., and Hammond JR. Differential regulation of purine transport in 
primary human cardiac microvascular endothelial cells. IUPHAR XVI, 
Copenhagen, Denmark, July 2010. Basic Clin Pharmacol Toxicol. July 2010; Vol 
107 (Supplement s1) 
 
6. Bone, DBJ., Frieburger L, Troup, M., and Hammond JR. Discovery and 
characterization of a novel purine-selective nucleobase transporter, equilibrative 
nucleobase transporter 1. Canadian Student Health Research Forum; CIHR 
National Research Poster Presentation, Winnipeg, Manitoba, Canada. June 2, 
2010.  
 
5. Troup, M., Bone, DBJ., and Hammond JR. Hypoxia decreases equilibrative 
nucleobase transporter 1 (ENBT1) function in microvascular endothelial cells. 
Innovations in Pharmacology - CSPT 2009, Saskatoon, Saskatchewan, Canada. 
Can J Clin Pharmacol Vol 16 (2) Summer 2009:e298-e321; May 20, 2009. 
 
4. Bone, DBJ., Choi, DS., and Hammond JR. Microvascular endothelial cells from 
equilibrative nucleoside transporter 1 (ENT1)-knockout mice have altered purine 
uptake and metabolism profiles. Poster presented at the 9th World Conference 
on Clinical Pharmacology and Therapeutics, Quebec City, Quebec, Canada, July 
2008. 
 
3.  Bone, DBJ., and Hammond JR. Nucleobase uptake is mediated by multiple 
facilitative mechanisms in mammalian cells. Banff2007: Pharmacology and 
Therapeutics Conference, Banff, Alberta, Canada. Proceedings of the Western 
Pharmacology Society. Volume 50, 2007.  
 
2.  Bone, DBJ., and Hammond, JR. Nucleoside and nucleobase uptake by human 
cardiac microvascular endothelial cells (hMVECs): Evidence of a novel 
transporter. IUPHAR XV, Beijing China, July 2006. Acta Pharmaca Sinca July; 
Supplement 1 
  
1.  Bone, D., Stolk, M., and Hammond, J.R. Functional and pharmacological 
characterization of equilibrative nucleoside transporter splice variants. 
Proceedings of the British Pharmacological Society at 
http://www.pa2online.org/abstracts/Vol3Issue2abst008P.pdf 
 
Invited Oral Presentations 
3. Bone, DBJ., and Hammond JR. Purine transport and metabolism in microvascular 
endothelial cells. Presented at National Institute of Diabetes and Digestive and 
Kidney Diseases, National Institutes of Health, Bethesda, USA. February 1, 2011. 
 
253 
 
 
2. Bone, DBJ., and Hammond JR. Function and regulation of purine equilibrative 
transporters in human cardiac microvascular endothelial cells. Presented at 
Institute of Experimental and Clinical Pharmacology, Friedrich-Alexander 
University Erlangen-Nürnberg, Erlangen, Germany. July 26, 2010. 
 
1. Bone, DBJ., and Hammond JR. Consequences of equilibrative nucleoside 
transporter 1 knock-out. Presented at Department of Physiology and 
Pharmacology Seminar Series, The University of Western Ontario. April 26, 2010. 
 
Awards and Scholarships 
 The Hari and Gudrun Sharma Award – Awarded annually to an outstanding 
pharmacology PhD student, Departmental, 10/2010 
 Honourable Mention – CIHR National Research Poster Presentation, Canadian 
Student Health Research Forum, 06/2010 
 Canadian Institutes of Health Research Doctoral Research Award, $44,000, National, 
05/2008-04/2010 
 Schulich Graduate Scholarship, $23,100, Institutional, University of Western Ontario, 
01/2007-08/2010 
 
 Ontario Graduate Scholarship in Science and Technology, $15,000, Institutional, 
University of Western Ontario, 05/2007-04/2008 
 
 Western Graduate Research Scholarship, $5,400, Institutional, University of Western 
Ontario, 09/2005-12/2006 
 
 Mogenson Trust Graduate Student Travel Award, $500, Institutional, University of 
Western Ontario, 10/2006 
 
Teaching 
 
 2005-2010: Teaching Assistant, 3rd-year Pharmacology Lab, Department of 
Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The 
University of Western Ontario 
 
 2008: Nominated for Graduate Student Teaching Award 
 
 2007: Nominated for Graduate Student Teaching Award 
 
 
 
254 
 
 
Academic Activities – Committees  
 
 2009-2010: Departmental Graduate Students’ Council – Founding Member 
 
 2008-2010: Departmental Graduate Studies Sub Committee – Pharmacology Student 
Representative 
 
 2008-2010: Departmental Communications and Outreach Sub Committee – Student 
Representative 
 
Supervision and Mentoring 
 
 2005-current: 5 fourth year honors thesis students 
 
Professional Affiliations 
 
 Canadian Society of Pharmacology and Therapeutics – Student Member 
 
